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Infectious disease is a major issue facing the livestock industry. Further 
understanding of the role of genetic factors in the observed phenotypic variability of 
the immune response to pathogens and vaccination could assist in designing 
improved preventative measures such as more efficacious vaccines and targeted 
breeding strategies to select for disease resistance. Major candidate genes for 
controlling immune responsiveness are located within the major histocompatibility 
complex (MHC). The highly polymorphic classical MHC genes are key determinants 
in the strength and type of immune response.  However, it has proved difficult to 
establish genotyping approaches to define functionally relevant allelic variations for 
outbred species such as cattle, not least because the peptide binding clefts (PBC) of 
classical MHC molecules are highly polymorphic, and the genes within the MHC 
complex are closely linked. 
The overall aim of this project was to investigate the role of MHC genes in immune 
responsiveness in approximately 200 F2 and backcross Holstein-Charolais cattle. 
These animals were generated as part of the Roslin Bovine Genome (RoBoGen) 
herd, established through a quantitative trait loci (QTL) project, in which a number 
of phenotypic traits including immune traits were measured.  The immune traits 
included responses to a Foot-and-mouth disease virus (FMDV) peptide, and vaccines 
against bovine respiratory syncytial virus (BRSV), para-influenza virus 3 (PIV-3) 
and bovine herpes virus-1 (BHV-1), as well as T cell response to Staphylococcus 
aureus. The immune phenotypes measured included IgG and interferon-γ (IFN-γ) 
levels and T cell proliferation.  
The cattle MHC region, known as bovine leukocyte antigens (BoLA), resides on 
bovine chromosome 23. The BoLA region contains approximately 200 genes most of 
which are immune-related.  Class II gene polymorphisms were considered to be the 
most likely to influence the immune traits measured, and the project primarily 
focused on the best defined gene, BoLA-DRB3. A sequence-based typing technique 
was successfully improved to facilitate genotyping of the PBC of BoLA-DRB3 in all 
generations of the RoBoGen herd (approximately 400 animals) and identified 24 
 
vi 
distinct alleles. The sequence information obtained also enabled further analysis of 
the role of defined ‘pockets’ within the PBC, which directly determine peptide 
binding affinity.  
All datasets were statistically analysed using a residual maximum likelihood 
(REML) model and it was shown that several of the DRB3 alleles within the 
RoBoGen herd had highly significant (p<0.05) associations with the immune 
response to the FMDV peptide. In addition DRB3 alleles were identified which had 
significant associations with the response to the respiratory pathogen vaccinations 
and exposure to S. aureus.  The pocket analysis also enabled the identification of 
several amino acid positions within the PBC which were significantly associated 
with the immune response traits. 
In order to explore whether DQ Class II gene polymorphisms also played a role in 
the variability of responses and whether BoLA Class I-Class II haplotypes could be 
discerned, microarrays which utilized allele specific oligonucleotides for BoLA 
Class I and Class II DQ genes were employed. In addition, to investigate whether the 
number of DQ gene pairs per chromosome influenced the responses, a quantitative 
polymerase chain reaction (qPCR) assay to determine DQA gene dosage was 
developed.  However, due to the extremely complex nature of the BoLA region both, 
techniques would require improving to be used for large-scale studies. Nonetheless, 
information about haplotypes was determined from the microarray results and the 
qPCR technique lays the foundations for future development to investigate DQ gene 
dosage.   
The MHC region in cattle is very complex due the high level of polymorphisms and 
gene duplications. It is likely that many genes play a role in the immune response to 
both pathogens and vaccines. However, from the evidence presented here, 
polymorphisms in the PBC of BoLA-DRB3, particularly within the pockets, are 
significantly associated with variation in immune response to many different 
antigens and this information could be exploited in the design of vaccines or 
breeding cattle for improved disease resistance.  
 
1 General Introduction 
 
1.1 Introduction 
The immune system has evolved to protect individuals against infection by 
pathogenic organisms yet tolerate non-pathogenic organisms and not attack self. 
Pathogenic organisms, which include bacteria, viruses and parasites, have co-evolved 
to defeat the hosts’ immune system. This conflict between the pathogenic organisms 
and the individual has resulted in the evolution of an immune system containing 
many interacting cells and chemicals. The vertebrate immune system is highly 
complex and involves the interaction of two divisions: the innate and the adaptive 
immune response. 
The innate immune response acts rapidly in a non-specific way against invading 
pathogens and as such acts as a primary barrier to infection. It also performs a vital 
role as it initiates and directs the adaptive response. The adaptive immune response 
on the other hand is slow acting upon first exposure to the pathogen, but because it 
acts in a specific, targeted manner, subsequent exposure initiates a rapid response.  
1.2 Adaptive immune system 
Vertebrates have developed highly sophisticated mechanisms to target pathogens in a 
specific way: the adaptive immune response. After initial exposure to a pathogen the 
adaptive immune system generates memory cells which are capable of initiating a 
rapid response upon subsequent exposure to the pathogen. A deeper understanding of 
the mechanism involved in the adaptive immune response could be utilised for 
improving resistance to infectious disease.  
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1.3 Genetics of disease resistance 
Increasing disease resistance and improving response to vaccination is a goal of the 
livestock industry as it would result in improved animal welfare as well as a 
reduction in costs. An avenue for improvement is the study of the genes and 
pathways underlying the response to pathogens and vaccines. However, the genetics 
underlying traits related to host susceptibility or resistance to disease are complex 
and likely will involve many genes each of which is likely to have a relatively small 
effect. In humans there have been extensive studies investigating immunogenetics 
which have found associations with both MHC and non-MHC genes (e.g. cytokine 
genes and innate immune receptor genes) (reviewed by Hill (1998)).  
1.4 Major histocompatibility complex (MHC) 
Peter A. Gorer in 1937 is credited with describing the role of histocompatibility in 
tumour rejection in mice (Gorer 1937). This built on previous congenic mouse strain 
work by George Snell and his discovery of a histocompatibility locus (Silverstein 
2009). However, it was not until the 1970s, when Zinkernagel and Doherty published 
their work on the restriction of T cells, that the full function of the MHC became 
apparent (Zinkernagel & Doherty 1974). They discovered that only histocompatible 
cells can present antigen to T cells as part of the adaptive immune system.  
In the mammalian genome the MHC locus can be subdivided into three distinct 
regions, I, II and III. The Class I and Class II loci encode molecules which are 
involved in the presentation of antigen to CD8+ or CD4+ T cells respectively 
(Germain 1994). In addition, in the last 15 years or so, it has become apparent that 
MHC Class I molecules are also involved in the function of natural killer (NK) cells 
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(reviewed by Ljunggren & Karre (1990)). In contrast, the Class III region is more 
diverse, containing immune genes such as tumour necrosis factor α and β, 
complement proteins as well as other secreted proteins.  
All vertebrate genomes have an MHC locus, although the gene composition, order 
and sequence divergence varies between species (Kelley, Walter, & Trowsdale 2005; 
Belov et al. 2006). The adaptive immune system is believe to have evolved about 
500 million years ago in ancestral jawed vertebrates and one of the most primitive 
MHC regions is found in nurse sharks (Ohta et al. 2000; Flajnik & Kasahara 2001). 
Selective pressures such as pathogens and population dynamics have led to 
considerable diversity involving gene gain and loss in the MHC regions of different 
animals (Kelley, Walter, & Trowsdale 2005). The human MHC (human leukocyte 
antigen (HLA)) region spans 3.6 Mb and has 128 functional genes (The MHC 
sequencing consortium 1999), whilst the chicken has one of the smallest MHC 
regions with only 19 functional genes in 92 Kb (Kaufman et al. 1999). 
The MHC locus is very important in the defence of the host against pathogens and 
the human MHC has been associated with more diseases than any other region in the 
genome (Ghodke et al. 2005). Studies have found that genes within the MHC locus 
are statistically associated with autoimmune diseases, e.g. Diabetes type 1 
(Gorodezky et al. 2006), and with susceptibility and resistance to a range of 
infectious diseases, such as human immunodeficiency virus (HIV) (Kaur & Mehra 




1.5 Molecular biology of MHC genes and proteins 
1.5.1 Class I 
1.5.1.1 Genes 
The mouse MHC (H-2) Class I region was the first MHC region to be described, and 
now complete sequences of the whole MHC locus are available for a variety of 
species, including both mouse 
(http://imgt.cines.fr/textes/IMGTrepertoireMHC/Polymorphism/haplotypes/mouse/M
HC/Mu_haplotypes.html) and human (The MHC sequencing consortium 1999). 
In humans the Class I genes have been well defined. There are several loci: the 
polymorphic Class Ia (HLA-A, -B,-C) and the less polymorphic or oligomorphic 
Class Ib (HLA -E, -F and -G). The HLA-B locus is one of the most polymorphic 
within the human genome with 2069 alleles identified to date 
(www.ebi.ac.uk/imgt/hla/stats).   
In humans the HLA-A, B and C loci have 8 exons: exon 1 encodes the leader 
peptide, exons 2 and 3 encode the functionally important α1 and α2 domains, exon 4 
encodes the α3 domain, exon 5 encodes the transmembrane domain, exons 6 and 7 
encode the cytoplasmic tail and exon 8 contributes the last two nucleotides for the C-
terminal amino acid and the 3’ untranslated region (in HLA-B exon 8 is entirely 
untranslated) (Crew 1997).  
1.5.1.2  Molecules 
The classical Class I molecule is a heterodimer consisting of an α chain and a slightly 
polymorphic β2 microglobulin chain (not encoded in the MHC locus) (Figure 1.1).  
 
 5 
These molecules are found on most nucleated cells and act to distinguish between 
‘self’ and ‘non-self’. The α chain is highly polymorphic, with the majority of 
polymorphisms located within the α1 and α2 domains which form the peptide 









Class I Class II
peptide
 
Figure 1.1 MHC Class I and Class II ribbon structure. The green ribbon represents the α chain 
and the yellow ribbon represents the β chain. The blue ribbon represents a peptide which ‘sits’ 
within the binding cleft. (Picture adapted from Stern et al. (1994). 
1.5.1.3  Antigen processing and presentation 
The main function of the Class I molecules is to present bound peptide to CD8+ T 
cells. The peptides presented by Class I molecules are obtained from the cytosol of 
the cell and are derived from either ‘self’ proteins or intracellular pathogens (viruses, 
bacteria, or protozoa). As part of the normal machinery of the cell metabolism, 
proteins that are misfolded or no longer needed are degraded in the cytosol by the 
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proteasome and translocated by the transporter associated with antigen presentation 
(TAP) molecules (Momburg & Tan 2002) to the protein synthesis organelle, the 
endoplasmic reticulum (ER). Intracellular pathogen proteins are also targeted by this 
pathway as any cell can be invaded by a pathogen. The Class I molecules are 
assembled within the ER with the assistance of calnexin, calreticulum and ERP57. 
The MHC Class I molecule in complex with the ER chaperones; calreticulum and 
ERP57 associate with TAP and tapasin to facilitate peptide binding. The Class I 
molecule and peptide are transported to the Golgi apparatus and finally to the surface 
of the cell (reviewed by Cresswell (1994); Pamer & Cresswell 1998). 
Under normal circumstances the MHC Class I molecules present ‘self’ peptides to 
the T cells which are tolerant to these peptides (Heemels & Ploegh 1995). The Class 
I molecules also interact with NK cell receptors. Many intracellular pathogens and 
tumour cells often down regulate MHC Class I molecules to escape the attention of 
CD8+ T cells.  However, an additional layer of defence is provided by NK cells as 
down regulation of MHC Class I may activate NK cells, potentially resulting in the 
destruction of the infected/or tumour cell (Trowsdale 2001).  
Cross-priming of CD8+ T cells by dendritic cells (DC) allows the presentation of 
extracellular proteins (e.g. from tumours) or viruses which do not infect APCs to be 
presented via the Class I pathway, as first described by Bevan (1976).  
1.5.1.4 Peptide binding cleft of Class I molecules 
The peptide binding cleft (PBC) is formed from 2 α-helices and a β-pleated sheet, 
which forms a groove for the peptide to ‘sit’ in (Figure 1.1). The MHC Class I 
molecule forms a complex with a short cytoplasmically derived (8-11 amino acids in 
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length) (Engelhard 1994) for presentation to CD8+ T cells. The peptide is anchored 
by both ends by the pockets that line the peptide binding groove. This results in only 
part of the peptide being exposed to the T cell receptor (TCR). The PBC pockets are 
very polymorphic which allows a wide range of peptide to be bound to the 
molecules.  
1.5.2 MHC Class II 
1.5.2.1 Genes 
The Class II region of the MHC encodes both α and β chains that form the Class II 
heterodimers. In humans, the classical Class II gene pairs are DRA and DRB, DQA 
and DQB, DPA and DPB. There is a high degree of polymorphism within the Class 
II genes. The most polymorphic human Class II gene is HLA-DRB1 with 809 alleles 
so far reported (www.ebi.ac.uk/imgt/hla/stats). The human Class II genes have 6 
exons: exon 1 encodes the leader peptide, exons 2 and 3 encode the extracellular 
domains, exon 4 encodes the transmembrane domain, exon 5 encodes the 
cytoplasmic tail and exon 6 is untranslated.  
1.5.2.2 Molecules 
The α and β chains are integral membrane glycoproteins which are not ubiquitously 
expressed, unlike MHC Class I molecules, but are displayed on the surface of antigen 
presenting cells (APCs), including macrophages, dendritic cells (DC) and B cells 
(Cresswell 1994).  In addition, MHC Class II genes are expressed on other cells in 
response to IFN-γ (Steimle et al. 1994).  The α1 and β1 subunits form the 
polymorphic PBC (Figure 1.1).  
 
 8 
1.5.2.3 Antigen processing 
The function of the Class II molecules is to present bound peptide to CD4+ T cells. 
The peptides which are bound to the Class II heterodimer are primarily derived from 
internalized proteins. The proteins/pathogens are internalized through the process of 
phagocytosis by macrophages, DCs and by Fc-mediated uptake by B cells.  Once 
foreign proteins have been internalized they are degraded through the action of 
enzymes in vesicles called endosomes (Pieters 1997). 
An invariant chain (Ii) prevents premature binding of peptides to the newly 
synthesised Class II molecule in the ER and stabilises the heterodimer. The Class II-
Ii chain complex is transported via a vesicle to fuse with the endosome. The enzymes 
in the endosome cleave the Ii chain leaving a smaller peptide, Class II-associated Ii 
peptide (CLIP) which sits within the peptide binding cleft. The Class-II like molecule 
DM binds to the Class II-CLIP complex which catalyses the release of CLIP and 
allows the binding of the pathogen derived peptide (Weenink & Gautam 1997; 
Jensen 1998). The Class II-peptide complex then is translocated to the cell surface 
















Figure 1.2 Simplified diagram of Class I and II antigen presentation pathways.  
Ii: invariant chain, ER: endoplasmic reticulum, transporter associated with antigen processing 
(TAP): transporter. 
 
1.5.2.4 Peptide binding cleft of Class II molecules 
The structure of the Class II molecule is similar to the Class I molecule, with 2 α 
helices and a β pleated sheet which form the functional PBC. These molecules form a 
complex with exogenous derived peptides of between 12-19 residues in length, 
although peptides of up to 30 amino acids have been reported (Engelhard 1994).  The 
PBC has a number of ‘pockets’ which bind the amino acid side chains of the peptide, 




Figure 1.3 HLA-DR molecules peptide binding pockets labelled 1-9 in a predicted molecular 
surface of peptide binding cleft of HLA-DR4 (Parra-López et al. 2006). 
 
1.5.2.4 MHC Class II antigen presentation  
The MHC Class II molecules present peptide on the cell surface to CD4+ T cells. 
The binding of a peptide to the Class II molecule is dependent on the polymorphisms 
present in the PBC. However, the binding of a peptide to an MHC molecule does not 
necessarily mean that an immune response will be generated as the peptide:MHC 




1.6 T cells 
T cells are part of the adaptive immune response and play major roles in both 
regulation and effector mechanisms of the adaptive immune response which become 
activated upon exposure to antigen in the form of peptide presented on MHC 
molecules. T cells are produced by the thymus where they go through a positive and 
negative selection process to ensure that T cells are tolerant to self-peptides but are 
reactive to foreign peptides (Kappler et al. 1987).  
 MHC Class II molecules present to CD4+ T cells which are also known as T helper 
(Th) cells. T cells are activated through the interaction of TCR-MHC-peptide and co-
stimulatory molecules. Once CD4+ T cells are activated they will go through a clonal 
expansion and assist in the production of humoral immunity through production of 
cytokines and interaction with B lymphocytes. It was once perceived that activated 
Th cells could only be sub-divided into two distinct groups depending on their 
function; either Th1 or Th2 (Mosmann & Coffman, 1989). Th1 cells are involved in 
the activation of macrophages and production of IFN-γ whilst the Th2 cells are 
linked with isotype switching of antibodies and production of IL-4. However, other 
subsets of Th cells have now been described human and mouse, including Th17, 
Treg, Th9, Th22 and TFH which cross-regulate and have involvement in the immune 
response (O’Shea & Paul, 2010).   
1.6.1 T cell receptor 
The activation and expansion of the T lymphocytes is reliant on the recognition of 
antigen bound to MHC molecules. The TCR is either a αβ or γδ heterodimer, with 
the αβ TCR interacting with the MHC molecules. The TCR repertoire is highly 
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diverse which permits the MHC-peptide complexes to interact with a large number 
of TCRs (Valitutti et al. 1995).  In addition, a diverse range of TCRs can recognise a 
single peptide-MHC complex (Garboczi et al. 1999). The specificity of the TCR is 
restricted to a small number (three to five) of the peptide amino acid residues which 
protrude from the peptide-MHC complex (Babbitt et al. 1985). The kinetics of the 
interaction between the peptide and the TCR would suggest that the affinity of the 
binding of TCR and peptide-MHC has an impact on the diversity of the clonal 
expansion of T cells (Baumgartner et al. 2009). The high levels of polymorphism 
seen within the MHC along with the highly diverse repertoire of the TCR results in 
an increased possibility that a pathogen will stimulate an adaptive immune response. 
1.7 MHC polymorphisms and heterozygote advantage 
The genes of the MHC Class I and Class II regions are highly polymorphic and this 
can be linked to their function. A widely held explanation for the extreme level of 
diversity observed within the MHC locus is that it is driven by pathogens. A MHC 
molecule that will bind many peptides at differing affinities would allow the host to 
maintain its effectiveness against fast evolving pathogens. Therefore a selective 
advantage would exist for those individuals that carry the widest possible variety of 
MHC alleles, and the majority of individuals are heterozygous at the MHC loci 
(Jeffery & Bangham 2000). This is sometimes referred to as “heterozygote 
advantage”. The main school of thought is that the polymorphism is maintained 
through balancing selection as a consequence of host–pathogen interactions (Jeffery 
& Bangham 2000; Woelfing et al. 2009). However there are other theories, including 
rare allele advantage, whereby an allele which is at a low frequency within a 
population may confer an advantage if a new pathogen is introduced. If the new 
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pathogen is particularly virulent then it can exert a strong selective pressure and the 
rare allele would become more frequent (Jeffery & Bangham 2000). 
The polymorphisms observed in the MHC molecules are primarily located in the 
PBC. The PBC determines whether a peptide binds and will have an impact on the 
resultant T cell response. The diversity seen in the PBC is thought to be maintained 
by several mechanisms, including mating preferences (Woelfing et al. 2009). There 
is no conclusive theory of how diversity is maintained within the MHC region, but it 
is likely that combinations of these mechanisms are at play in most species.  
1.8 Cattle and disease resistance 
Cattle are very economically important and they have been domesticated and used by 
humans for centuries for milk and beef production. Therefore the management and 
prevention of infectious disease is essential. To a certain extent infectious disease can 
be controlled by clean management practices, however these do not prevent all 
outbreaks of disease.  The growing numbers of antibiotic resistant pathogens together 
with the unpopularity of modern pharmaceuticals are directing research to other 
methods of disease control. Understanding the genetic mechanisms involved in the 
immune response would help with the management of the infectious disease by 
providing avenues for improvement in vaccine design as well as implementing 
breeding programs for disease resistance.  
The use of cattle in the study of disease resistance has been limited due to the costs 
and logistics involved. Cattle studies have mainly focussed on collecting field data, 
which is subject to other confounding factors. However, with ever improving 
technologies it became easier to search in an unbiased way for candidate genes using 
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whole genome scans, for example by using microsatellite markers in linkage studies 
such as the quantitative trait loci (QTL) study on trypanotolerance (Hanotte et al. 
2003).  More recently with the advent of dense single nucleotide polymorphism 
(SNP) markers, loci associated with resistance can be mapped more confidently, and 
a study is underway at the Roslin Institute on the genetics of tuberculosis resistance 
in cattle using 700,000 SNP markers (Allen et al. 2010). These studies have the 
potential to highlight possible important genes for further investigation. Nonetheless, 
as in the human and mouse studies, the cattle MHC genes remain likely candidates to 
affect the outcome of infectious disease.  
1.9 Vaccination 
Vaccination is a practice of priming the immune system to protect an individual 
against infectious pathogens. It is considered one of the most effective methods of 
preventing infection. The majority of vaccines usually consist of either killed or 
inactivated forms of a pathogen, and will therefore contain immunogenic proteins, 
which have the ability to stimulate the adaptive immune response. There is however 
substantial problems with current veterinary vaccines in that they are expensive, 
require the use of adjuvants, often require multiple inoculations, and provide little or 
no protection to neonates due to the presence of maternal antibodies (reviewed by 
Shams (2005)). There are also a number of infectious disease to which there are no 
vaccines available e.g. Mycobacteria. Another problem within veterinary 
vaccinology is being able to differentiate between those animals with an infection 
and those which have been vaccinated (DIVA) (Van Oirschot 1999). In the case of 
foot-and-mouth disease virus (FMDV) it is important for trade to be able to 
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differentiate animals which have been vaccinated and those that have been exposed 
to the virus (further discussed in Chapter 3).  
An ideal vaccine is one in which all animals are protected with few inoculations at a 
low cost to the industry. In the livestock industry there are a limited number of 
commercially available vaccines and so it has become necessary to research 
alternative vaccination protocols, one such avenue for research is using subunit or 
synthetic vaccines. There are examples of successful use of synthetic subunit vaccine 
in animals e.g. canine parvovirus (Langeveld et al. 1994) and mink enteritis virus 
(Langeveld et al. 1995). The advantages of a subunit or synthetic vaccines would be 
that they are safer and allow for DIVA in those animals which have been vaccinated, 
however a considerable problem is the variation in immune response to these 
vaccines. As a peptide would be required to be presented by MHC molecules to 
provoke an immune response, it is likely that the polymorphism with in the PBC will 
in part determine the efficacy of a vaccine.  
1.10 Bovine MHC 
In Bos taurus and B. indicus the genomic region which harbours the MHC locus 
maps to chromosome 23 and is collectively named the bovine leukocyte antigen 
(BoLA) locus. The cattle MHC region has a few interesting attributes including a 
variable Class I haplotypes and duplicated DQ genes. A number of reviews have 
been published  which have illustrated the complexity of the bovine MHC with high 
levels of polymorphism and gene duplication (Ellis & Ballingall 1999; Lewin, 
Russell, & Glass 1999; Ellis 2004; Takeshima & Aida 2006).  
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1.11 Mapping of the BoLA region 
As with many known MHC regions, the cattle BoLA genes are a group of physically 
linked gene families. The use of radiation hybrid mapping has helped to elicit 
information on the gene arrangement of the bovine MHC (Band et al. 1998). The 
bovine MHC Class II went through a large inversion event resulting in two separated 
regions, designated Class IIa and Class IIb, which are approximately ~2.5 Mb apart, 
with the Class IIb region closer to the centromere (Childers et al. 2006). This region 
contains 20 genes, including BoLA-DYA, DYB, DOA, DOB, DMB, DMA and 2 
TAP genes, and is indicative of a single inversion event (Childers et al. 2006). 
The entire bovine genome has now been sequenced to a 7.1X coverage (The Bovine 
Genome Sequencing and Analysis Consortium et al. 2009). The BoLA region was 
included in a community-led effort to annotate the genes in the new assembly. There 
are predicted to be 154 coding genes (from the genome annotation project) within the 
BoLA region (~2.5 Mb) which encompasses all 3 MHC classes (personal 
communication L. Skow). The animals (Domino and Dominette) which were used 
for the generation of the bovine genome were considered to be homozygous at all 
loci. However, in the MHC region this proved not to be the case and led to 
difficulties in assembly and annotation. For example, in the sequence annotation 3 
separate loci were identified for DQA, but previous research on a number of different 
breeds has suggested that there is a maximum of 2 loci for DQA per haplotype 
(Andersson & Rask 1988; Russell et al. 1997b). The extra locus is most likely due to 
the animals being heterozygous for one of the DQA genes and the difficulties in an 
automated system has in arranging sequences of high similarity in complex regions 
such as the BoLA region.  
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However, using the bovine genome sequence information (The Bovine Genome 
Sequencing and Analysis Consortium, et al. 2009) together with the Basic Local 
Alignment Search Tool (BLAST), it proved possible to ‘build’ a more detailed map 
of the BoLA region (Figure 1.4). This figure has been generated using human MHC 
mRNA sequences (Appendix A.1) listed at 
http://www.sanger.ac.uk/HGP/Chr6/current_MHC_gene_list.shtml and identifying 
bovine equivalents (http://www.ncbi.nlm.nih.gov/gene) (with assistance from Dr. Jan 
Aerts (formerly The Roslin Institute). Those human mRNA sequences which had a 
bovine equivalent located on BTA23 were taken forward to generate the in silico 
map (n=146) (Appendix A.1) (Figure 1.4). The map is annotated with the human 
mRNA sequences which were originally used to create the figure.  
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Figure 1.4 In silico Map of BoLA Class IIa, III and I regions. The map was generated and annotated using BLAST of human mRNA MHC sequences on the 
bovine genome with an e-value cut off at -50. The arrows indicate the direction of the genes. The Class IIb region is not represented on this map. 
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The MHC Class IIb region is not included as full sequence was already available 
(Childers et al. 2006). Originally the map was intended to be used to locate SNPs 
across the BoLA region in the hope of generating a SNP-based typing method for the 
whole BoLA region.  However, there are limitations to the building of an in silico 
map in that the accuracy is affected by the stringency of the BLAST threshold, which 
therefore affects the positioning of the genes, especially in a region where there are 
high levels of duplication. The quality of the genome sequence and the assembly 
information also has an effect on the ability to accurately assign gene positions. This 
map broadly shows the orientation of the Class I, II and III genes, and also highlights 
the gaps (no sequence data) in the genome sequence (denoted by the extra long 
genes). As it was primarily human genes which were used to generate the map, it is 
possible to notice differences, as the bovine genome lacks some of the human genes. 
For example, in human there are Class II DPA and DPB genes. However on the 
generated map the DPA maps to the DRA locus indicating high homology.  
It was possible with some degree of confidence to locate 75 genes on the in silico 
map of the bovine MHC region, which is 79 genes less than the predicted genes 
(although 20 will map to the Class IIb region). The in silico map has ‘hits’ for the 
HLA Class I genes which are all located at similar positions. As the exact position of 
the BoLA Class I genes are unknown it would be unlikely that this positioning is 
correct.  
This map only gives a broad representation of the BoLA region and more detailed 
analysis of the gene sequences would be better. Nonetheless this map covers 1.8 Mb 
of the bovine genome (BoLA ~2.5 Mb), with the most gene dense region being the 
Class III, and the Class I region showing a lower level density. However, there are 
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still problems with the genome assembly across the BoLA region and caution should 
be advised due to potential inaccuracies (Brinkmeyer-Langford et al. 2009).  
1.12 BoLA Class I  
The BoLA Class I genes are highly polymorphic and a number of haplotypes have 
shown associations with immune responsiveness (Longeri et al. 1993; Aarestrup, 
Jensen & Ostergard 1995).  The organisation of the Class I region of the bovine 
MHC is more complicated and less well understood than that of the MHC II genes. 
The total number of Class I loci in the cattle MHC is estimated to be 20, but this can 
vary between haplotypes (Holmes et al. 2003). However, evidence indicates that 
there are only six functional classical MHC Class I loci and the rest are probably 
pseudogenes.  In addition, it appears that of these independent loci, a maximum of 3 
genes are expressed per haplotype (Ellis 2004). The complexity of the cattle MHC 
Class I region is likely due to interlocus recombination and this has assisted in 
increasing the diversity amongst the alleles (Holmes et al. 2003). It is estimated that 
the number of alleles within the BoLA Class I region is high, but due to the 
complexity within the region few studies have been undertaken to type all of the 
alleles (Babiuk et al. 2007).  
The original typing of these molecules used serology with alloantisera (generated 
from multiparous cattle), and a single A-locus for the Class I molecules was 
designated (Bernoco et al. 1991), but later techniques demonstrated that this was not 
accurate, as there is in fact more than 1 locus (Joosten et al. 1992; Ellis et al. 2005). 
The Class I region has six separate loci but it is still unknown which alleles map to 
which loci (Birch et al. 2006). There are three polymorphic Class I genes which 
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appear to be expressed only in certain combinations, with gene 2 being expressed on 
nearly all the known haplotypes (Birch et al. 2006).  
As the Class I molecules present intracellular peptides to CD8+ T cells and interact 
with NK cells, it is highly likely that the polymorphisms in the Class I genes will 
have an influence on the immune response, especially to viral infections 
(Childerstone et al. 1999; Guzman et al. 2008). However, the number of association 
studies has been limited due to the unknown haplotype structure. Nevertheless 62 
alleles have been identified (http://www.ebi.ac.uk/ipd/mhc/bola/) and associations 
have been found between Class I serotypes and disease, e.g. mastitis and 
Mycobacterium bovis (Longeri et al. 1993; Aarestrup, Jensen, & Ostergard 1995), 
although it is unclear whether this is because of linkage to BoLA Class II genes.  
The gene structure of the BoLA Class I region has not been fully described (Ellis et 
al. 2005), and has not been annotated on the genome sequence (The Bovine Genome 
Sequencing and Analysis Consortium et al. 2009). However, the location of three of 
the Class I genes has been described using a BAC contigs (Di Palma et al. 2002).  
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1.13 BoLA Class II 
The classical BoLA Class II molecules are expressed on APCs. There has been 
considerable research into the Class II genes and their polymorphisms and this 
indicates that they play a vital role in disease resistance and susceptibility in cattle. In 
cattle, DR and DQ are the principal MHC Class II glycoproteins which are 
expressed. Cattle do not have DP genes, unlike the human MHC region. The genes 
that code for these proteins are BoLA-DRA, DRB3 and BoLA-DQA and DQB3 (Ellis 
& Ballingall 1999).  
1.13.1  BoLA DR 
The DR Class II molecule is a heterodimer consisting of the monomorphic α chain 
DRA and the highly polymorphic β chain DRB (Figure 1.5). Of the three DRB genes 
present in the cattle genome, it appears that only the DRB3 gene is functionally 
expressed.  
DRB3 has six exons. Exon 2 encodes for the PBC and is highly polymorphic (Russell 
et al. 1997a). The sequencing of DRB3 exon 2 has revealed 106 different alleles to 
date (http://www.ebi.ac.uk/ipd/mhc/bola/), with many studies illustrating that the 
polymorphisms present are significantly associated with the immune response (Dietz 
et al. 1997; Sharif, Mallard & Sargeant 2000; Sharif, Mallard, & Wilkie 2003; 
Ballingall et al. 2004; Baxter et al. 2009). Whilst as yet there are no studies 
demonstrating that the polymorphisms present within the PBC directly affect the 







Figure 1.5 3D ribbon structure of a bovine DR molecule. The α- helixes and the β-pleated sheet 
form the peptide binding cleft. This is where the peptide ‘sits’ for presentation to T cells. Figure 
generated from modelling the bovine allele DRB3*1601 amino acid sequence onto the human 
HLA DRB*0101 crystal structure (details of bioinformatic 3D modelling in Chapter 3). 
1.13.2 BoLA DQ 
The MHC Class II DQ genes encode a heterodimer consisting of an α chain: DQA 
and a β chain: DQB.  Unlike the DR genes, both are polymorphic. In humans the DQ 
genes have been associated with autoimmune disease however, no such associations 
have been noted in cattle. To date 46 DQA and 52 DQB alleles have been identified 
(http://www.ebi.ac.uk/ipd/mhc/bola/). This region has a further layer of complexity 
unique to cattle, as in approximately half of the known haplotypes the DQ genes are 
duplicated (Andersson & Rask 1988; Ballingall, Luyai & Mckeever 1997; Ellis & 
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Ballingall 1999) and when the genes are duplicated they are expressed (Xu, Park, & 
Lewin 1994). This has led to difficulties in accurately typing the alleles at the loci. 
Moreover it has meant that research on polymorphisms in the DQ genes has been 
limited, especially when compared to DRB3. Little is known about how BoLA DQ 
polymorphisms in the PBC influence the immune response to pathogens.  
From the limited research available, an interesting association is, that animals with 
DQB*1804 are susceptible to bovine dermatophilosis (Maillard et al. 2003). 
However, as this DQ allele was linked to a DRB3 haplotype (DQB*1804-
DRB3.2*09/*45), it was unclear if disease was linked to the effects of DQ or DR 
polymorphisms. Recently DQA heterozygosity has been associated with resistance to 
mastitis (Takeshima et al. 2008), although again it may be linkage to resistant DRB3 
alleles which accounts for this. However, it is likely that these genes may be 
important in variation in immune responses to infectious pathogens, as their gene 
products present peptide to T cells  (Glass, Oliver, & Russell 2000; Norimine & 
Brown 2005). 
The DQ molecules may increase the repertoire of peptides that can be presented to T 
cells through the phenomena of inter- and intra-haplotype pairings, as the α and β 
chains from either chromosome, and in the case of duplicated haplotypes from either 
locus, can form functional DQ molecules (Glass, Oliver, & Russell 2000; Norimine 
& Brown 2005). 
1.13.2.1 DQA 
It has been hypothesised that the DQA genes can be split into 5 different loci, DQA1-
5, with a maximum of two loci per haplotype (Ballingall, Luyai, & Mckeever 1997; 
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Gelhaus et al. 1999). The DQA loci have not been fully described due to differences 
between breeds and haplotype structure. It is thought that the DQA haplotype 
structure consists of either a single DQA gene, or DQA1 and DQA2, or DQA2 and 










Figure 1.6 DQA haplotype structure. Adapted from Ellis & Ballingall (1999).  
1.13.2.2 DQB 
The DQB genes can be subdivided into several loci, DQB1-5, although only a 
maximum of two DQB genes are found per haplotype (Nasir et al. 1997; Wang et al. 
2005). All DQB1-5 are thought to be polymorphic (Davies et al. 1997; Takeshima & 
Aida 2006) and can be duplicated as seen with the DQA. Having duplicated DQA 
genes does not necessarily result in duplicated DQB genes (Lewin, Russell, & Glass 
1999). DQB3-5 loci have only been reported in Bos indicus breeds of cattle.   
Little to no research has been reported on the DQB alleles or loci and there is only a 
single study showing a DQB allele association with disease (bovine dermatophilosis) 




1.14 Binding pockets 
Detailed analysis of both human and murine Class II molecules has revealed that the  
peptide-binding affinity of specific DR alleles, and therefore presentation to T cells, 
is dependent on the interactions between peptide side chains and ‘pockets’ within the 
PBC (Stern et al. 1994; De Groot et al. 2003; Zavala-Ruiz et al. 2004). Several 
pockets have been identified in the human DR molecule along the PBC (1-9) (Figure 
1.3), with pockets 1, 4, 6, 7, 9 and potential pocket 10 each showing high levels of 
polymorphism (Brown et al. 1993; Zavala-Ruiz et al. 2004).  Specific positions and 
motifs along the PBC in both human (Zerva et al. 1996) and cattle DR (Sharif, 
Mallard, & Sargeant 2000) molecules have significant association with the immune 
response to pathogens. The specific polymorphic positions within the PBC have a 
wide variety of amino acids (Table 1.1). In human HLA-DR molecules, pocket 4 is 
important for the binding of peptides over and above all the other pockets (Fu et al. 
1995).  
The DQ molecules have specific binding pockets and again there is high homology 
between HLA-DQ and BoLA-DQ, although, due to the complexity of the DQ region 
in cattle, little research has been carried out.  
The BoLA-DR molecule has a high degree of homology to HLA-DR and so it is 
possible to define pockets similar to those found in the human molecules. The 
identified possible amino acids (using all known DRB3 allele sequences) within each 
pocket are detailed in Table 1.1. Studies have indicated that pocket 4 is important in 
the binding of peptides in the BoLA DR molecule (Zerva et al. 1996; Sharif, Mallard, 
 
 27 
& Sargeant 2000). Motifs have been identified within pocket 4 which have either a 
beneficial or detrimental association with the immune response to different 
pathogens and vaccine responses. Motifs which have been identified include a lysine 
deletion at position 65 (Kβ65) (Sitte et al. 2002), which changes the properties of 
pocket 4, glutamic acid and arginine (E-R) motif at position β70-71 (Xu et al. 1993, 
Baxter et al. 2009), glutamic acid (E) at position β70 (Sharif, Mallard, & Sargeant 
2000) and a glutamic acid, isoleucine, alanine and tyrosine (EIAY) motif at positions 
β66/67/74/78 (Maillard, Martinez, & Bensaid 1996). 
Other binding pockets in human DR molecules (pockets 1, 6, 7, 9 and 10) are also 
important (Zavala-Ruiz et al. 2004; Cardenas et al. 2005; Bondinas, Moustakas & 
Papadopoulos 2007) and also likely to play a role in peptide binding in BoLA Class 




Pocket Position Amino acid  



















10 56 P,Q,R 
Table 1.1 Identified polymorphic pockets and amino acid residues at each position in all known 
BoLA-DRB3 alleles. A: arginine; C: cysteine; D: aspartic acid; E: glutamic acid; F: 
phenylalanine, G: glycine; H: histidine; I: isoleucine; K: lysine; L: leucine; M: methionine; N: 
asparagine P: proline; Q: glutamine; R: arginine; S: serine; T: threonine; V: valine; W: 




1.15 BoLA and infectious disease 
The BoLA genes have been associated with many diseases (Table 1.2). In addition, 
quantitative trait loci (QTL) studies have indicated that some genes influencing 
infectious disease outcome lie on bovine chromosome 23, suggesting that the BoLA 
region  may be involved (Klungland et al. 2001). The alleles of the BoLA-DRB3 and 
DQ genes have been linked to either resistance or susceptibility to viral and bacterial 
infections. Modern genotyping methods have allowed the alleles and the binding 
pockets of DRB3 to be studied in more detail and associations with response to 
pathogens have been revealed (Sharif, Mallard, & Sargeant 2000; Baxter et al. 2009).  
The BoLA genes clearly have significant associations with disease/vaccine 
responses, and they are highly polymorphic. A possible avenue for the manipulation 
of the genetic merits of the BoLA genes could be through the use of selective 
breeding and has been used successfully for bovine dermatophilosis (Maillard et al. 
2003). However, modern cattle breeding in the developed world relies on using a few 
sires which are considered optimal for production traits. This then limits the diversity 
seen in the BoLA alleles in the resulting offspring, which possibly may be 
detrimental on a herd-wide basis.  Nonetheless breeding programs can be used to 
manipulate the BoLA allele frequencies and thus potentially affect the pathogen or 
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Sitte et al. 2002 
1 BoLA DRB3 alleles shown as RFLP nomenclature; 2 the IPD (immuno polymorphism 
database) nomenclature (http://www.ebi.ac.uk/ipd/mhc/bola/nomen_rules.html) 
 
Table 1.2 BoLA DRB3 alleles associated with resistance or susceptibility to disease, and with 
vaccine responses. 
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1.15.1 BoLA associations with vaccine response 
Vaccines harness the adaptive immune system’s ‘memory’ mechanism to protect 
against a variety of pathogens. Traditionally, vaccines are live-attenuated or 
inactivated pathogens. However, more recently there has been a move towards new, 
safer and cheaper synthetic vaccines. Animal to animal variation may be a significant 
obstacle against the use of these new sub-unit/synthetic vaccines (Sitte et al. 2002).  
Although potentially effective in the majority of individuals, vaccines may not elicit 
an effective immune response in all animals (Ellis 2004; Glass 2004). The main 
difficulty with synthetic vaccines is that they are generally comprised of fewer T-cell 
epitopes then whole virus pathogens.  Therefore it is important that the vaccine-
derived peptides are designed to bind to the greatest number of MHC molecules for 
presentation.  Each animal has a different set of MHC alleles and consequently 
synthetic vaccines need to be designed to allow for this variation. A synthetic 
vaccine which is not compatible with all BoLA types in the herd could result in a 
lower response compared to that induced by conventional vaccines (Court et al. 
1998). This would leave animals within the herd, which did not respond to 
vaccination, susceptible to infection.  
Currently there is on-going research into improving vaccines, especially in humans 
(reviewed by Berzofsky, Ahlers & Belyakov (2001)). One possible way to improve a 
vaccine is to increase the number of possible peptides which can bind to the MHC 
alleles. Distinct amino acid sequences in the PBC which permit the binding of 
specific peptides have been identified using a variety of algorithms that predict 
human T-cell epitopes in vaccine design (Nielsen et al. 2008).  
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The same methodology could be implemented in the design of livestock vaccines. 
This would be especially beneficial to combat infections where the current 
vaccination protocols are far from ideal, e.g. foot and mouth disease (Chapter 3). 
Since the complete genome sequence of many pathogens, including many of 
importance for livestock such as cattle, are now available, in theory it would be 
possible to use binding motifs of the BoLA DR molecules to find the most likely 
important epitopes, thus facilitating design of specific peptide vaccines.   The most 
relevant polymorphisms in the BoLA DR molecules are likely to be those in the 
binding pockets, although only five of the ten pockets seem to be significant for 
differences in peptide binding, at least in the limited studies to date (Sharif, Mallard, 
& Sargeant 2000; Baxter et al. 2009; Yoshida et al. 2009). The advances in in silico 
tools mean that the design of vaccines could be tailored to the PBC and therefore  
knowing the amino acid sequence of the PBC becomes extremely important (De 
Groot et al. 2001). Research with pattern-matching programs have shown some 
success in predicting epitopes for MHC Class I and MHC Class II restricted T cells 
in cattle (Vordermeier, Whelan, & Hewinson 2003). However, currently there is a 
lack of information on binding motifs in cattle and so these techniques are 
possibilities for the future. 
1.16 Aims of PhD project 
The overall aim of this project was to investigate the role that the MHC genes have 
on immune responsiveness in a cattle cross Holstein-Charolais population, set up at 
the Roslin Institute (RoBoGen). The MHC genes are good candidates for influencing 
the outcome of disease and vaccination due to their integral role in the adaptive 
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immune response. Prior to the start of this project the RoBoGen animals were 
immunised with a foot-and-mouth disease virus peptide and two respiratory vaccines, 
and several immune phenotypes were measured in the herd. These included the 
antibody response to the two commercial vaccines (Rispoval against bovine 
respiratory syncytial virus and Imunresp against para- influenza 3 and bovine herpes 
virus-1), the peripheral blood mononuclear cell (PMBC) proliferative response to 
Staphylococcus aureus and phytohaemagglutinin (PHA), and the IgG1, IgG2, T cell 
proliferative and IFN-γ responses to a foot-and-mouth disease virus peptide 
(FMDV15) and Concanavalin A (ConA).  
Aims: 
• The optimisation and utilisation of typing techniques for the BoLA Class II 
genes (Chapters 2 and 5) 
• Identification of the polymorphisms present in BoLA-DRB3 (chapter 2) 
• Investigation of the associations between the alleles of the BoLA-DRB3 gene 
and measured immune phenotypes (Chapters 3 and 4) 
• Investigation of the associations between the pocket polymorphisms and 
measured immune phenotypes (Chapters 3 and 4) 
1.17 Hypothesis 
The genes and polymorphisms present at the BoLA loci will have an association with 
the immune responses measured in the Holstein-Charolais cattle population.  
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2 Sequence-based typing method for BoLA-DRB3 
2.1 Introduction 
The classical major histocompatibility complex (MHC) Class II genes are highly 
polymorphic and important in the defence against many pathogens. They have been 
associated with infectious disease in many host species.  Therefore these genes are of 
interest when studying immune responsiveness. In cattle the BoLA-DRB3 gene has 
been linked to a number of immune traits and thus is an ideal candidate for 
investigating the role of the MHC genes within the context of this project. BoLA-
DRB3 is highly polymorphic and so a sequence-based typing technique was refined 
and implemented to type the RoBoGen herd. 
2.1.1 Background 
Human medicine has long been at the forefront of advancements in major 
histocompatibility complex (MHC) typing techniques. This is mainly due to the 
requirement for near exact human leukocyte antigen (HLA) type matches for 
successful organ/bone marrow transplantation. HLA typing procedures have evolved 
from the early sera-based techniques to the present day DNA-based methods. The 
advent of the polymerase chain reaction (PCR) technique has permitted allelic 
differences in HLA genes to be distinguished with a high degree of accuracy, thus 
enabling the identification of over 3000 alleles present for some of the HLA loci, such 
as HLA-B and HLA-DRB1 (Erlich, Opelz & Hansen 2001). As well as the practical 
immediate use for HLA typing there has, in addition, been a sustained focus looking 
for associations between polymorphisms in the HLA genes and disease outcome, for 
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example with human immunodeficiency virus (HIV) (Kaur & Mehra 2009) and with 
leprosy (Cooke & Hill 2001).  
Sequence-based typing (SBT) has many advantages over previous techniques, 
including the ability to investigate single nucleotide polymorphisms (SNPs) as the 
entire DNA sequence is identified. Having the DNA sequence permits the 
investigation of the effect of SNPs on the protein structure of the MHC molecules as 
well as providing the opportunity to discover new alleles.  
In the livestock industry there is also a desire to investigate the role of the MHC genes 
and their polymorphisms in disease outcome, due to the impact that infectious 
diseases have on both animal welfare and economics (Glass 2004). In order to 
investigate these associations, it is first necessary to know the variation present within 
these genes. International BoLA workshops have worked towards providing more 
information on the variability of the bovine MHC Class I and II genes and molecules 
(Davies et al. 1994; Davies et al. 1997). Throughout these workshops a number of 
typing methods were employed: serology (Davies et al. 1994), 1-dimensional 
isoelectric focusing (Joosten et al. 1992), restriction fragment length polymorphism 
(RFLP) (Sigurdardottir et al. 1992) and various PCR techniques (Van Eijk, 
Stewarthaynes & Lewin 1992). A comparison of the different typing methods was 
reported in the 5th BoLA annual report (Davies et al. 1994). From this international 
effort it was concluded that it was difficult to use serology and 1-dimensional 
isoelectric focusing for molecules coded by the Class I region to define the number of 
alleles, as the antisera recognise more than one gene product.  
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In addition, the workshops identified many Class II alleles; 63 DRB3, 31 DQA and 26 
DQB alleles within the Class IIa region which was mainly achieved though the use of 
RFLP using human probes. Since then, numerous studies have focused on the typing 
of a single BoLA Class II gene, DRB3  (Glass 2004). It has become clear that BoLA 
DRB3 is highly polymorphic, with the majority of these polymorphisms located in 
exon 2 which encodes the peptide PBC of the Class II molecule. To date 106 alleles 
have been defined for exon 2, using a variety of methods which have gradually 
improved the resolution of alleles as technology has progressed 
(http://www.ebi.ac.uk/ipd/mhc/bola). With such a high degree of polymorphism, 
sequencing of exon 2 is clearly the best way to discriminate between alleles. A 
historical summary of the various methods for typing is provided below which sets the 
context for this chapter on sequence-based typing for BoLA DRB3. The following 
work detailed in this chapter has been published (Baxter et al. 2008). 
2.1.2 DRB3 and exon 2 
MHC Class II molecules present peptides derived from extracellular sources (e.g. 
from bacteria) on antigen presenting cells to CD4+ T cells. These peptides are 
approximately 15-24 amino acids in length and bind to the PBC of the DR or DQ 
molecule. Exon 2 of the DRB3 encodes the polymorphisms which affect binding of 
peptides.  
The polymorphisms in the PBC are functionally important as they determine the 
binding affinity for peptides and thus potentially influence the T cell response to 
pathogens. In cattle, the DR molecule is a heterodimer formed from a beta chain 
(DRB3) and a monomorphic alpha chain (DRA). Significant associations have been 
found between the polymorphisms in the cattle DRB3 gene and immune 
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responsiveness to infectious disease, e.g. mastitis and foot-and-mouth disease virus 
(Maillard, Martinez, & Bensaid 1996; Sharif et al. 1999; Garcia-Briones et al. 2000; 
Glass 2004). The DRB3 gene is located within the MHC region on BTA23. The gene 
contains 6 exons with the second exon coding for the functionally important PBC 
(Figure 2.1).  
 





Figure 2.1 Basic DRB3 gene structure showing 6 exons and the number of base pairs 
 
Due to the high number of polymorphisms within BoLA DRB3 exon 2, it has been 
difficult to establish a genotyping approach to define all the functionally relevant 
allelic variations. Many of the techniques mentioned above were used to report new 
allelic variants in the various BoLA workshops. However, none of these techniques 
lend themselves to genotyping large numbers of animals which is generally a pre-
requisite for studies investigating associations of gene variants with complex 
phenotypic traits, such as immune responsiveness or disease resistance. Sequencing, 
on the other hand, gives reliable and consistent results and enables a thorough 
examination of all the alleles and more importantly all the polymorphisms within the 
PBC. This then enables an in-depth examination of how polymorphisms result in 
conformational changes in the PBC, which would have an affect on peptide binding 
affinity.  
   
 38 
2.1.3 Typing techniques: Class II in cattle 
 
As the PBC coded for by DRB3 exon 2 is considered to be important in immune 
responsiveness, there have been many methods used to investigate the 
polymorphisms, either at the DNA or protein level. More recently, technological 
advancements have enabled the DNA sequence to be determined.  
2.1.3.1  Serology 
 
Serology was one of the original methods of typing MHC both in humans and in 
cattle. However, in cattle it proved difficult to produce serological reagents through 
alloimmunisation; as due to the close linkage across the MHC region the allosera 
produced were multispecific. Despite this, several laboratories matched for Class I 
and then conducted alloimmunisation. The results were reported at the 4th and 5th 
BoLA workshops (Bernoco et al 1991; Davies et al. 1994). From this work, five 
defined Class II specificities were accepted by the bovine research community (Dw 
designation) and eight others had enough evidence to be designated as clusters (Dc 
designation) (Davies et al. 1994). However, with the advent of PCR methods, 
serology has largely become redundant and the classifications have since been 
superseded with the sequence-based nomenclature (Davies et al. 1997). 
2.1.3.2  Isoelectric focusing 
 
A previous method used to identify DRB3 types was isoelectric focusing. This method 
showed the Class II polymorphism at the protein level by isoelectric focusing of 
immunoprecipitated Class II antigens (Joosten et al. 1990; Glass et al. 1992). This 
technique involves the separation of molecules based on their electric charge on a gel. 
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However, this method seriously underestimates the polymorphisms present at the gene 
level, as only 12 variants were accepted by the international community (Davies et al. 
1994). Nonetheless the ID-IEF method distinguished DRB3 alleles that are 
functionally distinct (Glass, Oliver, & Spooner 1991; Glass et al. 1992).   
2.1.3.3  Restriction Fragment Length Polymorphism (RFLP) 
 
PCR-RFLP analysis involves the restriction endonuclease digestion of PCR products. 
Restriction endonucleases are enzymes which cut DNA at specific nucleotide 
recognition sites. PCR amplification of a 284 base pair region for all of exon 2, 
followed by enzyme digestion with RsaI (cut-site), BstYI (cut-site) and HaeIII (cut-
site) identified 54 separate DRB3 alleles (Van Eijk, Stewarthaynes, & Lewin 1992). 
This technique has also been used to type other BoLA genes, e.g. DQA with 13 
DQA1, 5 DQA2 and 7 DQA3 alleles (Ballingall, Luyai, & Mckeever 1997) and DQB 
with 10 DQB1 and 4 DQB2 alleles (Sigurdardottir et al. 1992). However, although 
many DRB3 alleles were discernable using this technique, it has limitations as the 
number of detectable alleles is dependent on the presence of suitable enzyme 
restriction sites and the resolution of fragments by gel electrophoresis.  
2.1.3.4  PCR single-strand conformation polymorphism 
(PCR-SSCP) 
PCR-SSCP involves labelled and amplified PCR product which is denatured and 
resolved by polyacrylamide gel electrophoresis (PAGE).  Mutations are detected as 
altered mobility of separated single strands in the autoradiogram. This method does 
allow for in depth analysis of MHC genes but has some limitations. For example, the 
time that it takes to optimise the conditions and the skill required for interpreting the 
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results reduces efficiency of typing (Hauser 2004). Nevertheless this technique has 
been used for typing bovine, ovine and equine MHC Class II alleles (Kostia et al. 
1998; Pipalia et al. 2004; Diaz et al. 2008).  
2.1.3.5  Typing microarray  
Another method of typing at the BoLA DRB3 locus has been reported that involved a 
microarray-based approach. The typing microarray consisted of 15-22 bp 
oligonucleotide probes spotted onto a Teflon masked glass slide. Using biotinylated 
primers, exon 2 was amplified using a PCR reaction, and the product hybridised to the 
probes (Park et al. 2004). The method identifies DRB3 alleles, but cannot detect novel 
sequences and lacks the resolution to clearly distinguish between alleles with high 
similarity. In chapter 5 the microarray technique is discussed further.   
2.1.3.6  Sequence-based typing 
Sequencing of PCR products of exon 2 allows the identification of all known alleles 
as well as the potential discovery of unknown sequences. The first sequence-based 
typing (SBT) method for BoLA Class II genes was reported by Takeshima et al. 
(2001).  They used a sequence-specific amplification of eight separate polymorphic 
groups, which provided sequence information on exon 2 of DRB3. This technique was 
complicated by the requirement for eight separate PCR reactions. A second simpler 
technique was reported, which involved nested PCRs to amplify the whole of exon 2 
which therefore allowed the amplification of all known and unknown alleles 
(Miltiadou, 2001). One major drawback of this technique was that it involved gel-
based sequencing which was time consuming, and only a maximum of 8 samples 
could be processed per day.  Furthermore, the method required the manual 
identification of bases, which can introduce errors and is subjective. A new method of 
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sequencing is pyrosequencing, which involves the detection of released 
pyrophosphate (PPi) during DNA synthesis. This has been used for the detection of 
equine DRA alleles (Diaz et al. 2008), and has high resolution and so is able to 
identify many alleles. 
2.2 Aim 
To develop a fast, reliable and accurate method of typing at the DRB3 locus in a cross 
population of Holstein- Friesian and Charolais cattle.  
2.3 Materials and methods 
2.3.1 Animals 
The population was a 2nd generation herd Holstein-Charolais cross.  The herd was 
bred from four pure-bred Charolais sires and eight F1 Charolais-Holstein sires. The 12 
sires were used to produce a second generation cross composed of inter-crossed (F1 x 
F1 n=292), and backcross (Charolais x F1 n=79 and Holstein x F1 n=92) animals, 
giving a total of 463 animals that were included in this study. The herd was 
established as an experimental population to investigate quantitative trait loci (QTL) 
associated with commercially relevant production traits. The animals were born and 
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Figure 2.2 RoBoGen breeding and herd structure. F0, F1 and F2 represent the founding animals, 
the first generation animals and the second generation animals respectively. 
2.3.2 DNA 
Blood samples were collected from the jugular vein in acid citrate dextrose (ACD). A 
phenol/chloroform extraction method was used to extract DNA from blood (Miltiadou 
2001).  
2.3.3 Amplification of DRB3 exon 2 
The amplification of the DRB3 exon 2 hypervariable region was based on earlier work 
(Miltiadou 2001). The original method involved using a 2-step nested PCR followed 
by an internal sequencing reaction. A nested PCR reaction amplified a 319 bp region 
which was then sequenced using an inner primer set resulting in a sequence of 
approximately 245 bp.  However, I have adapted the method so that only a single set 
of primers were used, DRB3FRW (5’-CGCTCCGTGAYCAGTCTATCCT-3’) and 
DRB3REW (5’-GTGAGCGCGGGGTGG-3’), which both lie in the intronic region 
surrounding exon 2 and therefore amplify all of exon 2 (Figure 2.3).  










Figure 2.3 The primers DRB3FWD and DRB3REW (marked in green) amplified the 
hypervariable region (capital letters) by PCR. The red underlined region was used to align the 
sequence traces. 
In detail, approximately 50 ng genomic DNA was used in the PCR reaction in a final 
volume of 50 µl containing 48 µl PCR mix (50 mM KCl, 10 mM tris-HCl, 1.5 mM 
MgCl2) (Roche, UK), 200 µM of each dNTP (Bioline, UK) 15pmol each primer and 1 
unit of Taq polymerase (Roche UK).  The PCR was run for 2.5 min at 94oC, then 30 
cycles of 30 sec at 94oC, 30 sec at 57oC and 1 min at 72oC with a final extension of 5 
min at 72oC. The PCR product was run on a 1.5% agarose gel and a clear single band 
of 281 bp was visible (see examples in Figure 2.4). Contaminating salts, 
unincorporated dNTPs, and primers were removed prior to sequencing using a 
Montage® PCR µ96 Plate (Millipore, UK).  
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Figure 2.4 Examples of DRB3 exon 2 PCR products from four different animal samples run on a 
1.5% agarose gel, showing clear single bands of the correct size of PCR product (281 base pairs). 
Lane 1:  molecular weight marker hyperladder I (Appendix B.2 for molecular weight); Lane 2: 
negative control; Lane 3: animal 15095; Lane 4: animal 10775; Lane 5: animal 15057; Lane 6: 
animal 14810. 
2.3.4 Sequencing reaction  
All sequencing reactions were performed using a 96-well plate format. Sequencing 
reactions were achieved using BigDye® v 3.1 terminator sequencing kits (Applied 
Biosystems, UK) in brief BigDye reaction premix 4X, BigDye sequencing buffer 2X, 
primers (2.5 pmol), dimethyl sulfoxide (DMSO) 2X, ‘cleaned’ PCR template and H2O 
in a final volume of 10 µl. The DNA was primed with either DRB3FRW or 
DRB3REV primers to obtain forward and reverse sequence which was analysed on a 
3730xl DNA analyser (Applied Biosystems, USA) using the Run 3730 Data 
Collection v2.0, Sequencing Analysis 5.1.1 (Applied Biosystems, USA) software. 
Paired sequence reads were aligned using the BioEdit program (Hall 1999) and 
visually checked to ensure correct allocation of heterozygous positions using BioEdit. 
All files were saved in a final FASTA format for use in Haplofinder. Many 
heterozygous bases were automatically assigned ambiguity codes (Cornish-Bowden 
1985), with little requirement for manual intervention. 
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2.3.5 Haplofinder 
Miltiadou et al (2003) used a simple python script (Haplofinder) to assign the DRB3 
alleles. This programme uses all the known alleles to create a list of all possible 
heterozygous combinations using the IUPAC ambiguity codes (Appendix B.1). The 
DRB3 sequence (FASTA) files are then inputted into the Haplofinder program which 
compares them to the list of possibilities. The output from Haplofinder is the two 
most likely alleles which would give the inputted heterozygous/homozygous 
sequence. The functionality of the original Haplofinder software reported by 
Miltiadou et al (2000) has been extended by adding a pre-processing step 
(‘quicklook’) which first scans the input sequences and reports differences from the 
consensus sequence. This removes the requirement for manual examination of input 
sequences and identifies putative polymorphic bases, which improves the efficiency 
of processing large numbers of samples 
(http://www.bioinformatics.roslin.ac.uk/haplofinder/haplofinder.py). 
 




The animals from the F2 and backcrosses (409) were successfully sequenced at the 
DRB3 locus (Appendix B.1). It was not possible to sequence 54 animals due to quality 
issues with the genomic DNA or lack of DNA sample in this population. Miltiadou et 
al (2000) also typed 128 of the F2 animals and the 12 founder sires by SBT. The sires 
had also been typed using PCR-RFLP for confirmation. All the F2 animals were re-
typed with the new method to verify the alleles. An example of a heterozygous animal 
from the RoBoGen herd (Figure 2.5) shows the clarity of the sequence read and the 
ease with which heterozygous bases are identified. Twenty-two distinct alleles were 
identified in the population and their frequencies are shown in Figure 2.6. 
The allele with the highest frequency was *2707, which resulted from the herd design 
which involved four F0 Charolais sires, three of which had this allele.  The Charolais 
backcross population had a frequency of 41% for the *2707 allele (Figure 2.7).  In 
contrast, in the Holstein backcross population the most common alleles were *1101 at 
19% frequency, and *2707 at 13% frequency (Figure 2.7). The F2 population had 
more allelic diversity, but again due to the herd design, *1101 and *2707 (6% and 4% 
respectively) remained at the highest frequency (Figure 2.7). The Charolais backcross 
population only had 12 different alleles, although again this is most likely a reflection 
of the breeding structure from the 4 purebred Charolais sires. The *2707 allele 
seemed to have originated only from the Charolais sires. The Holstein backcross 
population had more alleles (18), although some of these were very similar, e.g. 
*1101 and *1102 only differed by 2 base pairs.  




Figure 2.5 Sequence trace of DRB3 exon 2 hypervariable region from animal 14910 showing forward sequence read, red boxed bases are heterozygous peaks and 
are designated with heterozygous codes as stated by IUPAC (www.IUPAC.org) nomenclature  (Appendix B.1) . The sequence trace is for animal 14910 which was 
typed as heterozygous: DRB3*2707 and *0701. 
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Figure 2.6 Alleles identified and their frequencies within the RoBoGen Charolais-Holstein cross population.





























































































































Figure 2.7 Allele frequencies in the Holstein backcross, Charolais backcross and F2 populations. 
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Each allele present in the RoBoGen herd has polymorphisms in the functional regions 
of the PBC. These functional regions have been defined as ‘pockets’ as they are the 
main point of interaction between the side chains of the bound peptides and the DR 
molecule (Sharif, Mallard, & Sargeant 2000). Table 2.1 shows the amino acids within 
the DRB3-encoded pockets for the alleles in the RoBoGen population.  
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 Pockets/Amino Acid Positions 
 1 4 6 7 9 10 
DRB3 
allele 
86 13 70 71 74 11 28 30 47 61 67 71 9 37 57 60 61 56 
*0101 M S E K E S D Y F W F E E T D Y W Q 
*0201 V S R A A S D Y Y W I R E F D Y W P 
*0501 V S R K N H D Y Y W I R E Y D Y W P 
*0601 G R R K E C D C F L I R E F V H L R 
*0701 V R E R E C D C F W F E E F V Q W R 
*0801 V S D E S A D Y F L F D E L S H L P 
*0901 G S R K N S E S Y W I R E N D Y W P 
*0902 G S E R E S E S Y W I E E N D Y W P 
*1001 G S R A A S D Y Y C F R E Y V Y C R 
*1002 G R R A A Y D Y Y C F R E Y V Y C P 
*1101 V G R R E H D H F W F R Q Y S Y W P 
*1102 V G R K E Y D H F W F R E Y S Y W P 
*1201 G K R A A T N Y Y W I R E F D Y W P 
*14011 V G Q K E H D H F W F Q E F A Q W P 
*1501 V S R E Y S D Y Y L T R E F V Q L P 
*1601 G K E K A T D Y Y W F E E F D Y W P 
*1701 G S R E Y A H Y F W I R E Y D Y W P 
*1801 V S R E Y A H Y F W T R E F A Q W P 
*2002 G R Q R A C D Y F W F Q E R D Y W P 
*2703 G R E R E Y D C F W F E E T D Y W P 
*2707 V R E R E Y D C F W F E E T D Y W P 
*3201 G R R E Y C D Y F W I R E Y D Y W P 
Table 2.1 RoBoGen DRB3 alleles and amino acids present in binding pockets. 
A: arginine; C: cysteine; D: aspartic acid; E: glutamic acid; F: phenylalanine; G: glycine; H: histidine; K: lysine; L: leucine; M: methionine; N: 
asparagine; P: proline; Q: glutamine; R: arginine; S: serine; T: threonine; V: valine; W: tryptophan; Y: tyrosine.
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2.5 Discussion 
In order to assign functional importance to particular SNPs in polymorphic genes, it 
is clearly important to be able to accurately distinguish alleles. This is particularly 
relevant for the MHC loci as there are many polymorphic genes, most of which 
impact on the immune response to infectious pathogens and vaccines.   
BoLA DRB3 polymorphisms have in particular been associated with many diseases 
in cattle (Maillard, Martinez, & Bensaid 1996; Sharif et al. 1999; Garcia-Briones et 
al. 2000; Glass 2004). This gene is highly polymorphic and each allele contains 
many SNPs, unlike most other polymorphic genes.  In order to determine which 
SNPs have functional importance in immune trait association studies, much greater 
accuracy can be achieved with exact sequence information.  
The SBT technique described here has enabled the typing of 409 animals at the 
DRB3 locus, with 22 different alleles successfully identified. Each of the 22 alleles 
has polymorphisms in the defined peptide binding pockets resulting in an amino acid 
change. This demonstrates that even small coding differences, e.g. 2 bp between 
*2707 and *2703 results in an amino acid change of glycine to valine in pocket 1, 
potentially have functional consequences.  
In the RoBoGen herd there is a mixture of Holstein-Friesian and Charolais DRB3 
alleles. The Holstein breed has been extensively examined at this locus and the 
majority of known DRB3 alleles have been described in Holstein-Friesian animals 
(http://www.projects.roslin.ac.uk/bola/drb3pcr.html). It was therefore interesting to 
see if the Charolais back-cross animals had any new, previously unidentified alleles 
and if the frequencies differed in Holstein back-cross and Charolais back-cross cattle, 
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as they are genetically distinct breeds (McKay et al. 2008) which have been exposed 
to different selection pressures, i.e. milk versus beef production.  The Charolais had 
less variety in alleles, although this is most likely due to the experimental design. 
The *2707 allele seems to originate from the Charolais and is very similar to the 
Holstein *2703 allele, except for two base pairs. Even the 2 bp difference can have a 
functional impact (Chapter 3 and 4). However, both populations had similar alleles 
and other than the *2707 allele, no significant differences in allele frequency were 
noted.  A more comprehensive survey of the original breeds would be required to 
draw definite conclusions about allele presence and frequency. 
Distinguishing between highly polymorphic alleles is difficult and needs a high 
resolution sequencing approach. Older techniques such as RFLP-PCR resolved some 
of the alleles at the DRB3 loci but it had limitations, as not all alleles can be detected. 
Other methods e.g. PCR-SSCP provide a higher resolution compared to RFLP-PCR 
and additionally allow the identification of new alleles, as has been shown for ovine 
MHC genes (Kostia et al. 1998).  
SBT, however, is a powerful technique which allows the genotyping of large 
numbers of animals with relative speed and ease. The improvement in the SBT 
technique described in this chapter significantly reduces the time and extent of 
manual intervention required to generate accurate genotype information. It is 
possible to then use this information to look at associations between polymorphic 
alleles and immune traits, e.g. response to disease or vaccines. Another major 
advantage of the SBT technique is the possibility of finding de novo alleles.  
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Miltiadou et al. (2003) successfully implemented a sequence-based typing method 
for DRB3 alleles in the RoBoGen herd. Nonetheless Miltiadou (2001) reported 
difficulties in accurately typing all animals due to problems towards the end of the 
hypervariable region. The previous method did not allow complete typing of this 
region because of the placement of the primer sets. However, this is overcome in this 
analysis by only using the outer set of primers, which allows the complete 
sequencing of exon 2 and therefore the unambiguous identification of all alleles.  
Another difficulty with the original method was in deciphering the sequence after a 
deletion. In the RoBoGen herd, allele *0201 (frequency of 6%) has a 3 base pair 
deletion (bp 180, 181 and 182). The sequence trace post-deletion in a heterozygous 
animal has many more heterozygous peaks (Figure 2.8). The input files in 
Haplofinder contained *** at the deletion point which consequently did not allow for 
the identification of the *0201 allele. A change to the input file together with the 
increased quality compared to the gel sequencing method have made the allele 
identification process relatively straightforward.    
Point of deletion
 
Figure 2.8 RoBoGen animal 119, DRB3 *0201 and *1101 after 3 bp deletion. The sequence trace 
shows the point of deletion for the *0201 allele and after this point the majority of bases are 
heterozygous.   
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As most of the polymorphisms in the DRB3 gene occur with the PBC encoding exon 
2, it is interesting to see how this impacts upon the amino acid sequence. All of the 
alleles identified here have differences in the PBC, moreover they all have 
differences in the defined ‘pockets’ of the PBC. Therefore having the sequence data 
for the alleles allows a more in depth analyses of the interactions between the PBC 
and possible peptides. 
The original typing of four animals was inaccurate, most likely due to the difficulties 
in base calling, especially in heterozygous animals, as a result of the gel-based Li-
Cor system employed. Those which were different from the Miltiadou work were re-
typed several times to confirm the new allele allocations (Table 2.2). The new allele 
allocations are likely to be correct as they achieved a quality score of at least 99% in 
the sequence traces. The increased length of the reads also means that the quality of 
the base calling towards the end of the sequence is increased.  The increase in length 
of read has resulted in animal 44 being retyped as *1201 instead of *1202 (Table 




  Miltiadou et al. alleles1   Baxter et al. alleles 2 
16 R21  *1101 *1801  *1101 *1101 
21 R02  *2707 *2707  *2707 *0601 
31 R11  *2707 *0902  *2707 *1101 
44 R11  *0501 *1202  *0501 *1201 
Table 2.2 Comparison of original allele assignment with new allele assignments (Baxter et al. 
2008). * Animal ID from Miltiadou et al. 2003. 
1  Miltiadou, Law & Russell 2003. 
2 Baxter et al. 2008  
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Other cattle MHC genes which are extremely likely to be important in the immune 
response against pathogens are the DQ genes. However, these genes have an extra 
layer of complexity as in some haplotypes the genes are duplicated. Therefore, using 
a SBT technique becomes harder, if not impossible, as an individual can have up to 4 
different DQA and/or DQB alleles. An additional problem is that the alleles of the 
DQ genes are poorly defined. However, a group has now developed an SBT method 
for BoLA-DQA1, utilising the Haplofinder programme (Takeshima et al. 2007) to 
amplify only the DQA1 genes, thereby reducing the complexity as these genes are 
not duplicated (although DQA2 genes maybe present in the same haplotype). Whilst 
this method provides information on the DQA1 alleles, it is limited as it does not type 
DQA2, DQA3 or DQA4 and it would not detect any duplication. In Chapter 5 I will 
describe a microarray typing technique for DQA genes and a qPCR method for 
detecting duplication in the DQ genes.  
Using improved sequence-based technology, it proved possible to accurately and 
rapidly type over 400 animals at the DRB3 locus, providing detailed information of 
the SNPs present. The use of immune phenotypes together with results of the typing 
at DRB3 will allow detailed investigation of associations between the polymorphisms 
and immune response, which is detailed later in this thesis (Chapter 3 and Chapter 
4). It seems likely that higher throughput sequencing technology will continue to 
develop and become even simpler and more affordable.  In the future, it may be 
possible to harness this technology to investigate the association of DRB3 and 
potentially other BoLA Class II genes, with larger phenotyped populations.  Such 
data could then be used to quantify the extent to which MHC loci have an impact on 
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immune (and other commercial) traits. This information would enable breeders to 
make informed selection decisions. 
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3 Responses to Foot and mouth disease virus peptide and 
their associations with BoLA-DRB3 in the RoBoGen herd  
 
3.1 Introduction 
3.1.1 Foot and mouth disease 
Foot and mouth disease virus (FMDV) is a single-stranded, non-enveloped RNA 
aphthovirus of the Picornaviridae family, which affects cloven-hoofed animals. The 
virus particle contains 60 copies each of four structural proteins (VP1-4) which form 
an icosahedral capsid with seven serotypes (A, O, C, Asia 1 and SAT1-3) (reviewed 
by Grubman and Baxt (2004)) (Figure 3.1). The G-H loop is a major structural 
feature, which is highly immunogenic. The G-H loop has a highly conserved 
tripeptide arginine-glycine-aspartic acid (RGD) which mediates cell attachment 
(Burman et al. 2006). The high reproductive capacity of the virus, its ability to 
change its antigenic structure, persistence in the environment and its pathogenic 
consequences on productivity render it a serious threat to the beef and dairy 
industries in many countries (Thompson et al. 2002; Bates, Carpenter, & Thurmond 
2003; reviewed by Grubman & Baxt (2004)).  




GH loops on 
capsid surface
 
Figure 3.1 Diagram of FMDV capsid structure. There are three surface proteins, VP1, VP2, and 
VP3, labelled 1–3, respectively. The G-H loops which are highly immunogenic protrude from 
the capsid surface (Picture adapted from Frank, 2002). 
FMDV is highly contagious and infection results in high morbidity especially in high 
producing cattle breeds, and can be fatal in immature animals (Kitching 2002). 
Recent outbreaks of FMD in Taiwan, South Korea and United Kingdom resulted in 
the slaughter of millions of animals and huge economic losses, due to restrictions on 
export of animals and meat and dairy products (Davies 2002). The management and 
control of the disease is therefore a major concern worldwide. In FMDV endemic 
regions, such as Africa, Asia and South America, control measures involve regular 
vaccination with inactivated virus vaccines (Sobrino et al. 2001; Anonymous 2003). 
These vaccines are not used in FMDV-free states such as the US and the EU, mainly 
because the benefits of trade in FMDV certified free products are considered to 
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outweigh the increased risk to susceptible livestock populations and costs of 
vaccination as a preventative measure. Additionally, in the UK, vaccination against 
FMDV has never been implemented and vaccination to control the two UK 
outbreaks was ruled out, possibly because of ideological doctrine as well as ensuing 
trade restrictions (Sutmoller et al. 2003). In the past, the use of inactivated viral 
vaccines made it difficult to distinguish vaccinated from infected animals (DIVA), 
but vaccines prepared from purified components do not contain, and therefore do not 
induce, antibodies to non-structural proteins (Sutmoller et al. 2003). In compliance 
with international law, outbreaks are controlled in FMDV-free states by a ‘stamping-
out’ policy of quarantine and slaughter. However, following recent outbreaks 
recommendations have been made which may result in vaccination becoming the 
preferred option for controlling future outbreaks (The Royal Society 2002; Paton, 
Sumption & Charleston 2009). Unfortunately the commercially available vaccines 
have low efficacy, requiring regular boosts (Grubman & Baxt 2004). Biosecurity and 
biocontainment remain additional concerns, particularly as global trade and 
movement of livestock is likely to increase, and in the EU, countries that are adjacent 
to countries outside the EU that are not FMDV-free would appear especially at risk 
(Sutmoller et al. 2003). Additionally the accidental release of the virus during 
vaccine preparation and storage has been the origin of several FMD outbreaks, 
although with newer methods of inactivation this is a lesser concern (Sutmoller et al. 
2003).   
Alternative strategies for vaccine design are therefore needed such as, synthetic 
vaccines, which have the potential to be used in emergency situations to supplement 
current control measures, or as a replacement for the present vaccines in endemic 
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countries (Taboga et al. 1997).  However, the design of a synthetic FMDV vaccine 
that elicits strong and long-lasting protection has proved difficult, although Wang et 
al. (2002) reported near complete protection of swine against challenge infection 
with FMDV after vaccination with a synthetic peptide.  
The design of effective vaccines requires the identification of epitopes capable of 
inducing uniform strong and long-lasting immune protection in an outbred 
population.  Furthermore, activation of humoral and cell-mediated immune responses 
is required for effective FMDV vaccine protection (Sobrino et al. 2001). Protection 
against FMDV has been associated with a high serum neutralising titre (SNT), 
dominated by immunoglobulin G1 (IgG1) and immunoglobulin G2 (IgG2) antibody 
subclasses (Collen, Dimarchi & Doel 1991; Sadir et al. 1999). The induction and 
maintenance of immunological memory is T cell dependent,  thus it was considered 
that a strong CD4+ T cell response must be necessary for an efficacious FMD 
vaccine (Collen, Dimarchi, & Doel 1991).  Interestingly, more recent work has 
suggested that resolution of an acute primary FMDV infection may be T cell-
independent and the repeating nature of the capsid structure may enable T-
independent antibody class switching to occur (Juleff et al. 2009). Nonetheless it 
seems probable that a protective vaccine would need to induce the development of 
both T cell and antibody memory responses.  In addition, CD8+ T cells may play a 
role in protection (Collen 1994; Childerstone et al. 1999; Sobrino et al. 2001; 
Guzman et al. 2008).   
Although a humoral response is generally accepted as the main protective 
mechanism against FMDV, the correlation between the levels of neutralising 
antibody and protection are not always apparent, especially in the case of peptide or 
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subunit vaccines, and it is clear that other factors play a role, including both innate 
(Summerfield et al. 2009) and different aspects of adaptive immunity (Collen 1994).  
In terms of the latter, about which more is known, FMDV IgG1 titres were shown to 
correlate with protection (Capozzo et al. 1997), and IgG1 is an antibody isotype in 
cattle associated with a Th2 response (Estes & Brown 2002).  In contrast, another 
study has shown that an interferon-γ (IFN-γ) response also correlates with protection 
(Parida et al. 2006), which makes sense as this T cell-derived cytokine can inhibit 
FMDV replication in vitro (Zhang et al. 2002). T cell-derived interleukin (IL)-2 also 
plays a role in protection (Amadori et al. 1992).  Although T cells responding to the 
inactivated viral vaccine produced mRNA for IFN-γ and not IL-4, (Van Lierop et al. 
1995), it seems likely that both Th1 and Th2 responses play a role in protection 
against FMDV.  
The major neutralising antibody epitopes have been identified as the amino acids that 
make up a prominent G-H loop structure of the viral capsid protein, VP1, together 
with the VP1 C-terminal residues which are contiguous in the native virion 
(Dimarchi et al. 1986). A synthetic vaccine against FMDV would therefore be 
required to include a region that mimics this loop structure. In addition to this, a 
synthetic peptide would need to include regions identified as potential T cell 
epitopes, for example the RGD integrin binding motif and the lysine-valine-alanine-
arginine (KVAR) T cell motif (Rothbard & Taylor 1988). A 40-mer peptide 
(FMDV15) representing the G-H loop region and containing both the RGD and 
KVAR motifs elicited high levels of neutralising antibody and protection of cattle 
against FMDV (Dimarchi et al. 1986). The 40-mer peptide has two cysteines at the 
N-terminus and a proline-cysteine-glycine (PCG) at the C-terminus with a proline-
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proline-serine (PPS) spacer to mimic the GH loop structure. Nevertheless, high-dose 
inoculation with FMDV15 was required, and the levels of SNT obtained did not 
correlate with protection (Dimarchi et al. 1986). Subsequent studies following 
improvements in peptide design and vaccine delivery have led to more consistent 
protection against FMDV (Cubillos et al. 2008; Greenwood et al. 2008).   
In the move towards more refined vaccines, variable immune responses and hence 
variable protective efficacy are beginning to be recognised as problems, with some 
individuals remaining as non-responders even after repeated vaccinations (Poland, 
Ovsyannikova, & Jacobson 2008). These differences are partly determined by 
environmental factors, such as the presence of maternal antibodies, poor nutrition or 
concurrent infections, and partly by the genetic background of the vaccine recipients. 
The genetic differences in vaccine-induced immune responses may be explained by 
the diversity of genes expressed in the immune system, such as the toll-like receptors 
and cytokines (Poland et al. 2007).  However, the role of host genetics, which may 
underlie variable immune response to vaccination has not been thoroughly explored 
(reviewed by Glass (2004)). The effect of host genetic variation on vaccine response 
is most likely mediated through polymorphisms in many genes. There has been a 
renewed focus on the major histocompatibility complex (MHC), due to the important 
role MHC-encoded proteins play in the host immune response, particularly to 
epitope-based vaccines (Sette & Fikes 2003). Studies also suggest that where 
genetics is shown to play a role in the phenotypic variation in response to vaccines 
and pathogens, a significant proportion can be attributed to MHC genes (Glass 2004; 
Poland et al. 2007). Although there are QTLs which map to other regions within the 
genome for the response to the FMDV peptide (Leach et al. 2010). The limited 
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repertoire of epitopes in peptide/synthetic vaccines compared to the native organisms 
increases the importance of the interaction between the vaccine epitopes and the 
MHC molecules in generating an effective homogenous adaptive immune response 
in outbred populations.   
3.1.2 Cattle MHC and FMDV 
The MHC and bovine MHC in particular are described in Chapter 1.  This section 
concentrates on the relevance of the MHC to variation in the immune response to 
FMDV and antigen derived from it.  
MHC restriction may play a particularly relevant role in protective responses to 
FMDV, because unlike other members of the Picornaviridae family, the major 
protective mechanism, in the form of virus-neutralising antibodies, is focused on the 
prominent G-H peptide loop structure on its surface.  Two earlier studies have shown 
that DRB3 alleles influenced the immune response induced by FMDV peptides 
containing this neutralising antibody site (Glass, Oliver, & Spooner 1991; Glass & 
Millar 1994), with several of the alleles showing suggestive associations with 
protection against viral challenge (Garcia-Briones et al. 2000).   Glass and colleagues 
(2000) have also shown that an FMDV peptide containing the neutralising epitope 
induced T cells restricted by both BoLA DRB3 and DQ molecules.  A number of 
papers have also described associations of BoLA DRB3 with response to other 
epitopes in the native virus and also inactivated viral vaccines (Collen, Dimarchi, & 
Doel 1991; Van Lierop et al. 1995; Gerner et al. 2007). Recently, Gerner et al. 
(2009) identified a putative DQ epitope in VP4.  However, the role of BoLA DQ 
alleles in variation in immune responsiveness to FMDV is unclear.  Additionally, 
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infection with native virus and an inactivated viral vaccine generated FMDV-specific 
BoLA Class I-restricted CD8+ T cells (Guzman et al. 2008).  BoLA Class I is also 
complex, with different numbers of BoLA Class I molecules encoded depending on 
haplotype (Ellis 2004).  However again, what role, if any, BoLA Class I alleles might 
play in variation in the protective immune response to FMDV is unknown.    
Thus the available evidence would suggest that an effective vaccine to FMDV has to 
interact with BoLA molecules, include the major epitope of the component of FMDV 
recognised by the neutralising antibody, and take account of BoLA polymorphism, 
especially BoLA DRB3.  
The binding pockets (described in Chapter 1) will play an important role in the 
binding of the peptide for presentation. In human HLA-DR molecules, pocket 4 has 
been found to be important for the binding of peptide (Fu et al. 1995). This may be 
due to pocket 4 being located in the centre of the PBC. In addition it has been 
reported in cattle that the pocket 4 motif can have a significant effect on the immune 
response (Sharif, Mallard, & Sargeant 2000; Sitte et al. 2002). Pockets and motifs 
other than pocket 4 also affect the immune response in both humans (Zerva et al. 
1996) and cattle (Xu et al. 1993; Maillard, Martinez, & Bensaid 1996; Sitte et al. 
2002; Zavala-Ruiz et al. 2004). Furthermore, the binding affinity of FMDV peptides 
to different allelic forms of purified BoLA-DRB3 correlates with T cell proliferation 
(Haghparast et al. 2000). 
3.2 Aim and Hypothesis 
The aim of this chapter was, therefore, to explore the associations between the 
BoLA-DRB3 alleles and the immune response to FMDV15, a 40-mer peptide derived 
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from FMDV Serotype 0 containing neutralising epitopes, which was the peptide 
described by DiMarchi et al (1986). The hypothesis was that it would be possible to 
find significant associations which would provide information on the role of BoLA-
DRB3 in immune responsiveness in cattle.   
3.3 Experimental design 
Specifically, a large crossbred cattle population was immunised with FMDV15 and 
IgG1, IgG2, T cell and IFN-γ responses were measured.  The cattle population 
(RoBoGen herd) were part of a larger study on the role of genetics in performance 
and immune traits.  They were naive to FMDV and thus provided a unique 
opportunity to investigate the role of MHC in the primary and secondary humoral 
and cellular responses to an antigen to which the animals had not previously been 
exposed.  The improvements in BoLA-DRB3 typing of exon 2, which encodes the 
PBC containing the majority of the polymorphic sites in the DR molecule (Baxter et 
al, 2008; see Chapter 2), made feasible the genotyping of a large number of animals.  
This in turn enabled the analysis of the impact of specific alleles, as well as the 
polymorphisms in individual amino acid positions and the anchor “pockets” of the 
PBC, on the response to FMDV15 to be determined.  This was accomplished through 
a mixed model statistical analysis of the associations between the alleles of BoLA-
DRB3 and the phenotypic immune measurements.  In addition, a preliminary 
exploration of the DR protein was studied through 3D modelling. Part of this chapter 
has been published, specifically the antibody response data (Baxter et al. 2009). 
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3.4 Materials and methods 
3.4.1 Animals 
The study population was a second generation cross between Charolais and Holstein 
cattle.  The herd was bred from four pure-bred Charolais sires and eight F1 Charolais-
Holstein sires. The 12 sires were used to produce a second generation cross 
composed of inter-crossed (F1 x F1 n=123), and backcross (Charolais x F1 n=31 and 
Holstein x F1 n=43) animals, giving a total of 197 female animals that were included 
in this study. Blood samples were collected across three separate cohorts from 1999 
to 2001. Immunisation age ranged from 469 to 609 days. 
3.4.2 Immunisation and sampling 
The FMDV15 peptide represents a fragment of the VP1 capsid protein that includes 
amino acids 200-213 and 140-158, coupled by a Pro-Pro-Ser spacer together with a 
dicysteine residue at the N terminus and Pro-Cys-Gly at the C terminus (Dimarchi et 
al. 1986) (Figure 3.2). The peptide was prepared by Dr A. Douglas, Veterinary 
Services Division, Agri-Food and Biosciences Institute, Belfast, on an ABI 431A 
peptide synthesiser using FMOC chemistry. Following deprotection and cleavage, it 
was purified by preparative reverse phase HPLC (Beckman System Gold HPLC 
using a Phenomenex Luna C18 column). 
CCRHKQKIVAPVKQTLPPSVPNLRGDLQVLAQKVARTPCG
200 213 140 158
 
Figure 3.2 FMDV15 40-mer amino acid sequence derived from VP1 capsid protein. The red 
letters are the spacer amino acids and the N-terminus and C-terminus additions. The green 
letters are the identified B and T cells epitopes.  
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Animals were immunised subcutaneously with FMDV15 peptide (1 mg/animal) 
emulsified in Freund’s incomplete adjuvant, with a further immunisation (100 
µg/animal) 6 weeks later essentially as described previously (Dimarchi et al. 1986; 
Glass et al. 1991). To determine the animals’ immune response to vaccination, blood 
samples were collected by jugular venipuncture into serum tubes for antibody 
analysis (Greiner Bio-one, UK), and for the T cell and IFN-γ analysis, blood was 
collected aseptically into heparin tubes (Greiner Bio-one). Samples were taken at 
vaccination (day 0) and 1, 2, 4, 8 and 10 weeks later. Each cohort was immunised 
and sampled over three consecutive years. All animals were clinically normal. All 
experimental protocols were authorised under the UK Animals (Scientific 
Procedures) Act, 1986. 
3.4.3 ELISA for detection of FMDV15-specific IgG1 and IgG2 
The enzyme-linked immunosorbent assay (ELISA) for the detection of FMDV15-
specfic IgG1 and IgG2 is fully described in Baxter et al. 2009.  
3.4.4 Cell proliferation assay 
The proliferation assay was carried out essentially as previously described (Glass et 
al. 1991) with the exception that whole blood was used (Appendix C.2). Preliminary 
experiments confirmed that the major proliferating population was T cells (results 
not shown).  The stimulation index (SI) was calculated (ratio of cpm after culture 
with either FMDV peptide or ConA divided by the cpm of control cultures) and used 
in further analyses. 
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3.4.5 IFN-γ assay 
IFN-γ release by whole blood cells in vitro were determined by Enzyme Amplified 
Sensitivity Immuno Assay (EASIA) (Catalogue number KAC123, Biosource 
International, now Invitrogen) using whole blood in heparin, essentially according to 
the manufacturer’s guidelines, except that FMDV peptide and ConA were used as the 
test antigens, and ovine recombinant (r) IFN-γ (a kind gift from Professor Gary 
Entrican, Moredun Research Institute, UK) was used to determine IFN-γ 
concentrations (Appendix C.2). 
The negative control values for the IFN-γ levels were then subtracted from the results 
obtained for FMDV15 and ConA and these values were used in the statistical tests 
below.  Due to a late decision to include a positive control there are no ConA results 
for cohort 1.  
All immunisations and assays were carried out by technical and farm staff at The 
Roslin Institute.  
3.4.6 Sequence-based typing method of DRB3 
Exon 2 of the DRB3 gene was amplified from genomic DNA from all 197 animals. 
The resulting amplicons were sequenced by BigDye (Applied Biosystems) 
sequencing reaction as previously described (see Chapter 2; Baxter et al. 2008). 
DRB3 genotypes were allocated to all animals using Haplofinder 
(http://www.bioinformatics.roslin.ac.uk/haplofinder/haplofinder.py). 
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The amino acids at pocket positions were determined from the nucleotide sequences 
of the alleles (BioEdit Hall 1999) and the pocket positions (Sharif, Mallard & Wilkie 
2003). 
3.4.7 Statistical analysis 
Mixed linear models, such as residual maximal likelihood (REML) (Patterson & 
Thompson 1971), were considered to be the most appropriate for analysis of the 
effects of DRB3 alleles on antibody and T cell response to FMDV15. A REML 
model was chosen as it can account for a number of covariates and factors that have 
an impact on the traits whilst accounting for the relationship between animals in the 
form of a random effect of dam.  The fixed effects in the model with appropriate 
degrees of freedom (d.f.) were breed cross (Charolais Backcross (CB), Holstein 
Backcross (HB), F2 generation, (2d.f.)) and Cohort (1999, 2000, 2001 (2d.f.)). The 
effect of MHC allele or amino acid at certain positions was examined by contrasting 
each analysed variant with all other possible variants  (0: no copies, 1: a single copy 
or 2: two copies (2d.f.)).  Immunisation age was defined as a continuous variate and 
calf dam was included as a random effect.  Thus the linear model was:  
 
yijkl= li+cj+uk+MHCijkl+aijkl +eijkl 
 
where: yijkl is the observed phenotypic trait; li fixed effect of breed-cross (CB, HB or 
F2); cj fixed effect of the cohort (years 1, 2, or 3); linear regression of the MHC 
allele/amino acid (0, 1 or 2 copies); uijkl random effect of the dam; aijkl covariate 
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effect of the age of the animals at time of vaccination, eijkl is the residual error. All 
statistical analysis was performed using Genstat with the significance of fixed 
effects, such as MHC variant being assessed by a Wald test (Genstat 9.0v VSN 
international). If MHC variants were significant (at least p<0.05), then further 
analysis was conducted by generating predicted means and conducting a Student’s t-
test using pair-wise comparisons. All statistical analysis was performed using 
Genstat. 
3.4.8 IgG1 and IgG2 
The IgG1 and IgG2 concentration data were normalised by Loge transformation to 
obtain a normal distribution. 
3.4.9 T cell proliferation  
The T cell assay had three concentrations of FMDV15 peptide (0.1, 1 and 2 µg/ml) 
and three concentrations of the positive control, ConA (0.25, 2.5 and 10 µg/ml). The 
data were analysed using loge transformed stimulation index (SI). However, there 
were difficulties analysing this data set as there was a low response after exposure to 
the FMDV peptide, with some of the control results having a higher rate of 
proliferation than the test FMDV results. Each of the transformed data sets was used 
in the REML model (see above). Only the results from the FMDV 2 µg/ml and ConA 
10 µg/ml are shown, but the significant alleles remained significant across 
concentrations.  
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3.4.10 IFN-γ   
The IFN-γ dataset had many non-responders (animals which did not make IFN-γ 
above 0 after control levels have been subtracted) at each time point (88, 31, 37 and 
56 animals at weeks 0, 4, 8 and 10 respectively), including 8 animals which did not 
make any detectable IFN-γ response at any of the time points. It would be expected 
that as the animals were naïve to the FMDV15 peptide all would not respond at week 
0 (see discussion).  Due to the high numbers of non-responders, transforming the 
data through Loge transformation and square-root transformation did not normalise 
the distribution. Thus, to analyse this dataset a generalised linear mixed model 
(GLIMM) approach with a binomial distribution was chosen.  
 A generalised mixed linear model was implemented:  
yijkl= li+cj+uk+MHCijkl+aijkl +eijkl 
where: yijkl is the observed IFN-γ level either 0 for non response or 1 for response; li 
fixed effect of breed-cross (CB, HB or F2); cj fixed effect of the cohort (years 1, 2, or 
3); linear regression of the MHC allele/amino acid (0, 1 or 2 copies); uijkl random 
effect of the dam; aijkl covariate effect of the age of the animals at time of 
vaccination, eijkl is the residual error. All statistical analysis was performed using 
Genstat with the significance of fixed effects, such as MHC variant, being assessed 
by a Wald test (Genstat 11.0v VSN international). 
3.4.11 Area under the curve 
To examine the overall response across time points to the FMDV15 peptide, the area 
under the curve (AUC) was calculated using the trapezoid rule (Appendix C.1) for 
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IgG1 and IgG2, and was used in the REML model. Due to the structure of the IFN-γ 
and T cell dataset the AUC was not calculated.  
 
3.4.12 3D modelling of DRB3*1001 and *1601 
Overall the results presented in this chapter showed that the DRB3 pocket positions 
were highly significantly associated with the magnitude of the ensuing immune 
response. Thus it would seem highly probable that this is due to the binding affinity 
of peptide to the DRB3 molecule. It was decided that the use of 3D modelling might 
provide more insight into the structure of the BoLA DR pockets. The modelling of 
both the BoLA-DR molecules represents very preliminary data. Two alleles were 
chosen for the modelling, DRB3*1601 and *1001, as they were shown in the 
statistical analysis to be associated with lower and higher IgG1 and IgG2 responses 
respectively. As there is no crystal structure available for bovine DRB3, the 
modelling was based on a human equivalent. The modelling of the MHC molecules 
was undertaken at the Roslin Institute by Dr. Zen Lu.  
The initial step in the modelling was to identify the most appropriate template. In 
order to complete this, the DRB3*1601 sequence was submitted to the Template 
Identification tool of the Swiss-Model web server 
(http://swissmodel.expasy.org/workspace/index.php?func=tools_targetidentification1
) and also BLASTed against the PDB database 
(http://www.pdb.org/pdb/search/advSearch.do). It was found, from aligning all the 
various DRB3 alleles from all mammalian DRB3 sequences available using the 
program ClustalW (version 1.83), that the bovine allele *1601 is most closely related 
   
 74 
to the human leukocyte antigen DR52a (HLA-DRA, DRB3*0101) (PDB accession 
number: 2Q6W, http://www.pdb.org/pdb/explore/explore.do?structureId=2Q6W ). 
The HLA β-chain of 2Q6W shares about 84% sequence identity with BoLA 
DRB3*1601. 
The confidence of 2Q6W being the best template is further enhanced by the fact that 
when DRB3_1601 was submitted to the Swiss-Model for automated model 
prediction (http://swissmodel.expasy.org/ ), the server also picked the same structure 
to model the *1601 allele.  
Sequences of DRB3*1601 and 2Q6W were next aligned against each other and 
resubmitted to the Swiss-Model server for alignment-mode modelling. The modelled 
structure together with the template were downloaded and imported into the Swiss 
PdbViewer (version 4.0) where several rounds of iterative Magic Fit and Energy 
Minimization (tools available in Swiss PdbViewer) were applied to get a more 
reliable structure for DRB3*1601. The template structure was removed before saving 
the final BoLA DRB3*1601 structure. This improved DRB3*1601 was validated 
using the Protein Structure & Model Assessment Tools of the Swiss-Model server. 
The Anolea atomic mean force potential and Stereochemical quality Procheck 
(Laskowski et al. 1993) of the modelled structure were calculated to check for any 
anomaly. 
The DRA α chain was also modelled by following the steps above. The template 
used was the crystal structure of the DR alpha chain of human HLA Class II 
histocompatibility antigen (PDB accession number: 1JWU, 
http://www.pdb.org/pdb/explore/explore.do?structureId=1JWU).  
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To construct the functional dimerised unit of the bovine Class II histocompatibility 
antigen, the two modelled β- and α-chains of DRB3*1601 and DRA were merged 
using the 2Q6W (complete human DR molecule) as the template: The structure 
2Q6W was loaded into the program GRASP2 
(http://wiki.c2b2.columbia.edu/honiglab_public/index.php/Software:GRASP2). The 
modelled BoLA DRB3*1601 and BoLA DRA were next imported into the Swiss 
PdbViewer.  The merged bovine DRA and DRB3*1601 structures were finally saved 
as a single dimer and validated as above. The same process was carried out for the 
modelling of DR molecule with the DRB3*1001 allele.  
3.5 Results  
3.5.1 FMDV15-specific IgG1 and IgG2 
The dose and time course intervals were chosen based on earlier studies that had 
characterised the response to the FMDV15 peptide in Holstein cattle (Glass et al. 
1991). It was expected that the majority of animals would respond. The FMDV-
specific IgG1 and IgG2 concentrations were measured by ELISA in all 197 animals. 
The levels of both IgG isotypes were not significantly different from zero at weeks 0 
and 1. From week 2 onwards, both IgG1 and IgG2 responses showed a high degree 
of variation among individuals in response to immunisation with the FMDV peptide 
(Figure 3.3). The mean IgG1 concentrations increased with time and at weeks 2, 4, 8 
and 10 were 69.6, 166.0, 289.6 and 175.0 µg/ml, respectively (Figure 3.2a).  The 
AUC had a mean of 1648 µg/ml and a range of 0.068-642.0 µg/ml.   
IgG2 levels were lower than the IgG1 levels in the majority of animals, but still 
showed a consistent response to the FMDV15 peptide.  The mean FMDV15-specific 
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IgG2 concentrations at weeks 2, 4, 8 and 10 were 5, 13, 23.97 and 23.30 µg/ml 
respectively (Figure 3.3b).  The AUC had a mean of 101 µg/ml and range of 0-372 
µg/ml. The majority of the animals had responded by week 2. However there were a 
small number of animals that had a low response even after week 4. Fifteen of the 
197 animals did not make any detectable IgG2 response to the FMDV15 peptide at 
any time point.  
 
 







































































Figure 3.3 Antibody responses after immunisation with FMDV15 peptide. Anti-FMDV15 IgG1 
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3.5.2 T cell proliferation to FMDV15 and ConA 
3.5.2.1  FMDV15 
The analysis for the T cell proliferation is only shown at the highest concentration for 
both FMDV15 and ConA for simplicity (the lower concentrations had similar graph 
profiles). Proliferation of T cells after immunisation with the FMDV15 peptide 
showed a SI increase from 1.13 to 4.58 (week 0 to week 10) with a high degree of 
animal to animal variation observed at weeks 8 and 10 (Figure 3.4a).  
3.5.2.2  ConA 
The mean T cell proliferation for ConA was higher than for FMDV15 with weeks 0, 
4, 8 and 10 mean SI values of 13.85, 17.67, 13.35, and 18.76 respectively. The T cell 
proliferation after exposure to ConA was virtually equal across all weeks. However 
high animal to animal variation was observed across all time points (Figure 3.4b).  























































































Figure 3.4 T cell proliferation after immunisation with 2 µg/ml FMDV15 (a) and 10 µg/ml ConA 
(b). Mean SI across time points ± SD. 
 
 
Weeks after immunisation 
   
 80 
3.5.3 IFN-γ response to FMDV15 and ConA 
The results from the IFN-γ assay showed many animals failing to produce any 
detectable IFN-γ at each time point (Table 3.1). In addition there were high levels of 
animal to animal variation (Figure 3.5a and b).  
 FMDV15 (week) 
 0 4 8 10 
nonresponders 
(%) 
65 21 24 36 
 ConA (week) 
 0 4 8 10 
nonresponders 
(%) 
30 29 23 41 
Table 3.1 Percentages of nonresponders IFN-γ to FMDV15 and ConA at each week following 
immunisation. 
3.5.3.1 FMDV15 
The mean values of the IFN-γ response to FMDV15 were 106, 622, 714 and 435 
pg/ml for weeks 0, 4, 8 and 10 respectively (Figure 3.5a). The greatest variation in 
levels of IFN-γ in response to the FMDV peptide was at the peak week (week 8) with 
a range of 0-1665 pg/ml.  
3.5.3.2 ConA  
ConA was the positive control for the production of IFN-γ. The levels of IFN-γ with 
a concentration of ConA at 10µg were 100, 219, 761 and 189 pg/ml for weeks 0, 4, 8 
and 10 respectively (Figure 3.5b). Unfortunately weeks 0 and week 4 for cohort 1 do 
not have any ConA results. The greatest variation was seen at week 8 with a range of 
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0-1887 pg/ml with 41 animals failing to make any detectable IFN-γ response. Five 
animals did not make any detectable IFN-γ response to either the FMDV15 or the 
ConA at any time point. The IFN-γ FMDV15 levels were positively correlated with 



























































Figure 3.5 T cell derived IFN-γ levels after immunisation with FMDV15 (a) and ConA (b). Mean 
concentration (pg/ml) across time points ± SD.  
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3.5.4 Alleles within the herd 
All 197 female animals were genotyped at the DRB3 locus using a sequence-based 
typing method (Baxter et al. 2008). However, 19 animals were excluded due to poor 
quality genomic DNA that resulted in poor sequence data. A total of 18 different 
DRB3 alleles were identified in these animals (Table 3.2). The allele with the highest 
frequency was DRB3*2707 (20%) primarily due to the crossbred herd structure as 3 
of the 4 founding sires had DRB3*2707. Alleles *1101 (16%) and *1601 (10%) were 
the second and third most frequent within the population. Six alleles (*1501, *1701, 
*1801, *2002, *2703 and *3201) were represented six times or less in the herd and 
were excluded from the REML analysis presented in this chapter (Appendix C.2, 
C.3).  
3.5.5 Association of DRB3 alleles with the IgG1and IgG2 
response to FMDV15 peptide 
3.5.5.1 IgG1 
IgG1 mean, median and upper and lower quartile levels for week 8 (peak week) were 
examined for each of the DRB3 alleles present within the herd (Table 3.2). The 
alleles were ranked according to the mean IgG values. The IgG1 levels were 
positively skewed as indicated by the median and quartile values. DRB3 *0901 allele 
was associated with the highest mean value, whereas DRB3*1801 allele was 
associated with the lowest value. The DRB3 alleles which showed a significant 
association with IgG1 levels (p<0.05) for more than a week are shown in Table 3.3 
and all other allele results are shown in Appendix C.2. The top ranked allele, 
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DRB3*0901 (Table 3.2), was significantly associated with the IgG1 response at both 
weeks 2 and 8 (Table 3.3) (p<0.05 for both time points). DRB3*1001, which was 
ranked 8th (Table 3.2) and also significantly correlated with the IgG1 responses 
(p<0.05), had a significantly positive effect across the time points (Figure 3.6a). The 
most frequent allele in the herd was DRB3*2707, with a frequency of 20%, and was 
associated with the 3rd lowest mean response, while the 3rd most frequent allele 
DRB3*1601 also gave a low scoring mean value (Table 3.2), ranked 5th from last. 
Both (*2707 and *1601) of these alleles were highly significantly associated with the 
IgG1 response at several time points (Table 3.3). The presence of DRB3*1601 allele 
was correlated with lower IgG1 levels (Figure 3.6b). Animals positive for 2 copies of 
*2707 had a significantly lower IgG1 response (p<0.001) to the FMDV15 peptide 
than animals which did not have a *2707 allele (Figure 3.6c). The predicted means 
values used for the student’s t test were 0 copies of *2707 and 2 copies of *2707.  
Two further alleles, DRB3*0701 and DRB3*0902, were associated with higher and 
lower responses respectively (Table 3.2) although both alleles were only significant 
at a single time point, albeit that in the case of DRB3*0701 the total response (AUC) 
was also significant (Appendix C.2).  
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*0901 0.06 22 468.0 412.0 200.0 735.0 
*0701 0.02 8 422.8 209.0 150.0 806.0 
*2002 0.01 4 398.9 421.0 323.0 474.7 
*2703 0.01 3 385.8 430.7 179.3 581.1 
*1101 0.16 52 379.7 307.5 109.5 533.5 
*1201 0.06 22 355.2 280.0 211.0 464.0 
*3201 0.01 2 349.4 349.4 208.4 490.4 
*1001 0.05 18 332.1 284.0 110.0 494.0 
*0501 0.04 13 311.3 236.0 118.5 412.8 
*0601 0.06 18 308.9 258.0 56.0 394.0 
*1501 0.02 6 256.8 132.3 94.3 193.0 
*0201 0.07 25 255.2 211.0 81.5 335.0 
*0101 0.06 21 241.5 138.0 79.0 315.2 
*1601 0.10 37 239.6 166.3 82.2 341.4 
*0902 0.04 13 206.2 195.0 59.2 297.2 
*2707 0.20 68 205.1 140.4 67.4 279.8 
*1701 0.01 2 116.0 116.0 11.0 221.0 
*1801 0.01 4 111.6 89.0 69.5 153.6 
Overall 1.0 178 289.0 213.8 102.1 405.2 
Table 3.2 DRB3 alleles in the population: mean, median, upper and lower quartiles at peak 
week (week 8) for FMDV15 specific IgG1 (µg/ml).  
Q1 and Q2 represent the lower and upper quartiles, respectively. 
*The frequency of each allele. 
 









weeks     weeks   
2 0.031 n.s. 0.035 <0.001 2 0.013 <0.001 
4 n.s. n.s. 0.004 n.s. 4 n.s. <0.001 
8 0.015 0.031 0.023 0.041 8 0.005 <0.001 
10 n.s. 0.038 0.007 n.s. 10 0.012 0.003 
AUC 0.005 0.009 0.006 0.049 AUC 0.009 <0.001 
Table 3.3 Significant DRB3 alleles for both FMDV15 peptide specific IgG1 and IgG2 responses 
across time. 
AUC: area under the curve; n.s.: not significant. 
p values determined by Wald test. Only those alleles with AUC p<0.05 and that had significant 
values for more than 1 week are shown. 
 
 


















































































































































Figure 3.6 (a) anti-FMDV15 IgG1 responses and DRB3*1001 animals: with 0 copies:  and 
with 1 copy:  (b) anti-FMDV15 IgG1 responses and DRB3*1601 animals: with 0 copies:  and 
with 1 copy:  (c) anti-FMDV15 IgG1 responses and DRB3*2707 animals: with 0 copies:, 
with 1 copy:  and with 2 copies ▲. p values determined by Student’s t-test from predicted 








IgG2 mean, median, upper and lower quartiles demonstrate that the responses were 
positively skewed (Table 3.3). On further analysis, it was clear that many of the 
animals were non-responders at one or more time points. Fifteen of the 178 
genotyped animals did not produce any IgG2 response at any of the time points. The 
majority of these non-responders had alleles DRB3*2707 (6 of the 15 with 1 
homozygote) and DRB3*1601 (9 of the 15) with 3 animals having both *2707 and 
*1601. The mean peak responses were primarily at week 8 although DRB3*0501, 
*1001, *2703, *2707 and *3201 had peak values at week 10 (Table 3.3). Animals 
positive for DRB3*1001 had the highest mean IgG2 response in the IgG2 data set, 
and also the highest median value, whereas this allele only ranked 8th in the IgG1 
dataset but was still significantly associated with higher IgG1 levels, albeit to a lesser 
extent. A single copy of this allele was associated with greatly increased mean IgG2 
levels at weeks 8 and 10 (Table 3.4 and Figure 3.7a). In contrast, DRB3 *0901 which 
was ranked 1st in the IgG1 data set was only ranked 14th in the IgG2 data set, and 
only the AUC was significant. Animals expressing DRB3*1601 produced 
significantly lower levels of FMDV15 peptide-specific IgG2 (p<0.001) (Table 3.4) 
from week 2 onwards (Figure 3.7b) and had a similar ranking for IgG1 and IgG2 
(14th and 16th respectively). 
 
 
   
 88 
















*1001 0.05 18 80.7# 27.0 17.5 53.6 
*1501 0.02 6 52.3 24.9 12.2 61.3 
*0601 0.06 18 32.7 13.6 2.3 31.4 
*0902 0.04 13 32.2 18.3 0.0 64.3 
*1101 0.16 52 31.5 19.8 8.5 36.3 
*1701 0.01 2 27.0 8.9 0.6 18.4 
*1201 0.06 22 26.9 11.0 0.0 46.6 
*0701 0.02 8 26.5 1.4 0.0 34.3 
*0501 0.04 13 25.6# 10.1 1.2 31.5 
*2707 0.20 68 24.2# 18.8 1.5 34.5 
*2703 0.01 3 23.1# 12.6 4.6 45.4 
*3201 0.01 2 18.7# 12.2 5.6 30.2 
*2002 0.01 4 17.1 9.9 2.1 26.9 
*0901 0.06 22 15.9 4.4 0.0 16.8 
*0201 0.07 25 13.2 0.6 0.0 11.6 
*1601 0.10 37 8.7 7.6 5.4 11.9 
*0101 0.06 21 4.3 4.3 0.0 8.6 
*1801 0.01 4 2.1 2.1 0.0 4.1 
Overall 1.0 178 26.0 10.8 0.0 25.8 
Table 3.4 DRB3 alleles in the population and mean, median, upper and lower quartiles at peak 
week for FMDV15-specific IgG2 (µg/ml). 
#Week 10 peak values and means. *The frequency of each allele. 









































































































Figure 3.7 (a) anti-FMDV15 IgG2 responses and DRB3*1001 with 0 copies:  and with 1 copy: 
  (b) anti-FMDV15 IgG2 responses and DRB3*1601 with 0 copies:  and with 1 copy:  .       
p values determined by Student’s t-test from predicted means; **p < 0.001, *< 0.05. 
(a) 
(b) 
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Interestingly, animals positive for the most common allele, DRB3*2707, had 
significantly lower IgG1 and IgG2 responses to the peptide at week 2 (p<0.001), 
although for IgG2, the association was only detected at this week, whereas for IgG1 
week 8 was also significant (Table 3.4; Appendix C.2 and C.3). 
3.5.6 Association of DRB3 alleles with T cell proliferation to 
FMDV15 and ConA 
3.5.6.1 FMDV15 
The T cell mean, median and upper and lower quartiles were examined for the peak 
week for each of the DRB3 alleles for response to FMDV15 (Table 3.5). Allele 
*1001 had the highest T cell SI mean, which is identical to the ranking for IgG2. 
However *0902 was the lowest mean value for the T cell results and is ranked 4th for 
IgG2. Both these alleles, DRB3*1001 and *0902, were found to be significantly 
associated with FMDV15 specific proliferation of T cells at both 1.0 µg/ml and 2.0 
µg/ml FMDV15 concentrations. For DRB3*1001, weeks 8 and 10 were highly 
significant (p<0.001 and p<0.05 respectively at both concentrations) (Appendix C.4). 
Allele *0501 had highly significant (p<0.001) results for all FMDV15 concentrations 
but only at week 0. Animals with *0101 were significant (p<0.05) at week 4 for 
concentrations of 1.0 µg/ml and 2.0 µg/ml. Animals positive for *1101 were 
significant for week 0 at concentration of 2.0 µg/ml. 
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FMDV15 T Cell stimulation index (SI) 
 
DRB3 







*1001 18.47 2.42 1.86 9.65 
*1801 15.42 8.46 1.04 29.80 
*1501 9.20 1.85 1.76 14.81 
*0701 9.18 1.38 1.05 6.18 
*1601 7.92 1.31 1.09 2.20 
*2707 4.83 1.52 1.10 2.94 
*0101 4.44 1.82 1.49 5.03 
*2703 4.37# 2.63 2.00 7.18 
*0501 2.69# 1.50 1.08 2.55 
*0601 2.68 1.34 0.94 2.95 
*1101 2.60 1.53 1.21 2.50 
*3201 2.27 2.27 1.19 3.35 
*0201 2.19 1.24 1.07 1.87 
*0901 1.92 1.51 1.06 2.39 
*2002 1.77 1.98 1.01 2.53 
*1201 1.64 1.25 1.08 1.99 
*1701 1.42# 1.42 1.00 1.85 
*0902 1.36# 1.14 0.91 1.27 
Overall 2.67 1.44 1.06 2.51 
Table 3.5 DRB3 alleles in the population and mean, median, upper and lower quartiles at peak 
week for FMDV15 T cell proliferation (SI). 
# Week 10 peak values and means. 
Q1 and Q2 represent the lower and upper quartiles, respectively. 
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3.5.6.2 ConA 
The T cell mean, median and upper and lower quartiles were examined for week 8 so 
that they were directly comparable to the FMDV peak week for each of the DRB3 
alleles for response to ConA (Table 3.6). Animals positive for allele DRB3*2002 had 
the highest mean value whilst animals expressing DRB3*0902 had the lowest 
responses. Animals positive for DRB3*1001 (n=18) had a high response but it was 
not significant, whilst animals positive for *1701 (n=2) (week 10 p<0.05 at 10 µg/ml 
ConA) had a low response to ConA.  Allele DRB3*1201 had strikingly distinct 
results, as animals positive for a single copy of this allele did not respond to ConA at 
any week (p<0.05) at both 2.5 µg/ml (results not shown) and 10 µg/ml ConA (Figure 
3.8).  There were no correlations between the ranking of alleles for response to 
FMDV and ConA (data not shown). 
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 ConA T Cell stimulation index (SI) 
DRB3 







*2002 33.95 37.05 17.29 50.60 
*1001 21.13 8.86 3.82 24.54 
*0201 20.49 13.29 4.51 34.05 
*0501 17.49 5.15 2.28 35.01 
*1501 17.19 15.55 8.03 26.97 
*1101 17.18 8.68 3.60 24.00 
*1601 15.4 10.74 2.63 15.29 
*2707 13.51 6.09 2.96 13.70 
*0101 12.03 7.97 5.97 13.58 
*1801 10.99 9.84 4.07 17.92 
*0901 10.94 5.22 1.58 17.43 
*1701 10.79 10.79 0.55 21.03 
*0902 10.11 3.94 1.63 8.94 
*2703 9.91 4.58 2.04 19.12 
*0601 9.57 3.18 1.37 13.62 
*1201 9.44 4.75 1.70 11.69 
*3201 4.66 4.66 2.32 6.99 
*0701 4.21 3.58 2.41 5.23 
Overall 14.08 7.02 2.95 17.94 
Table 3.6 DRB3 alleles in the population and mean, median, upper and lower quartiles at peak 
week for ConA (10 µg/ml) T cell proliferation (SI). 
Q1 and Q2 represent the lower and upper quartiles, respectively. 
  
 










































Figure 3.8 T cell proliferation response (SI) to ConA (10µg/ml) and DRB3*1201 with 0 copies: 
 and with 1 copy: . p values determined by Student’s t-test from predicted means; 
**p<0.001. 
3.5.7 Association of DRB3 alleles with IFN-γ responses to 
FMDV15 and ConA 
3.5.7.1 FMDV15 
IFN-γ mean, median, upper and lower quartiles demonstrate that the responses were 
positively skewed (Table 3.7). The mean peak responses were primarily at week 8 
although animals positive for alleles DRB3*0501, *1001, *2703, *2707 and *3201 
had peak values at week 10 (Table 3.7).  On further analysis, it was clear that many 
of the animals were non-responders at one or more time points. Thirteen of the 178 
genotyped animals did not produce any IFN-γ response at any of the time points. The 
majority of these non-responders were positive for alleles DRB3*2707 (8 of the 13) 
and DRB3*1101 (7 of the 13) with 5 animals being heterozygous for *2707 and 
*1101. Only alleles DRB3*1101 and *1201 were significantly associated with 
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responses at more than 1 time point. Animals positive for DRB3*2707 were 
significantly associated with non-response for week 10 (p<0.05). Animals positive 
for DRB3*1101 had lower IFN-γ responses (p <0.001 at week 4 and p<0.05 for week 
10), with homozygous animals showing even lower responses than animals which 
were heterozygous for DRB3*1101 (Figure 3.9). The predicted means values used in 
the students t tests were 0*1101 and 1*1101 for week 4 and 0*1101 and 2*1101 for 
week 10. Animals positive for allele *1201 had p<0.05 values at both week 4 and 
week 10.  
   
 96 
 FMDV15 IFN-γ assay 
DRB3 





*1801 2035 417 199 3872 
*0101 1483 399 32 1025 
*3201 1248 1248 108 2388 
*1501 1173 79 0 545 
*0501 953 308 25 459 
*0701 953 679 63 1828 
*0601 881 126 0 361 
*2707 710 219 29 746  
*1601 633 117 0 562 
*1101 627 215 9 440 
*0901 535 369 102 563 
*1001# 502 325 0 854 
*1701 497 497 495 500 
*2703 374 438 196 535 
*0201 268 33 0 323 
*0902# 260 55 0 215 
*1201  253 84 0 429 
Overall 679 219 10 600 
Table 3.7 DRB3 alleles in the population and mean, median, upper and lower quartiles at peak 
week for IFN-γ (pg/ml) response to FMDV15. 
#Week 10 peak values and means.  
Q1 and Q2 represent the lower and upper quartiles, respectively. 



































Figure 3.9 IFN-γ response after immunisation with FMDV15 and DRB3*1101: 0 copies:; 1 
copy:   and 2 copies:. p values determined by Student’s t-test from predicted means: 
**p<0.001 (0*1101 and 2*1101), *<0.05 (0*1101 and 1*1101).  
3.5.7.2 ConA 
A high number of non-responders were also seen for ConA response, with 12 
animals failing to make any detectable IFN-γ at any of time points (5 of the 12 
animals also did not produce IFN-γ in response to FMDV either). No alleles were 
significant for more than one time point, however several alleles were highly 
significant (p<0.001) at week 4 (*0101, *0501 and *2707).  
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 ConA IFN-γ assay 
DRB3 





*0501 1505 666 231 753 
*1501 1490 387 127 788 
*0101 1406 459 238 1022 
*1801 1405 464 220 2590 
*3201 1370 1370 731 2009 
*0701 1306 732 529 2100 
*0601 965 325 38 668 
*0902 861 475 0 685 
*1701 843 843 567 1118 
*1601 821 423 158 819 
*2707 623 354 127 648 
*0901 601 589 141 913 
*1101 569 356 0 688 
*1201 567 446 112 654 
*1001 404 315 0 718 
*2703 398 317 300 517 
*0201 336 101 0 457 
Overall 751 405 61 712 
Table 3.8 DRB3 alleles in the population and mean, median, upper and lower quartiles at peak 
week for IFN-γ (pg/ml) response to ConA. 
Q1 and Q2 represent the lower and upper quartiles, respectively. 
   
 99 
3.5.8 Summary of trait allele rankings 
The correlations for the ranking of the alleles were investigated. None of the allele 
ranking positions were significantly correlated across any of the traits. However 
DRB3*0501 is ranked at 9th place for IgG1, IgG2 and T cell response to FMDV15. In 
addition alleles *0901, *1001 and *3201 are all ranked at the same position for IgG2 
and T cell response (14th, 1st and 12th respectively).  
3.5.9 Non-responders 
There was a single animal which failed to make any T cell, IFN-γ or IgG2 response 
to FMDV15 at any time point. This animal was heterozygous (*0201 and *1101). In 
addition there was a single animal which did not make a T cell or an IFN-γ response 
which was homozygous for allele *2707, and two animals which did not make any 
IFN-γ or IgG2 response which were both heterozygous (*2707, *1601 and *2707, 
*0101). Thus the *2707 allele may be associated with the non-responders. This allele 
was also ranked low for IgG1, IgG2 and IFN-γ responses (Table 3.1, 3.2 and 3.7). 
3.5.10 Binding pockets 
There are several defined peptide binding pockets within the MHC Class II PBC 
which are encoded by both the alpha and beta DR chains (Bondinas, Moustakas, & 
Papadopoulos 2007). As the bovine DRB3 molecule has a similar PBC to other 
species, most of the polymorphisms in the BoLA DRB3 alleles also encode amino 
acids found in the pockets (Sharif, Mallard, & Sargeant 2000) (Chapter 2).  
Pocket 1 position β86 has 3 possible amino acids but most of the animals in the study 
population had either valine or glycine, with the exception being animals with allele 
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DRB3*0101 (n = 20) which has methionine at position β86. Pocket 4 has 5 amino 
acid positions which are entirely coded by DRB3. Pocket 4 position β70 has 3 
possible amino acids (glutamic acid, glutamine or arginine) although only a single 
allele DRB3*2002 (n = 4), in the study population had a glutamine at this position.  
Pocket 6 has a wide range of residues possible, with a total of 6 amino acids (serine, 
histidine, cysteine, threonine, alanine or tyrosine) in the 18 alleles present in the 
study population. Pocket 7 has 6 positions with position β71 also creating part of 
pocket 4 and position β61 also forming part of pocket 9. Pocket 9 has 5 positions 
which show considerable variability in the amino acids present. Pocket 10 forms 
more of a ‘shelf’ structure rather than a deep pocket and has several amino acids 
shared with pocket 9 (Zavala-Ruiz et al. 2004).  
 
The animals were all subdivided according to pockets and results were fitted in the 
REML model. For IgG1, grouping of animals according to pocket sequence was for 
the most part not significant, with only pocket 9 position β37 having consistently 
significant effects (Appendix C.2). However, pocket 4/7 position 71 was highly 
significant at week 2; individual amino acids were analysed further but were not 
highly significant (Appendix C.2). 
In contrast, for IgG2 the grouping of animals according to the pocket sequence 
revealed that several positions were associated with significant effects (Appendix 
C.3). Three of the positions within the pockets of the PBC were associated with the 
magnitude of the IgG2 levels over the majority of the time points: position β70 
(pocket 4), position β57 (pocket 9) and position β61 (pocket 7 and 9) (Table 3.9).   













E 119 23.9 9.0 0.0 20.9 
R 137 30.5 12.3 1.5 31.4 
4  
position 70 
Q 4 32.2 18.3 0.0 64.3 
D 161 25.5 10.0 0.0 25.1 
V 48 50.6 2.2 10.6 50.5 
A 4 8.7 7.6 5.4 11.9 
9  
position 57 
S 52 25.2 9.9 1.4 31.4 
C 17 86.7 30.5 17.5 67.0 
W 172 26.5 11.3 0.0 26.0 
7/9 
position 61 
L 23 22.4 11.6 0.3 25.9 
Table 3.9 IgG2 (µg/ml) significant binding pockets/amino acids present with the mean, median 
and lower and upper quartiles at week 8.  
 
In terms of the T cell proliferation to FMDV15, there were a few pocket positions 
which were highly significant (p<0.05). Within pocket 7, positions 61, 71 and 76 and 
within pocket 9, positions 37, 57 and 61 were all significant.  However only 1 
position was significant for the T cell proliferation to ConA which was position 28 
within pocket 7 (Appendix C.4 and C.5) 
In contrast to this, there were many positions within the PBC which were highly 
significant for the IFN-γ response (Table 3.10).  
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1 86 4 0.013 10 <0.001 
13 n/s 8 0.001 
4 0.005 n/s 
n/s 8 <0.001 
4 
70 














30 10 <0.001 8 <0.001 
7 
47 4 <0.001 n/s 
7/9 61 10 <0.001 10 <0.001 
7 67 10 <0.001 n/s 
8 0.007 
9 4 0.008 
10 <0.001 
4 0.031   
37 
8 <0.001 8 0.004 
4 0.005 4 <0.001 
8 0.031 8 0.008 57 
10 <0.001 10 <0.001 
9 
60 10 <0.001 10 <0.001 
4 <0.001 
8 <0.001 10 56 
10 0.027 
n/s 
Table 3.10 Significant DRB3 pocket positions and p values for IFN-γ levels in response to 
FMDV15 and ConA. 
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3.5.10.1 DR molecule: binding pocket 1 
The IFN-γ response at week 4 for the FMDV15 peptide indicated that pocket 1, 
position 86, had a significant effect (p= 0.013) (Table 3.10). For the ConA analysis, 
pocket 1 was also highly significant (p< 0.001), but at a later time point (week 10).  
At this position there can be an M, V or G (glycine). However, as only 1 animal has 
the M/M genotype, the results should be treated with caution.  
3.5.10.2 DR molecule: binding pocket 4 
The effects of pocket 4, which is formed from amino acids at positions β13, 70, 71, 
74 and 78, were analysed using the REML model (Appendix C.2 and C.3). Position 
β70 was significantly associated with FMDV-specific IgG1 (p<0.001 at week 2) and 
IgG2 (p<0.001 at weeks 2, 4 and with AUC) (Appendix C.2 and C.3). Amino acids 
present at β70 are either a glutamic acid (E) (n= 119), an arginine (R) (n= 137) or 
rarely in this data set glutamine (Q) (n= 4). Thus, the IgG1 response both before and 
after the boost was strongly correlated with the presence of either glutamic acid or 
arginine at position β70. Animals homozygous for E at position β70 produced 
significantly lower levels of IgG1 and IgG2 over most time points compared to 
animals homozygous for R at this position (p<0.001) (Figure 3.10a).  Furthermore, 
there was no evidence of boosting of the IgG2 response in animals homozygous for 
E, which by week 8 were only producing about one quarter of the IgG2 levels 
compared to animals homozygous for R (p<0.001) (Figure 3.10b). The IFN-γ 
response to the FMDV15 peptide was also significant at β70. In contrast to the 
antibody response, animals with the R/R genotype had lower levels of IFN-γ 
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compared to animals which were heterozygous (E/R) (Figure 3.10c). The T cell 
proliferation was also significant for both E and R at week 4 (p<0.05). The predicted 
means values used in the Students t-test was between the two homozygotes (two 
copies of arginine and two copies of glutamic acid at position β70) for all figures. 

































































































































Figure 3.10 Pocket 4 position β70. (a) anti-FMDV15 IgG1 responses and position  β70 
homozygous for glutamic acid (E) ▲, heterozygous for E and R , or homozygous for arginine 
(R) ♦. (b) anti-FMDV15 IgG2 responses and position β70 homozygous for glutamic acid (E) ▲, 
heterozygous for  E and  R ,  or homozygous for arginine (R) ♦.  (c) IFN-γ levels and position 
β70 homozygous for glutamic acid (E) ▲, heterozygous for  E and  R ,  or homozygous for 
arginine (R) ♦. p values determined by Student’s t-test from predicted means: **p<0.001, 
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3.5.10.3 DR molecule: binding Pocket 7 
All positions in pocket 7 had at least 1 week which was highly significant (p<0.001) 
for IFN-γ levels. However, most of the pocket 7 positions have many amino acid 
combinations. For position β67 there are 5 combinations of amino acids, 
homozygous F/F or I/I or heterozygous F/I, F/T or I/T. Being positive for F/T at β67 
resulted in higher IFN-γ levels than animals positive for I/I across all time points 
Figure 3.11. The animals positive for I/I had the lowest mean IFN-γ levels compared 
to all other amino acid combinations at this position. The Students t-test analysis on 
the predicted means showed that the mean of animals with the F/F genotype was 
significantly different to the means of the animals with I/T at week 8 (p<0.001). The  
The T cell proliferation had several positions within pocket 7 which were significant; 
β28, 61, 67 and 71 (p<0.05) at weeks 8 and 10 (Appendix C.4 and C.5).  
 































Figure 3.11 Pocket 7 position β67 and IFN-γ  response to FMDV15 (pg/ml): Homozygous F/F ,   
heterozygous F/I , heterozygous F/T , homozygous I/I × and heterozygous I/T  .  p values 
determined by Student’s t-test on F/T and I/I from predicted means: **p<0.001, *<0.05. F/F and 
I/T predicted means values used in students t-test.  
3.5.10.4 DR molecule: binding Pocket 9 
Pocket 9 was significantly associated with IgG1 and IgG2 levels (Table 3.9). Pocket 
9 consists of β9, 37, 57, 60 and 61.  A significant effect was found at all of these 
positions, except β9, for IgG2 (Appendix C.3). The significant positions were 
analysed further for both IgG1 and IgG2. Position β37 amino acids include tyrosine 
(Y) (n=81), phenylalanine (F) (n=99), threonine (T) (n=84), arginine (R) (n=5), and 
asparagine (N) (n=34). N was significant for IgG1 (p=0.047), but for IgG2, T and N 
were both significant (p=0.006 and p=0.032 respectively). Having a T at position β37 
was associated with lower levels of IgG2, whilst having an N was associated with 
higher levels of IgG2 (Appendix C.3).  
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At position β57, the amino acid possibilities were alanine (A) (n=4), aspartic acid 
(D) (n=161), serine (S) (n=52) or valine (V) (n=48) (Table 3.9). The mean FMDV15 
specific IgG2 values for V/V, D/D and V/D were 23.91, 13.42 and 52.64 µg/ml 
respectively (Figure 3.12). The Student’s t-test to calculate the significance levels 
was between the D/D and V/D predicted means. Strikingly, the animals which were 
heterozygous for the V/D genotype produced higher levels of FMDV15 specific 
IgG2 whereas all other combinations resulted in lower levels (p<0.05 at weeks 4 and 
10, and p<0.001 at weeks 8 and 10). The highest mean value for the 48 animals 
possessing a V at position 57 (50.6 g/ml in Table 3.9) in fact reflected the 
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Figure 3.12 Pocket 9 position β57 and anti-FMDV IgG2 responses: neither D nor V▲, 
homozygous for V X, V/D ▄ or homozygous for D ♦. p values determined by Student’s t-test 
from predicted means:**p<0.001, *<0.05. D/D and D/V predicted means values used for the 
Student’s t-test.  
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At position β61 there can either be a cysteine (C) (n= 17), leucine (L) (n= 23) or 
tryptophan (W) (n=172) (Table 3.9). Both C and W were associated with both IgG1 
and IgG2 levels (p<0.05; data not shown). Further analysis revealed a complex 
relationship between alleles as animals heterozygous for W produced significantly 
higher levels of IgG2 than any other combination yet animals homozygous for 
tryptophan had the lowest response (Figure 3.13). The 0W and 2W predicted means 
values were used in the Student’s t-test analysis.  In particular, animals with the 
genotype C/W had the highest response of all and this effect was particularly 
















































Figure 3.13 Pocket 9 position β61 and anti-FMDV IgG2 responses: no copies of W ◊, single copy 
of W   ▄ or homozygous for W ▲. p values determined by Student’s t-test from predicted means: 
**p<0.001, *<0.05.  0W and 2W predicted means used in the Student’s t-test 
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3.5.10.5 DR molecule: binding Pocket 10 
Pocket 10, which consists of β56, 57 and 60, overlaps with pocket 9. Position β56 is 
significantly associated with IgG2 levels but not IgG1 (Appendix C.2 and C.3). 
Amino acids possible at this position include proline (P), R or Q. Both Q and R were 
significantly associated with IgG1 and IgG2 response, with a single copy of the R 
having a highly significant effect for specific IgG2 (data not shown). Having an R 
was associated with an increase in IgG2. The IFN-γ response was highly 
significantly associated with β56 with weeks 4, 8 (p<0.001) and week 10 (p<0.005) 
and an R at this position is highly significant (p<0.05).  
The remaining pockets were also analysed (Appendix C.2, C.3, C.4 and C.5). Pocket 
1 (position β86) had significant effects on IgG1 antibody levels (p<0.05) at week 10 
and IgG2 weeks 4 and 8. Pocket 4 position β13 was significant at weeks 4 and 8 for 
IgG2, but at no time points for IgG1. Position β74 was only significant for a single 
time point, week 8 for IgG1 and week 2 for IgG2. Pocket 6 β11 was significant at 
week 2 for IgG1 (p<0.05) and IgG2 (p<0.001). None of the positions within pocket 7 
were significant for IgG1. However, for IgG2 there are several pocket 7 positions 
significant for a single time point (β28, 30, and 71).  The rest of the pocket positions 
were not significant (Appendix C.2, C.3, C.4 and C.5). 
3.5.11 3D modelling 
Overall it seemed apparent that the pocket positions had a profound influence on the 
ensuing immune response, and so it would seem highly probable that this is due to 
the binding affinity. As there is no crystalline structure for the bovine DR molecule, 
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modelling was attempted using the HLA-DR molecule as a template.  The modelling 
of both the BoLA-DR molecule and the peptide represents very preliminary data.  
The alleles *1001 and *1601 were highly significantly associated with the antibody 
response to FMDV15, with *1001 being positively associated and *1601 negatively 
associated. The preliminary data from the modelling of these two alleles show that 
the structure of the PBC is different in the two alleles. The two alleles differ most in 
pocket 4, where the DRB3*1001 has an overall positive electrostatic charge (Figure 
3.14) whereas *1601 has an overall negative electrostatic charge (Figure 3.15).  
These electrostatic differences were most likely determined by the negatively 
charged glutamic acid and positively charged arginine (DRB3*1601 and 
DRB3*1001 respectively) at position β70, within pocket 4. These were significantly 
associated with the IgG1, IgG2 and IFN-γ response to the FMDV15 peptide. The 
negatively charged glutamic acid at β70 may possibly be altering the binding of the 
FMDV15 peptide resulting in different levels of response. Due to difficulties in 
correctly modelling a small 40-mer peptide, it is not possible to accurately predict the 
docking of the peptide with each of the two alleles, although very preliminary data 
(not shown) indicates that this may be the case.    
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Figure 3.14 3D electrostatic model of DR molecule using DRB3*1001. Blue represents an overall 
negative charge, red represents an overall positive charge and white represents an overall 
neutral charge. Pockets 1, 4, 6, 7 and 9 are shown within the PBC. Pocket 4 is highlights in the 
green shading. 







Figure 3.15 3D electrostatic model of DR molecule using DRB3*1601. Blue represents an overall 
negative charge, red represents an overall positive charge and white represents an overall 
neutral charge. Pockets 1, 4, 6, 7 and 9 are shown within the PBC. Pocket 4 is highlights in the 
green shading. 
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3.6 Discussion  
For a vaccine to be considered successful an appropriate protective immune response 
has to be elicited in all individuals. Results in this chapter demonstrate that several 
BoLA-DRB3 alleles are significantly associated with the level of the adaptive 
immune response produced after immunisation with a synthetic peptide of the 
FMDV VP1 capsid protein. Furthermore, individual positions within the PBC are 
significantly associated with the levels of the specific antibody and IFN-γ, and to a 
lesser extent T cell, response to FMDV15. 
Even though the immunising antigen, FDMV15, is relatively simple compared to a 
pathogen or subunit vaccine, a considerable degree of variation is seen in the 
responses to the FMDV15 peptide post-immunisation, suggesting that not all animals 
are protected to the same degree.  Previous studies have indicated that DRB3 alleles 
are associated with variation in response to FMDV (Glass et al. 1991; Glass & Millar 
1994; Garcia-Briones et al. 2000) and with protection against viral challenge 
following immunisation with FMDV peptides (Glass et al. 1991; Garcia-Briones et 
al. 2000).   
BoLA-DRB3 is one of the most polymorphic genes within the bovine MHC locus and 
BoLA-DRB3 polymorphisms were more strongly linked to variation in the IgG2 
response and IFN-γ response than to the IgG1 response, with the fewest associations 
found for the T cell proliferation responses.  This might suggest that genes other than 
BoLA-DRB3 have greater impact on the variation in the IgG1 and T cell responses. 
However, it should be noted that the assays for the T cell and IFN-γ responses were 
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conducted with whole blood, and proliferation for logistical reasons was measured 
after 6 days of culture which is not optimal.  Furthermore it is also possible that at 
the later time points rising antibody levels in the blood may have inhibited the T cell 
and IFN-γ response by binding to the peptide antigen.  Nevertheless, significant 
associations were found for the cell-based assays. The bovine antibody isotype 
functions are not as fully described as human or mouse but it is thought that the IgG1 
contributes to phagocytosis whilst an IgG2 response has a neutralising effect. The 
switch between the IgG subclasses is complex and is not entirely understood, but it is 
hypothesised the affinity of peptide/MHC binding dictates the resultant IgG response 
(Mulcahy et al. 1990; Estes & Brown 2002). It is possible that the binding affinity of 
processed peptides may be different between different DRB3 alleles which might 
result in either an IgG1-biased or an IgG2-biased response. It is interesting to note 
that the IgG2 and IFN-γ responses (which are Th1) have a more significant 
association with the alleles of DRB3.   
There was evidence that certain alleles and amino acids in pockets 4 and 7 had 
different relationships with the primary and secondary responses, suggesting that 
DRB3 polymorphisms may also influence the duration of response. The level of IFN-
γ is correlated with the ability of a vaccinated animal to control replication of the 
virus (Parida et al. 2006), and there are many positions within the PBC which are 
highly significantly associated with the levels of IFN-γ post-immunisation.  
A number of animals responded to the FMDV15 peptide at week 0 for T cell 
proliferation and IFN-γ production, and this was unexpected as the animals were 
naïve to FMDV. A possible explanation for this may be the binding of the peptide to 
integrin receptors on the cell surface. FMDV is known to interact with these 
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receptors through the RGD loop on the viral capsid (Berinstein et al. 1995) which is 
also present in the FMDV15 peptide. It may be that this interaction between the 
peptide and the integrin receptors triggered the low level T cell proliferation and 
IFN-γ production in week 0.  
Although many of the associations described in this chapter are highly significant, 
they are not absolute, which would indicate that there are other factors playing a role 
in determining the variation in immune responses to the FMDV15 peptide. As the 
BoLA region, like other vertebrate species, is extremely gene dense with at least 154 
genes expressed (The Bovine Genome Sequencing and Analysis Consortium et al. 
2009), it is possible that the associations with BoLA-DRB3 polymorphisms are, at 
least partly, due to the influence of other linked loci, in particular DQA and/or DQB, 
both of which are polymorphic in cattle (Lewin, Russell, & Glass 1999). In fact, it 
has been shown that peptides derived from FMDV can be presented by DQ 
molecules (Glass, Oliver, & Russell 2000; Gerner et al. 2009). Certainly DR-DQ 
linked haplotypes have been described (http://www.ebi.ac.uk/ipd/mhc/bola; Lewin, 
Russell, & Glass 1999), but the majority of these haplotypes have been described for 
single breeds, and do not have a one to one relationship, as there are many more 
DRB3 alleles than DQA or DQB alleles. For example within the Holstein breed, 
DQA*0101/DQB*0101 was present on a haplotype containing DRB3*0101 as well 
as a haplotype containing DRB3*2002 (Glass, Oliver, & Russell 2000). In this 
chapter there were two DRB3 alleles (*0101 and *2002) were associated with 
different responses to the FMDV peptide, suggesting that the DQ restricted 
presentation could not account for the differential responses. In addition, as the 
population was a cross derived from a breed selected for beef qualities (Charolais) 
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and a breed selected for dairy characteristics (Holstein), it may be inappropriate to 
infer the DR-DQ haplotypes as these may also differ between the breeds. However 
the contribution of other loci in this study cannot be ruled out. The observed 
variation across the population is also partly accounted for by host genetics at other 
non-MHC loci (and partly by environmental factors) (Leach et al. 2010). In addition, 
DRB3 molecules can present FMDV-derived epitopes directly to bovine T cells 
using DR transfectants (Fraser et al. 1996) and anti-DR blocking mAbs (Fraser et al. 
1996; Glass, Oliver, & Russell 2000). The FMDV15 peptide used here is unlikely to 
bind to BoLA Class II molecules directly as it is a 40-mer, but is likely to be 
processed into subpeptides with the 140–160 bp region being immunodominant at 
least for T cell responses (Glass et al. 1991; Glass & Millar 1995).  Previous studies 
have indicated that DRB3 alleles are associated with variation in T cell response to 
FMDV peptides (Glass & Millar 1994; Garcia-Briones et al. 2000) and others have 
shown that the binding affinity of some FMDV peptides to certain BoLA-DRB3 
alleles is correlated with T cell proliferation (Haghparast et al. 2000).  T cell 
responses also correlate with serum neutralising titre (Glass & Millar 1994; Glass, 
unpublished observations) and with protection against viral challenge following 
immunisation with FMDV peptides (Garcia-Briones et al. 2000). Nonetheless 
epitopes derived from FMDV15 peptide may be different from those derived from 
the native virion (Van Lierop et al. 1995) and FMDV15-specific T cells primed in 
DRB3*1801 positive cattle were directed to the PPS spacer region (Glass & Millar 
1995), which may explain why DRB3*1801 positive animals were not protected by 
similar peptides (Garcia-Briones et al. 2000). Data presented in this chapter, although 
based on only four animals, would tend to confirm that DRB3*1801 is associated 
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with non-protection as it ranked as the lowest for both FMDV15 peptide-specific 
IgG1 and IgG2, and yet is ranked 2nd for T cell response.  Unfortunately logistics did 
not allow a fine mapping of T cell epitopes in this study, but it would have been 
interesting to determine if the animals positive for DRB3*1801 were indeed focused 
on the spacer region. It would further support the premise that the observed 
associations are DR-specific as similar results were also seen in both Argentinean 
Hereford cattle (Garcia-Briones et al. 2000) and UK Holstein–Charolais cross breeds 
(this study). The most frequent allele in the RoBoGen population is *2707. However, 
this allele seems to be associated with a lack of response of IgG2 and IFN-γ. 
Although a humoral response is generally accepted as the main protective 
mechanism against FMDV (Goris et al. 2008), the correlation between the levels of 
neutralising antibody and protection are not always apparent, especially in the case of 
peptide or subunit vaccines, and it is clear that other factors play a role (Collen, 
Dimarchi, & Doel 1991). Indeed it is clear that innate, cell mediated and different 
aspects of humoral immunity all play a role in determining whether an animal is 
protected against FMDV (Collen 1994; Sobrino et al. 2001; Summerfield et al. 
2009).  Furthermore, it is likely that a combination of Th1 and Th2 responses are 
necessary to provide protection as both IgG1 (Capozzo et al. 1997) and IFN-γ 
(Parida et al. 2006) (which in cattle are associated with Th2 and Th1 responses 
respectively (Estes & Brown 2002)), correlate with protection. However in none of 
these studies has the role of host genetics been considered, even though considerable 
animal to animal variation was observed.  By using a large number of animals with a 
consistent immunisation regime it has been shown here that BoLA-DRB3 
polymorphisms are linked to both cell-mediated and humoral responses to FMDV15. 
   
 119 
Further research in this area is clearly warranted as neither the antiviral antibody or 
protection against viral challenge has been measured, and different alleles were 
associated with each type of response.  
The relative balance of humoral and cell-mediated immunity as well as the isotypes 
of IgG, IgG1/IgG2, may dictate whether protective immunity is generated, as the 
ratio between the type of isotypes produced may be dependent on the binding affinity 
of the peptide to the MHC molecules. It would be feasible to test this hypothesis, for 
example using animals with allele DRB3*0901 and investigating any differences in 
IgG1/IgG2 ratios and protection levels after immunisation, as animals with this allele 
showed high mean levels for IgG1 but lower levels for IgG2 compared to the rest of 
the herd. The *1001 allele would be of use for further investigations, as this allele is 
top of the ranking for both IgG2 and T cell responses. It was also a good candidate 
for protection against viral challenge following FMDV-derived peptide 
immunisation (Garcia-Briones et al. 2000). These findings suggest that the DRB3 
alleles would be an important consideration in the design of any synthetic vaccine.  
There is likely to be a correlation between peptide binding affinity to restriction 
elements and the resultant immune response and indeed another study has shown that 
binding affinity of FMDV-derived peptides is correlated with T cell proliferation 
(Haghparast et al. 2000). Polymorphisms present within DRB3 exon 2 result in 
numerous amino acid changes in the PBC. Specific positions within the PBC form 
‘pockets’ where side chains of the FMDV15 peptide bind. The ability of a pocket to 
‘anchor’ a peptide is due to the electrostatic charges of the pocket region and the 
electrostatic charges of the peptide (Stern et al. 1994). Several of these pocket 
positions were significantly associated with FMDV-specific IgG1 and IgG2 levels. 
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Binding pocket 4 in particular has a significant impact on the IgG antibody level, and 
on the IFN-γ levels, which is likely to be due to its central position within the PBC 
(Fu et al. 1995; Cardenas et al. 2005). Pocket 4 is entirely encoded by exon 2, and 
includes five amino acids which together create a wide variety of amino acid motif 
possibilities. However, a single position, β70, had the most significant association 
with IgG1 and IgG2 response and was also significantly associated with the cellular 
responses. The change at β70 from a negatively charged glutamic acid to a positively 
charged arginine in allele *1001 and *1601 alters the conformation of the PBC in the 
3D models (Figure 3.14 and 3.15) and potentially impacts on the binding of the 
peptide within the PBC.  This may explain the strong association with the IgG and 
IFN-γ responses. E and R at β70 were significantly associated with the T cell 
proliferation at an early time point of week 4 perhaps suggesting that other factors 
are affecting the secondary T cell response. These results suggest that the 
relationship between BoLA-DRB3 polymorphisms and immune response may be 
because of differences in the strength of binding of peptide to the PBC in different 
alleles. More detailed molecular studies are required to ascertain if this is the case.  
The amino acids present in pocket 4 also influence the immune response to other 
pathogens. Positions β13, β71 and β74 are associated with mastitis resistance (Sharif, 
Mallard, & Sargeant 2000), and the amino acid motif ER at β70 and β71 was 
associated with resistance to persistent lymphocytosis (Xu et al. 1993).  Resistance to 
dermatophiliosis in Zebu cattle has been associated with the EIAY motif at positions 
β66-β67-β74-β78, which includes pocket 4 (Maillard, Martinez, & Bensaid 1996). 
The deletion of β65 in DRB3, present in allele DRB3*0201, affects the conformation 
of pocket 4 and the resultant immune response to a vaccine against ticks (Sitte et al. 
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2002). In humans significant associations have been found between the DRB allele 
and resulting immune responses, e.g. HLA-DR pocket 4 has been linked to resistance 
to tuberculoid leprosy (Zerva et al. 1996). A recent study on the diversity within the 
PBC in DRB3 alleles has revealed that pocket 4 and particularly position 70 in cattle 
are under greater positive selection than other mammalian species (Takeshima et al. 
2009), underlining the potential importance of pocket 4 for vaccine design. 
In a previous study, a trend towards protection against viral challenge following 
FMDV peptide immunisation was observed with alleles DRB3*1, *3 and *7 (*0501, 
*1001 and *0201 respectively) (Garcia-Briones et al. 2000). These alleles all have 
arginine at β70, which together with the data presented here provides further 
evidence that this residue may be critical for protection against FMDV challenge. 
Therefore potentially a more effective vaccine could be designed that comprised two 
separate FMDV peptides that bind to both types of amino acid at position β70.  Such 
a vaccine may result in FMDV protection in the major part of the population 
described here. However, at β70 there are two further possible amino acids: aspartic 
acid (negatively charged) and glutamine (neutrally charged) 
(http://www.ebi.ac.uk/ipd/mhc/bola/). Nonetheless, it may be feasible to create a 
vaccine containing different versions of the epitopes which would bind to a positive, 
negative or neutral charge at β70 and thus potentially elicit a universal response in all 
cattle populations. This could be formally tested by immunising and challenging 
appropriately typed cattle.   
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Positions in pockets 7, 9 and 10 were also found to be significantly associated with 
the antibody response. Two of these, β37 and β57 in pocket 9, were also associated 
with the IgG1 responses, and both of these residues are also under positive selection 
in cattle (Takeshima et al. 2009). 
All the pockets in the PBC were found to have a profound impact on the IFN-γ levels 
for both the response to ConA and the FMDV15 peptide. The IFN-γ levels were 
more significant than any of the other measured immune responses. There is no 
available literature examining the association between IFN-γ response and MHC 
alleles. 
Pocket 10 is not usually considered when investigating the PBC, however in human 
DRB the polymorphisms present at positions β56, 57, 76 and 60  (pocket 10) were 
found to be important for peptide binding (Zavala-Ruiz et al. 2004).  In the present 
study position β56 in pocket 10 was associated with IgG2 and IFN-γ levels, and the 
positively charged arginine at this position had the greatest effect on the levels of 
antibody and IFN-γ. Therefore several of the binding pockets, other than pocket 4, 
have the potential to significantly affect peptide binding affinity, and it would also be 
prudent to consider other T cell epitopes and their interactions with DR and DQ 
molecules in the design of any new vaccine to maximise the population response. 
Further studies are now warranted to test our predictions that DRB3 type is related to 
the level of response.  As pocket 4 seems statistically to be the most important it may 
represent the major host-derived consideration for future peptide vaccine designs.  
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MHC heterozygotes are hypothesised as having a selective immunological advantage 
over homozygotes, although the evidence for this has been mixed (Penn, 
Damjanovich, & Potts 2002). MHC heterozygote advantage has been described in 
human diseases such as those caused by Hepatitis B and HIV infection (Thursz et al. 
1997; Carrington et al. 1999). This benefit may be due to the increased diversity of 
peptides being presented to T cells and thus generating a more diverse T cell 
population (Penn, Damjanovich, & Potts 2002). In the cattle population used in this 
study most of the animals were heterozygous at the DRB3 locus (~89%), therefore it 
is statistically difficult to investigate heterozygote advantage. However, by 
investigating the individual pocket positions within the PBC, the level of complexity 
is decreased, which enabled the population to be divided into larger subsets than 
those for the individual alleles. Using this approach significant heterozygote 
advantage at two positions was identified: animals heterozygous at β57 (within 
pocket 9 and 10) for valine and aspartic acid had a higher IgG2 response compared to 
either of the homozygotes (Figure 3.10) and in addition, animals heterozygous for 
tryptophan/cysteine at position β61 also had a greater IgG2 response compared to 
homozygous animals (Figure 3.11). A heterozygote advantage was also observed for 
the levels of IFN-γ, within pocket 7 (Figure 3.9). These examples were the only 
evidence for heterozygote advantage seen in this population.  However it supports 
the premise that maintaining diversity in MHC alleles is important for greater disease 
resistance, although the limited use of particular sires in modern cattle herds may 
preclude such benefits.  
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In this chapter further evidence is presented that the limited success of the FMDV15 
peptide in inducing protection against the virus may be due to the polymorphisms 
present in the BoLA-DRB3 locus. It has been demonstrated that the BoLA-DRB3 gene 
affects the response to FMDV15 even in a diverse genetic background. Although it 
has not been shown whether the alleles directly affect the level of protection, it has 
been shown that the magnitude and nature of peptide-specific antibody was 
influenced by the polymorphisms present at the DRB3 locus. In addition it was 
demonstrated that the polymorphisms in the binding pockets, in particular pocket 4, 
mainly the β70 position, where there is a change from negative to positive charge, 
are likely to have the greatest impact in significantly altering the IgG and IFN-γ 
responses. However, the role that the binding pockets play in the T cell proliferation 
is likely to be more complex and other factors may be involved. Thus it may be 
possible to design an effective FMDV peptide vaccine, based on the conformation of 
the PBC, and the charges of the key amino acids in the population of cattle, such that 
that the majority of animals would be protected. Similar considerations could be 
adapted and used for the design of other vaccines.  
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4 BoLA-DRB3 alleles and polymorphisms and 
associations with the IgG to respiratory vaccines 
and association with peripheral blood 
mononuclear cell proliferation to Staphylococcus 
aureus and phytohaemagglutinin (PHA)  
4.1 Introduction 
The results from Chapter 3 indicated that alleles of DRB3 and polymorphisms in the 
PBC had significant associations with the response to immunisation with a synthetic 
40-mer peptide derived from FMDV (Baxter et al. 2009). A number of studies have 
also found evidence for diversity in DRB3 impacting on response to pathogens and 
other antigens (Xu et al. 1993; Garcia-Briones et al. 2000; Udina et al. 2003; 
Ballingall et al. 2004). It is thus reasonable to hypothesise that DRB3 alleles and 
PBC polymorphisms may also have significant associations with responses to 
commercially available vaccines and commonly occurring pathogens and that the 
experimental design described in Chapter 3 would facilitate such a study. 
Associations between DRB3 alleles and the PBC polymorphisms and response to two 
respiratory vaccines for bovine respiratory syncytial virus (BRSV), parainfluenza 
virus-3 (PIV3) and bovine herpes virus-1 (BHV1) (also known as infectious bovine 
rhinotracheitis virus (IBRV)) were explored in this chapter. In addition DRB3 allele 
associations with the response to a Staphylococcus aureus strain and to a mitogen, 
phytohaemagglutinin (PHA), within the same cattle population were studied. 
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4.1.1 Bovine respiratory disease  
 
Bovine respiratory disease (BRD) has a major economic and animal welfare impact 
worldwide and is estimated to cost the UK livestock industry more than £60 million 
per year (NADIS 2010). BRD is a complex of diseases with many viral and bacterial 
infectious agents. The viral pathogens which are known to contribute to the 
development of BRD include BRSV, PIV3, BHV1 and bovine viral diarrhoea virus 
BVDV. Often infection with viral respiratory pathogens results in secondary 
bacterial infections.  Currently the control methods for BRD include vaccination 
against the four viral pathogens (Bowland & Shewen 2000), as well as vaccination 
against the bacterial pathogens Mannhiemia haemolytica and Pasteurella multocida, 
associated with BRD (Fulton et al. 2004), although the efficacy of these vaccines has 
mainly not been subject to controlled challenge studies (Bowland & Shewen 2000). 
With no current antivirals for livestock on the market, the prospect of using genetic 
selection for increased response to vaccination would be appealing.   
4.1.2 Genetics of BRD 
The heritability for resistance to BRD is low ranging from 0.04 to 0.08 ± 0.1 
(Snowder et al. 2006; Heringstad et al. 2008). The low heritability would imply that 
any effort to breed for BRD resistance would require many cattle generations. 
However, BRD is a complex of diseases and it might be more beneficial to breed for 
resistance to individual pathogens. There is general agreement that BRSV is 
probably the most important factor in BRD.  There have been many studies 
investigating the genetics underlying the human form of RSV (HRSV), which 
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indicate that the host genetics do play a role in resistance to disease caused by HRSV 
(Janssen et al. 2007).  
4.1.3 Bovine respiratory syncytial virus  
Bovine respiratory syncytial virus (BRSV) is an enveloped, negative-sense single-
stranded RNA Pneumovirus of the Paramyxoviridae family.  It is ubiquitous in both 
dairy and beef cattle worldwide and causes high morbidity in young animals and is 
the most important cause of lower respiratory tract infection in young calves 
(Valarcher & Taylor 2007). The clinical signs of BRSV include severe infection of 
the lower respiratory tract, resulting in coughing and nasal discharge and abnormal 
breathing sounds (Antonis et al. 2003). Most of the pathology observed from BRSV 
infection is not caused by the virus but is due to the host response (Antonis et al. 
2003; Glass et al. 2010). Neither natural infection nor vaccination induces long 
lasting immunity (Meyer, Deplanche, & Schelcher 2008) and young calves are 
repeatedly infected.  It is generally considered that neutralising antibody constitutes 
the most important protective mechanism against infection, but it is likely that cell 
mediated immunity also plays a role. A further problem is that waning maternal 
antibody, which leaves calves at risk of this endemic pathogen, also inhibits 
induction of protection. 
Currently the control of BRSV infection is through management and vaccination 
programmes of calves using modified live virus (MLV) or killed virus vaccines 
(Meyer, Deplanche, & Schelcher 2008).  In humans no RSV vaccines are licensed 
due to severe lung pathology caused by host response to an inactivated virus vaccine 
(Hussell et al. 1998; Meyer, Deplanche, & Schelcher 2008). Although there are cases 
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of inactivated BRSV vaccines causing pathology in calves (Gershwin 2007), mainly 
these type of vaccines are considered safe for cattle (Meyer, Deplanche, & Schelcher 
2008). In the study described in this chapter, the animals were vaccinated with 
Rispoval RS (Pfizer), a live attenuated virus vaccine.  It is based on BRSV strain RB-
94 (a 1969 Belgian isolate) and has been used widely in Europe as a vaccine since 
1978 (Zygraich 1982). 
4.1.4 Bovine parainfluenza-3 virus  
Bovine parainfluenza-3 virus (PIV3) is a single-stranded RNA virus which is closely 
related to the human parainfluenza virus 3 (HPIV3) and is a member of the 
Paramyxoviridae family (Kapil & Basaraba 1997). Clinical signs of the disease can 
vary considerably but usually include acute respiratory illness, fever, and malaise 
(Horwood, Gravel, & Mahony 2008). Whilst PIV3 rarely causes death, it does 
provide opportunities for secondary infections especially when animals are under 
stress (Horwood, Gravel, & Mahony 2008). PIV3 is very prevalent in European 
herds with an  estimated 70-85% of animals  infected by 9 months of age (Stott et al. 
1980).  
The protective mechanism against PIV3 infection is primarily humoral although 
cellular mechanisms are also stimulated (Hussain & Mohanty 1984), with nasal 
antibody titres providing an accurate measurement of host resistance (Frank & 
Marshall 1971).  
Current management of infection is through intranasal vaccination. The vaccine used 
in this study was Imuresp (Pfizer) which consists of a live attenuated strain of PIV3 
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(ts RLB 103) and a live attenuated strain of IBR (ts RLB 106). This vaccine has been 
shown experimentally to provide significant levels of protection (Bryson et al. 1999). 
The role of the host genetics in influencing the levels of protection post-PIV3 
vaccination has not been thoroughly explored, however the study by O’Neill 
indicated a strong sire-based genetic effect (O'Neill 2006).  
4.1.5 Bovine herpes virus 1  
Bovine herpes virus 1 (BHV1) is a double-stranded DNA virus and a member of the 
alphaherpesvirinae subfamily and is the cause of infectious bovine rhinotracheitis 
(IBR) and infectious vulvovaginitis/balanoposthitis (Yates 1982). As with all alpha 
viruses, the herpes virus enters a latent state within the ganglionic neurons after 
infection (Lemaire et al. 2000), which results in the re-activation of BHV1 under 
stressful situations.  
Infection with BHV1 can result in immunosuppression with the down regulation of 
interferon (Henderson et al. 2004), apoptosis of CD4+ T cells (Winkler, Doster, & 
Jones 1999), and reduced expression of MHC Class I and II molecules (Hinkley et al. 
2000; Koppers-Lalic et al. 2008). 
BHV1 is a common pathogen amongst cattle with an estimated seroprevalence of 
42.5% in UK herds (Woodbine et al. 2009). Some countries have eradicated BHV1 
through culling of infected animals but most have chosen less extreme measures, 
instead choosing to vaccinate using either live attenuated or inactivated vaccines 
(Denis et al. 1996).  An effective vaccine against BHV1 should not only protect the 
animal against infection but also protect from the establishment of latency (Gogev et 
al. 2002).  
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Vaccination leads to long lasting immunity (Burroughs et al. 1982). A study into the 
humoral response of cattle to the vaccination was completed at the Roslin Institute 
(O'Neill 2006). This study showed that there is a large amount of maternal antibody 
passed to the calves presumably via the colostrum, since antibodies cannot cross the 
placenta to the developing calf during pregnancy. This circulating maternal antibody 
can have an effect on the resultant protection that the vaccine should elicit. 
4.1.6 Vaccination  
Any vaccination program needs to induce long lasting immunity to infection, 
although the exact requirements for this are still unknown. The main quantitative 
measurement of vaccine efficacy is generally the induction of antibodies.  However 
the mechanisms of protection and protective correlates are still being debated. It is 
highly probable that a substantial T cell response would also be required to induce a 
long lasting immune response. Indeed for the resolution of BRSV infection the 
correct balance of CD4+ and CD8+ T cell subsets are required (Taylor et al. 1995; 
Gaddum et al. 1996; Fogg et al. 2001) and for BHV1 the response of CD8+ cells is 
considered to be more relevant (Zatechka et al. 1999). 
Another major difficulty in the induction of immunity in young animals is the 
persistence of maternal antibodies (Siegrist 2003). Respiratory infections are a major 
problem for young cattle as for young humans.  There is a limited window in which 
maternal antibodies protect young animals before maternal antibody wanes.  
However, the maternal IgG levels have been shown to affect the efficacy of 
vaccination in humans (Glezen 2003) and in cattle (Vangeel et al. 2005). The levels 
of pre-existing maternal antibody appear to have had an impact on the vaccination of 
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the RoBoGen herd, with a decline of BRSV IgG prior to vaccination (O'Neill et al. 
2006).  
4.1.7 Genetics and vaccination 
Understanding the underlying host genetics may help in the design of more 
efficacious vaccines or lead to selective breeding programs. There is evidence that 
the host genetics can have an impact on the resultant immune response to vaccination 
in humans (Glass 2004; Poland et al. 2007). It is thus very likely that the bovine 
immune response to vaccination will also have a genetic element (Newman et al. 
1996). The study by O’Neill (2006) suggested that the response to the respiratory 
vaccines does have a genetic element, although the precise genes have not been 
identified. A follow-up study has revealed a number of quantitative trait loci (QTL) 
for the response to BRSV vaccination suggesting that the variation in response is 
under multigenic control (Leach and Glass, unpublished observations). BRD has a 
large economic impact on the livestock industry and vaccination is at best only 
partially successful in preventing infection and ensuing disease.  Thus it would be 
highly beneficial to identify genes that may play a role in host variation in the 
response to vaccination, as this might suggest ways to improve vaccine efficacy and 
perhaps reveal genes playing a role in resistance and susceptibility to disease. 
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4.1.8 DRB3 and vaccination 
Few studies have endeavoured to study the associations between the BoLA alleles 
and vaccination (reviewed by Glass (2004)). However, the experimental design of 
the RoBoGen herd provided an opportunity to investigate the genetics underlying the 
response after vaccination (Glass 2004; O'Neill 2006). 
As the classical MHC gene products are intimately involved in the activation of the 
adaptive immune response and variation in many humoral responses to viruses, they 
are highly likely to be, at least in part, responsible for the outcome to vaccination. 
The MHC locus has also been linked to the humoral response to pathogens in other 
species, e.g. the chicken MHC has been linked to antibody response to Marek’s 
disease (Bacon, Witter, & Silva 2001) and in humans the HLA genes have been 
associated with human immunodeficiency virus (HIV) infection outcome (Kaur & 
Mehra 2009). Whilst the DRB3 gene has not been associated with the response to any 
commercial virus vaccines in cattle, they have been associated with the humoral and 
cellular response to a FMDV peptide (Garcia-Briones et al. 2000) and to a tick 
vaccine (Sitte et al. 2002) (see also Chapter 1 Table 1.1).  BoLA haplotypes have 
also been associated with the response to natural BRSV infection (Schrijver et al. 
1997). There have been associations noted in humans with the alleles of the DRB 
gene and response to vaccination (Vidan-Jeras et al. 2000; Gelder et al. 2002). 
4.1.9 Staphylococcus aureus  
Staph. aureus is a gram–positive bacterium which is common in the environment. It 
is known to cause a wide variety of infections in mammals although symptomatic 
infection is uncommon. In cattle mastitis is caused by a variety of bacteria with a 
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major causative agent being Staph. aureus. Mastitis in livestock is a serious infection 
of the mammary gland which affects lactating cattle leading to low milk yield as well 
as causing severe welfare issues.  It results in considerable economic losses estimated 
to be around 150 to 300 Euros per diseased cow (Davies et al. 2009). 
Staph. aureus causes a chronic and recurrent infection which results in the reduction 
in both the quantity and the quality of milk (Wilson, Gonzalez, & Das 1997). The 
main immune mechanism against Staph. aureus infection is phagocytosis mainly 
through the action of neutrophils and macrophages (Paape et al. 1981). Unfortunately 
the inability of these cells to resolve infection is primarily due to a change in 
morphology and reduction of phagocytosis after the ingestion of caseins and milk 
fats (Paape & Guidry 1977). However, lymphocytes also play an important role in 
the clearance of infection (reviewed by Sordillo & Streicher (2002)). The data on the 
proliferation of PBMC, as measured by Young (2005), give an indication of the host 
immune response to Staph. aureus. A correlation has been demonstrated between the 
ability of the PBMC to proliferate in response to Staph. aureus in vitro  (a measure of 
innate immune response) and lower somatic cell counts (SCC) (Fitzpatrick et al. 
1999).  
Currently commercial vaccines are available for the prevention of Staph. aureus 
infection. However, the immune response elicited is very variable and they have 
limited capacity to prevent new infection (reviewed by Talbot & Lacasse (2005)). An 
ideal vaccine for Staph. aureus would likely require the ability to induce a long 
lasting and effective humoral and cellular immune response.  
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There have been many QTL studies investigating mastitis resistance/susceptibility, 
with QTLs discovered on almost all the bovine chromosomes (Davies et al. 2009). 
Although the heritability of resistance to mastitis is relatively low, it may be possible 
to use selection to improve the ability to fight infection (Rupp & Boichard 2003). 
There is considerable on going research into the use of genetic selection and the 
design of vaccines to prevent mastitis (reviewed by Talbot & Lacasse (2005)).  
Many studies have explored the associations between DRB3 alleles and resistance or 
susceptibility to mastitis (Table 4.1) (Kelm et al. 1997; Sharif, Mallard, & Sargeant 
2000; Park J.Y. et al. 2004; Rupp, Hernandez, & Mallard 2007; Hameed, Sender, & 
Korwin-Kossakowska 2008; Yoshida et al. 2009). These studies have indicated that 
there are several DRB3 alleles which confer either resistance or susceptibility to 
mastitis. Several groups have suggested that DRB3.2*23 is associated with resistance 
to mastitis (Kelm et al. 1997; Dietz et al. 1997; Rupp, Hernandez, & Mallard 2007) 
and DRB3.2 *22 is associated with susceptibility (Kulberg et al. 2007; Yoshida et al. 
2009).  
Sharif et al. (2000) demonstrated that the polymorphisms within the PBC can impact 
on susceptibility or resistance to Staph. aureus. This group found that a glutamine in 
pocket 4 at position β74 was associated with the occurrence of natural mastitis 
through Staphylococcus spp infection. Within the RoBoGen population, Young et al. 
(2005) found that sire was a significant factor in the PBMC proliferation in response 
to Staph. aureus. Thus, as the DRB3 alleles and pockets within the PBC have been 
associated with mastitis caused by Staph. aureus, it would seem likely that this study 
would also find associations. The BoLA genes have been widely acknowledged as 
being likely candidates for any breeding program for resistance to mastitis (Table 
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4.1). Nevertheless, even with a large quantity of data there is contradictory evidence 
as to which alleles are associated with resistance and/or susceptibility (Table 4.1), 
most probably due to reasons such as differences in the definition of mastitis, 
variation in the causative pathogens, cattle breed and the possibility that DRB3 is not 
the causative gene but is linked to the responsible gene(s).  
   
 136 






2 • increased risk 
 
• decreased risk 
 
Kulberg et al. 2007,  
Rupp, Hernandez, & 
Mallard 2007; Yoshida et 
al. 2009 
*11 (0901, 0902, 1202) • decreased risk 
 
Rupp, Hernandez, & 
Mallard 2007; Kulberg et 
al. 2007 
*24 (0101, 0102) 
 




• increased risk 
Rupp, Hernandez, & 
Mallard 2007; Kulberg et 
al. 2007 
Kelm et al. 1997; Yoshida 
et al. 2009 
*3 (1001, 1002) • decreased risk 
 
Rupp, Hernandez, & 
Mallard 2007, Kelm et al. 
1997 
*8 (1201) • increased risk 
 
 
• decreased risk 
Kelm et al. 1997; Rupp, 
Hernandez, & Mallard 
2007  
Park et al. 2004 
*23 (2701, 2702, 2705, 
2706, 2707) 
 
• decreased risk  
 
• increased risk 
 
• increased risk 
Rupp, Hernandez, & 
Mallard 2007 Kelm et al. 
1997 
Sharif et al. 1999  
Hameed, Sender, & 
Korwin-Kossakowska 
2008 
*16 (1501) • decreased risk 
 
• increased risk 
 
Kelm et al. 1997  
Sharif et al. 1999; Park et 
al. 2004; Yoshida et al. 
2009 
1
BoLA DRB3 alleles shown as RFLP nomenclature; 2 the IPD (immuno polymorphism database) 
nomenclature (http://www.ebi.ac.uk/ipd/mhc/bola/nomen_rules.html). 
Table 4.1 BoLA DRB3 alleles identified as having a significant association with mastitis and/or 
somatic cell counts (SCC). 
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4.2 Aims 
This chapter aims to investigate the association between the immune response (IgG 
levels) to BRSV, BHV1 and PIV3 after vaccination and the alleles and PBC of BoLA 
DRB3. In addition, the associations between the alleles of DRB3 and the PBMC 
proliferation to Staph. aureus and to the mitogen phytohaemagglutinin (PHA) have 
been investigated. 
4.3 Materials and methods 
All vaccination procedures, bleeding and assays were carried out by staff at The 
Roslin Institute.  
4.3.10 Animals 
The study population is the same as stated in Chapter 2. The 12 sires were used to 
produce 3 lines of F1 x F1 (N=255), Charolais x F1 (N=67) and Holstein x F1 
(N=82) giving a total of 407 animals (female=201, male=206). The animals were 
born and sampled over 3 years in 3 separate cohorts from 1999 to 2001. The age of 
the calves when immunised with the vaccines (see below) ranged from 60 to 167 
days. All of the animals received colostrum before 6 hours of age. The male calves 
had unrestricted access to their dams until approximately 4 months of age. The 
female calves were weaned by 36 hours and were raised indoors on milk-
replacement followed by a propriety compound diet. For the 77 day duration of this 
study all the animals were housed in single sex groups (O'Neill et al. 2006).  
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4.3.11 Vaccination protocol of animals 
Each animal was immunised on day 0 of the study with the attenuated BHV1 and 
PIV3 vaccine, Imuresp RP (Pfizer Animal Health, Surrey, UK), according to the 
manufacturer’s instructions. Vaccine which had been rehydrated was administered 
intranasally in a 2 ml dose, half of which was placed in each nostril. (O'Neill 2006) 
Each animal also received 2 ml of Rispoval RS (Pfizer Animal Health, Surrey, UK), 
an attenuated live vaccine intramuscularly, according to the manufacturer's 
recommendations, on day 28 following vaccination with Imuresp, and a boost 
intramuscularly was given 21 days after the first dose on day 42.  
4.3.12 Sampling for PBMC proliferation to Staph. aureus 
Both males and female calves were used for the analysis of the PBMC proliferation 
response to Staph. aureus (male n=130 and female n=138) which gave a total study 
population of n= 268 from 2 cohorts (Young et al. 2005). 
4.3.13 Sampling for vaccine responses 
Blood samples were collected by jugular venipuncture on days 0, 14, 28, 42, 63 and 
77 following vaccination.  Serum was collected within 2 hours of sampling and 
stored at −20°C until testing (O'Neill 2006). 
4.3.14 Vaccine ELISA 
The ELISA analysis was carried out by Dr Ronan O’Neill (O'Neill et al. 2006). The 
ELISA was performed by Dr Ronan O’Neill (O'Neill 2006).   
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4.3.14.1 PBMC proliferation assay- for Staph. aureus and 
PHA 
The proliferation assay was carried out by Dr. Fiona Young and described in her 
thesis and publication (Young 2002; Young et al. 2005).  
4.3.15 Statistical analysis for vaccine data 
The IgG relative optical density (ROD) data for each trait was normalised by Loge 
transformation to obtain a normal distribution. A REML model as described in 
Chapter 3 was considered the most appropriate for the analysis. The addition of sex 
as a factor (2 d.f.) and sire as a random effect were added to the model.  
Thus the linear model was:  
yijklmn= li+cj+uk+qn+bm+MHCijkmn+aijlmn +eijlmn 
 
where: yijkl is the observed phenotypic trait; li fixed effect of breed-cross (CB, HB or 
F2); cj fixed effect of the cohort (years 1, 2, or 3); bm fixed effect of sex (male or 
female); MHCijk linear regression of the MHC allele/amino acid (0, 1 or 2 copies); 
uijkl random effect of the dam; qijkl random effect of the sire; aijkl covariate effect of 
the age of the animals at time of vaccination; eijkl the residual error. All statistical 
analysis was performed using Genstat with the significance of fixed effects such as 
MHC variant assessed with a Wald test. If MHC variants were significant (at least 
p<0.05), then further analysis was conducted by generating predicted means and 
conducting a Student’s t-test using pair wise comparisons (Genstat v9.0 VSN 
International).  
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4.3.15.1 Statistical analysis for Staph. aureus PBMC 
proliferation 
The PBMC proliferation counts per minute (cpm) were normalised by Loge 
transformation to obtain a normal distribution. The REML model was the same as 
above with the added covariate of control proliferation and without animal age as a 
factor.  If MHC variants were significant (at least p<0.05), then further analysis was 
conducted by generating predicted means and conducting a Student’s t-test using pair 
wise comparisons. 
4.4  Results 
4.4.1 Animal information  
The animals were all typed at the DRB3 locus as described in Chapter 2. A total of 
407 animals were used in the analysis of the IgG vaccine responses and 287 animals 
were used for the PBMC proliferation response. Data were normalised by Loge 
transformation for all datasets. An analysis of the fixed and random factors for the 
BRSV vaccine response and the PBMC proliferation to Staph. aureus in the 
RoBoGen herd has already been published by others (O'Neill et al. 2006) and 
(Young et al. 2005).  In addition, similar analyses were carried out by O’Neill (2006) 
for the PIV3 and BHV1 data sets.  Although genetic and sire effects were observed, 
no previous research has attempted to identify any candidate genes (or chromosomal 
loci) for these data sets.  Thus the data analysis presented in this chapter is new and 
novel.    
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4.4.2 BRSV dataset 
The mean, median, and quartiles for the IgG response to BRSV vaccination, as 
measured by a commercial ELISA, have been published in O’Neill et al (2006) and 
there was a high degree of variation across all time points, which is partially 
accounted for by sire and breed cross as well as environmental factors including 
maternal antibodies and differences in management between sexes (O'Neill et al. 
2006). Overall, there was a decrease in IgG levels from day -28 to day 0 (day of 
vaccination) most likely due to the decline in maternally derived antibodies (O'Neill 
et al. 2006). There was an increase in IgG levels post-vaccination until a peak IgG 
response was attained at day 35. The mean ROD percentages for days -28, -14, 0, 14, 
35 and 49 were 27.10, 19.99, 13.79, 20.00, 38.94 and 31.20% ROD, respectively 
(O'Neill 2006). The IgG levels significantly increased across time (p<0.001).  
4.4.3 Effect of DRB3 alleles on the IgG immune response to 
BRSV vaccine 
The frequency of the 18 different DRB3 alleles can be found in Chapter 2.  The 
mean median and upper and lower quartiles were examined for the peak day (day at 
which highest % ROD was observed) for each DRB3 allele (Table 4.2). The peak day 
was on day 35 for the majority of alleles, with the exception of *1801, *14011 and 
*3201 where the peak day was on day 49 post-vaccination. The highest mean allele 
was *0801 (61.46% ROD) but this allele is represented only once in the herd. The 
second highest allele was *1501 (55.81% ROD) which is still a low frequency allele. 
The allele with the lowest mean level was *3201 (27.60% ROD).   
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Alleles *0901, *1002 and *1701 had significant p values post-BRSV vaccination 
(p<0.05). DRB3*0901 was significant at day 14 post-vaccination, while *1002 and 
*1701 were both significant at day 49 post-vaccination. Only allele *0801 was 
significant pre-vaccination at days -28, -14 and 0 (p<0.05).  
However, alleles *1002, *1701 and *0801 were at very low frequencies within the 
herd (<10%), and the significant p value generated from DRB3*0901 is due to a 
single homozygous animal.  















*0801 1 61.46 61.46 61.46 61.46 
*1501 7 55.81 58.91 42.96 71.94 
*1102 2 50.41 50.41 37.57 63.25 
*1801# 6 44.41 39.88 24.93 74.63 
*2002 9 44.32 42.75 27.05 52.75 
*1101 124 43.07 42.09 31.58 54.36 
*1701 10 41.90 39.40 29.98 61.78 
*0901 53 41.68 41.22 27.11 52.37 
*0501 28 41.15 35.84 26.31 55.56 
*0701 19 40.17 46.21 21.16 54.58 
*0201 49 40.00 37.82 30.23 49.17 
*2703 9 39.94 34.97 27.28 54.67 
*1001 36 39.69 39.50 19.90 53.12 
*1601 95 38.40 37.04 22.38 50.09 
*2707 156 37.14 34.31 19.27 51.43 
*0101 56 36.91 37.59 24.60 48.06 
*14011# 2 36.61 36.61 26.00 47.23 
*1201 45 35.97 33.21 22.05 47.79 
*0601 42 35.53 33.32 21.10 45.58 
*0902 17 32.73 22.29 17.03 46.51 
*1002 1 31.62 36.62 36.62 36.62 
*3201# 3 27.60 14.00 11.53 47.06 
Overall 407 38.94 37.45 23.58 51.21 
# Day 49 peak day 
Q1 and Q2 represent the lower and upper quartiles, respectively. 
Table 4.2 DRB3 alleles in the population: mean, median, upper and lower quartiles at peak day 
(Day 35) for BRSV IgG (% ROD). 
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4.4.4 Effect of binding pockets on response to BRSV vaccine 
There are several positions within the PBC which have a significant association with 
the IgG response to BRSV. Pocket 7 positions β28 and β30 are both significant at 
day 14 post-vaccination (p<0.05). Pocket 9 β37 is significantly associated before 
vaccination at day -28 (p=0.036).  
Pocket 4 β13 is significant at day 0 (p<0.05) and β70 at day 49. Further REML 
analysis revealed that an asparagine (N) at position β74 within pocket 4 is highly 
significant at day 14 (p<0.001) and had p values <0.05 for days 35 and 49 post-
vaccination. Further analysis revealed that animals homozygous for N at this position 
(n=4) had a lower mean IgG ROD % before vaccination (although not significant) 
but the antibody levels increased to the same levels as those in animals expressing a 
single N at β74 after the boost on day 21 (Figure 4.1). At day 49, animals without an 
N at this position had highly significantly greater IgG levels to the BRSV vaccine 
compared to those expressing at least one N (p<0.001 obtained by Student’s t test 
using 0N and 2N predicted means) (Figure 4.1).   
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Figure 4.1 BRSV IgG % ROD pre- and post-BRSV vaccination with position β74: homozygous 
for asparagine (N): ;  heterozygous for N:  ;  no copies of N: . p values determined by 
Student’s t-test from predicted means: * p<0.01, **p<0.001.  The homozygous  predicted means 
were used in Student’s t-test for significant values.  
4.4.5 PIV3 and BHV1 datasets 
The mean, median, and quartiles for the IgG response to vaccination with Imuresp 
against PIV3, as measured by a commercial ELISA, have been reported in O’Neill 
(2006) and there was a high degree of variation across all time points which is 
partially accounted for by sire and environmental factors (O'Neill 2006).  The PIV3 
response mean values for days 0, 14, 28, 42, 63 and 77 were 38.63, 36.17, 42.10, 
46.63, 52.62 and 55.96% ROD respectively. The PIV3 IgG levels showed a steady 
increase across the time points post-vaccination which is not significant across time 
points (Figure 4.2).  
The BHV1 mean values for days 0, 14, 28, 42, 63 and 77 were 34.60, 27.01, 22.83, 
18.58, 14.40 and 11.71% ROD respectively. The BHV1 IgG levels showed a steady 
decrease in the IgG levels post-vaccination (p<0.001) (Figure 4.3). The high levels of 
BHV1 antibody at day 0 are likely to be maternally derived and the subsequent levels 
of IgG post-vaccination do not show any convincing response.  



























Figure 4.2 PIV3 IgG (%ROD) post-vaccination levels of all animals as measured by ELISA 




































Figure 4.3 BHV1 IgG (%ROD) post-vaccination levels of all animals as measured by ELISA 
(using data from O’Neill 2006). Mean ± SD. 
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4.4.6 Effect of DRB3 alleles on IgG levels PIV3 and BHV1 IgG 
levels 
From the REML analysis there were no DRB3 alleles significant for the PIV3 IgG 
levels (results not shown). There were however several alleles which were significant 
for the BHV1 IgG levels: DRB3 *0201 and *0901 were significant at day 63, *1601 
at day 42 and *0701 at day 77 (p<0.05).  As these were only significant at single 
time points they were not analysed further.   DRB3*1701 was significant at days 14 
and 63 and was analysed further (Figure 4.4).  Animals positive for one copy of 
















































Figure 4.4 BHV1 IgG levels (%ROD) with 1 copy of *1701 or with no copies of *1701. p values 
determined by Student’s t-test from predicted means: *p<0.01, **p<0.001. 
4.4.7 Effect of binding pockets on PIV3 and BHV1 IgG levels  
As in Chapter 3, all animals were subdivided according to the PBC pockets and 
results fitted in the REML model.  The amino acids in each pocket position for each 
allele are shown in Chapter 2. 
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4.4.7.1 PIV3 
For the PIV3-specific IgG levels, pocket 7 had two positions which were significant 
from the REML analysis, β61 (p<0.001) at days 28 and 42 post-vaccination and β67 
(p<0.05) at day 28.  Glutamic acid (E) and arginine (R) at β70 within pocket 4 were 
both significantly associated with PIV3-specific IgG at day 28 (p<0.05). Two copies 
of E at β70 were associated with higher IgG levels whilst 2 copies of R were 
associated with lower levels of IgG to PIV3 vaccination (Figure 4.5). The two 








































Figure 4.5 Pocket 4 position β70. (a) anti-PIV3 IgG1 responses position β70 homozygous for 
glutamic acid (E) ▲, heterozygous for E and R, or homozygous for arginine (R) ♦. p values 
determined by Student’s t-test from predicted means: **p<0.001, *<0.05. The homozygote 
predicted means values were used in the Student’s t-test.  
 
4.4.7.2 BHV1 
The BHV1 IgG levels were significantly associated (p<0.05) with pocket 6 position 
β11 at day 77 post-vaccination, pocket 7 position β67 at days 0 and 14 and pocket 9 
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positions β37 at day 28 and β57 at day 0. Pocket 4/7 position β71 was also 
significant at day 77.  
4.4.8 Staph. aureus results   
At day 4 following culture, the PBMC proliferative response to Staph. aureus was 
23235.72 (cpm) and for response to PHA was 27187.14 (cpm). There was 
considerable variation observed for both the proliferation to Staph. aureus and PHA, 
which was partially accounted for by breed and sire effects (Young 2002). 
 
4.4.9 Effect of DRB3 alleles on proliferation to Staph. aureus 
and PHA 
Allele *1701 (n=6) was highly significant (p<0.001) for the PBMC proliferation to 
Staph. aureus, with the presence of the allele resulting in a higher level of 
proliferation. Allele *0601 was also significant (p=0.05), where a single copy of the 
allele resulted in a higher level of proliferation compared to no copies or 2 copies 
(n=4).  Other alleles worth noting are *2703 and *2707 which showed suggestive 
associations (p=0.09 and 0.07 respectively).                           
Alleles *1601 and *1701 were both significant (p<0.05) for the response to PHA, 
with the presence of *1601 resulting in lower levels of proliferation and *1701 
resulting in higher levels.  
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4.4.10 Effect of binding pockets on proliferation to Staph. 
aureus and PHA  
For the response to Staph. aureus, 4 positions within the PBC were significant: 
pocket 6 position β11 (p=0.032), pocket 7 position β28 (p=0.05), position 61 which 
is part of both pocket 7 and pocket 9 (p=0.02) and pocket 4 position β71 (p<0.05).   
Animals which expressed an E at position β71 had a higher level of PBMC 
proliferation.   
There were no significant positions in the PBC for the response to PHA. 
4.5 Comparison of associations with DRB3 alleles and PBC 
pocket positions and humoral and cellular response in 
the RoBoGen herd 
In Chapter 3 and this chapter there are many statistically significant associations 
with both the DRB3 alleles and positions within the PBC. To allow a clearer 
comparison across immunising agents and antibody and cellular responses these 
results have been organised into tables.  
 





Allele BRSV BHV-1 FMDV15 peptide 
   IgG1 IgG2 
*0201 N.A. 63 N.A. N.A. 




N.A. N.A. N.A. 
*0901 14 63 14; 56 N.A. 
*0902 N.A. N.A. 56; N.A. 
*1001 N.A. N.A. 56; 70 
14; 56; 70 (higher 
IgG2) 
*1002 49 N.A. N.A. N.A. 
*1601 N.A. 42 
14; 28; 
56;70 
14; 28; 56; 70 (lower 
IgG2) 
*1701 49 14; 63 N.P. N.P. 
*2707 N.A. N.A. 14; 56 14 (lower IgG2) 
#day following first immunisation with agent is shown in Table cells. Shading denotes a 
significant statistical association, N.P. not present. N.A. no association.  
Table 4.3 Comparison of the statistically significant effects of the DRB3 alleles on the antibody 
responses to different immunising agents in the RoBoGen herd: vaccines for BRSV and BHV-1, 
and FMDV peptide.  Note no alleles were significantly associated with anti-PIV-3.  










(Day 4 of 
culture) 
PHA T cell IFN-γ T cell IFN-γ 
*0101 N.A. N.A. 28 N.A. N.A. 28 




N.A. N.A. N.A. N.A. N.A. 
*0902 N.A. N.A. 56; 70 N.A. N.A. N.A. 
*1001 N.A. N.A. 56; 70 N.A. N.A. N.A. 






















N.P. N.P. N.P. N.P. 





*2707 Suggestive N.A. N.A. 70 N.A. 28 
#day following first immunisation with agent is shown in Table cells. Shading denotes a 
significant statistical or a statistically suggestive association, N.P. not present. N.A. no 
association.  
Table 4.4 Comparison of the significant effects of the DRB3 alleles on the cell mediated 
responses to different stimuli in the RoBoGen herd: FMDV peptide, Staph. aureus and ConA.  
No significant pocket effects were detected with PHA.  
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1 86 N.A. N.A. N.A. 70 28; 56 






















N.A. N.A. 56 N.A. 
4/7 71 N.A. N.A. 77 N.A. 14 
6 11 N.A. N.A. N.A. 14; 14 
28 14 N.A. N.A. N.A. 28 
30 14 N.A. N.A. N.A. 14 7 
67 N.A. 28 0; 14 N.A. N.A. 
7/9 61 N.A. 28; 42 N.A. 14; 56; 70 14; 56; 70 
37 -28 N.A. 28 14; 56 70 14 
57 N.A. N.A. 0 14; 
14; 28; 56; 
70 
9 
60 N.A. N.A. N.A. N.A. 14; 56 
10 56 N.A. N.A. 77 N.A. 
14; 28; 56; 
70 
#day following first immunisation with agent is shown in Table cells $animals expressing 
glutamic acid (E) had significantly greater (>) or lower (<) responses than animals expressing 
arginine (R) at this position. Shading denotes a significant statistical association, N.A. no 
association.  
Table 4.5 Comparison of the effects of the PBC pockets of DRB3 on the antibody responses to 
different immunising agents in the RoBoGen herd: vaccines for BRSV, PIV-3 and BHV-1, and 
FMDV peptide. 
 














FMDV peptide Con A 
   T cell IFN-γ T cell IFN-γ 
1 86 N.A. N.A. 28 N.A. 70 
13 N.A. N.A. N.A. 0; 70 56 
70 N.A. N.A. 28; 70 0; 56 56 
 
4 











6 11 √ N.A. 56 N.A. 56 
28 √ 56 56; 70 56; 70 N.A. 
30 N.A. N.A. 70 N.A. 70 




 67 N.A. 56; 70 70 56 N.A. 
7/9 61 √ 56; 70 70 N.A. 70 
9 N.A. N.A. 28 N.A. 56; 70 
37 N.A. 56 28; 56 N.A. 56 







60 N.A. N.A. 70 N.A. 70 
10 56 N.A. N.A. 28; 56; 70 N.A. N.A. 
#day following first immunisation with agent is shown in Table cells: $animals expressing 
glutamic acid (E) had significantly greater responses than animals expressing arginine (R) at 
this position. Shading denotes a significant statistical association, N.A. no association. 
Table 4.6 Comparison of the effects of the PBC pockets of DRB3 on the cell mediated responses 
to different stimuli in the RoBoGen herd: FMDV peptide, Staph. aureus and ConA.  No 
significant pocket effects were detected with PHA. 
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4.6 Discussion  
In this chapter the same female animals which were studied in Chapter 3, together 
with many of the second generation males, were analysed for DRB3 allele 
associations with their humoral response to several additional stimuli, including two 
vaccines, Rispoval against BRSV and Imuresp against BHV1 and PIV3, as well as 
cellular responses to a mastitis causing pathogen Staph. aureus and a mitogen, PHA.  
Considerable variation was seen in the response to all pathogens, some of which has 
been accounted for by genetic (sire and breed-cross) and environmental factors 
(cohort, age, sex, maternal antibody levels) (Young 2002; Young et al. 2005; O'Neill 
et al. 2006; O'Neill 2006). Although there are no previous reports on associations of 
BoLA DRB3 alleles and responses to viral vaccines in cattle, a number of studies 
suggested that it would be likely that significant associations would be seen between 
BoLA DRB3 alleles and the responses to the respiratory viral vaccines and to the 
mastitis-causing pathogen Staph. aureus. HLA alleles have been associated with 
efficacy of vaccination against viral pathogens in humans, most notably in Hepatitis 
B and measles vaccination (Blackwell, Jamieson, & Burgner 2009) and cattle 
responses to vaccination have also been associated with alleles of the BoLA region 
(Newman et al. 1996; Sitte et al. 2002). Furthermore many associations with BoLA 
Class II alleles were found for the response to an FMDV peptide in Chapter 3 
(Baxter et al. 2009) and a study on the antibody response to epitopes present in 
BRSV found that there were associations with either high or low response depending 
on BoLA haplotypes after natural infection (Schrijver et al. 1997). Additionally, 
there have been many studies on mastitis in cattle that show significant associations 
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with BoLA DRB3 alleles (Table 4.1) (Kelm et al. 1997; Sharif, Mallard, & Sargeant 
2000; Park J.Y. et al. 2004; Rupp, Hernandez, & Mallard 2007; Hameed, Sender, & 
Korwin-Kossakowska 2008; Yoshida et al. 2009) and the PBMC proliferation assay 
to Staph. aureus in young male calves may be predictive of the likelihood of mastitis 
in adulthood in their daughters (Fitzpatrick et al. 1999). Taken together these studies 
supported the hypothesis that variation in the responses measured in this Chapter 
would be related to BoLA DRB3 polymorphisms. However, despite the increase in 
animal numbers, fewer significant associations were found compared to Chapter 3.  
Seven DRB3 alleles were discovered to be significantly associated with the IgG 
response to vaccination. The PBMC proliferation response was significantly 
associated with four alleles for Staph. aureus and two alleles for PHA. Even when 
the animals were subdivided into pocket positions, fewer associations were observed 
compared to the FMDV15 peptide responses. There are many possible explanations 
for this including some technical reasons and these are discussed below.  
One possible reason for the differences between the studies may be due to 
differences between the assays used and the read-outs.  The FMDV ELISAs for IgG1 
and IgG2 were set up so that precise concentrations of specific antibody could be 
measured (see Chapter 3) whereas the vaccine ELISAs were commercial assays 
intended for epidemiological surveys of prevalence, and are not designed to measure 
precise levels in individual animals.  In contrast to the FMDV ELISAs where sera 
were diluted out until the readings fitted onto a standard curve, the vaccine ELISAs 
utilised fixed dilutions of sera, and compared the readings to a standard control 
provided with the kit.  This has an impact on the sensitivity and accuracy of the PIV3 
and BHV1 IgG-specific measurements. 
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From the results in this chapter it is possible to conclude that the Rispoval vaccine 
increased the level of circulating BRSV-specific IgG post-vaccination. However it is 
more difficult be confident about the efficacy of the Imuresp vaccine, as the levels of 
PIV3-specific IgG were not significantly higher after vaccination and the levels of 
BHV1-specific IgG declined post-vaccination.  In both vaccine studies the animals 
had high levels of pre-existing IgG to all three respiratory pathogens, which is due to 
either circulating maternal antibody and/or previous exposure to these pathogens. It 
is highly probable that the calves had already been exposed to the viruses prior to 
vaccination as they are endemic within British herds (Stott et al. 1980; Woodbine et 
al. 2009), although none of the animals had any obvious clinical signs. 
In humans the persistence of circulating maternal antibodies has an effect on the 
efficacy of vaccination against several important infectious diseases (Siegrist 2003). 
For example, one of the difficulties in designing an effective vaccine to human RSV 
is the need to vaccinate young infants who are compromised by the presence of 
maternal antibodies (Glezen 2003). A similar scenario exists for young calves, 
whereby it is considered preferable to vaccinate at an early age against BRSV 
(because it is endemic) yet maternal antibodies affect vaccine efficacy (Zygraich 
1982; Kimman, Westenbrink, & Straver 1989). In cattle maternal antibodies interfere 
with the humoral response to vaccination against BVDV, whereas a T cell mediated 
response is not affected (Endsley et al. 2003). In the present study the levels of anti-
BRSV IgG were declining prior to vaccination, which is most likely due to the 
reduction in the levels of circulating maternal antibody (O'Neill et al. 2006; O'Neill 
2006).  
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There is no reported study into the genetic influence on the clearance of maternal 
antibody in cattle. However, the transfer of IgG from dam to calf via the colostrum 
has high heritability (Norman, Hohenboken, & Kelley 1981). This suggests a genetic 
component influenced by both the dam and calf.  Polymorphisms in the Fc receptor 
α-chain gene have been associated with the levels of IgG in newborn calves 
(Laegreid et al. 2002). Here there is evidence that there is pre-existing IgG to all 
three respiratory pathogens.  If clearance of maternal antibody is under different 
genetic control than vaccine responses then it is possible that this too could help 
explain the observation that fewer significant BoLA DRB3 alleles were observed 
post-vaccination compared to the FMDV peptide results in Chapter 3, where all of 
the animals were naïve to the peptide.   
The Staph. aureus assay described in this chapter is likely measuring an anamnestic 
response to the bacteria, as a naïve response would have peaked at day 7 (not day 4) 
(Young 2002). As any previous exposure to mastitis pathogens is an unknown factor 
in the current study, this makes it more difficult to accurately discern any MHC 
effects. In addition this assay has only been reported in one study to have 
associations with susceptibility to mastitis (Fitzpatrick et al. 1999) and would need 
further validation in other populations.  
Fewer significant alleles were seen in association with the vaccine responses 
compared to the responses to the FMDV peptide (Chapter 3), with no significant 
alleles at all for response to PIV3 vaccination (summarized in Table 4.3). This is not 
unexpected as these vaccines contain whole virus particles and therefore many more 
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epitopes, which would decrease the chance that a single allele would be wholly 
responsible for the IgG response. The same consideration applies for the Staph. 
aureus results, since the bacterium has many more epitopes compared to a 40-mer 
peptide.  
Epitopes have been identified for BRSV, which induce antibody (Taylor et al. 1992) 
and T cell responses (Fogg et al. 2001). The extent of antibody response to the main 
BRSV epitope was associated with certain BoLA haplotypes in naturally infected 
cattle (Schrijver et al. 1997). However, it is interesting to note that Schrijver et al. 
(1997) noted differences between antibody specificities produced from those animals 
which were naturally exposed and those which were vaccinated. Epitopes have also 
been identified for the human form of PIV3 and evidence suggests that a number of 
these epitopes are shared between human and cattle (Coelingh et al. 1986). To the 
author’s knowledge there are no studies investigating associations between antibody 
response to bovine PIV3 epitopes and MHC alleles. A number of cytotoxic T-cell 
epitopes for BHV1 has been described (Zatechka et al. 1999), and epitopes have been 
identified for antibody response to BHV1 (Chowdhury 1997). Moreover it is possible 
to use allele-specific peptide motifs for BoLA Class I molecules and identify 
potential CTL epitope peptides (Hegde & Srikumaran 1996; Hegde et al. 1999). This 
opens up the possibility of using effective peptide vaccines, and the option of 
utilizing the information on the DRB3 alleles. 
How protection is achieved post-vaccination through the action of antibodies and T 
cells is still debated (reviewed by Burton (2002)). However, in most vaccine efficacy 
studies generally only a humoral response is equated with protection, as this is more 
easily measured, even though cellular responses are likely to play an important role. 
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Indeed for the protection against alphaherpesviruses such as BHV1 the CTL 
response is perhaps more important than the antibody titre (Zatechka et al. 1999). In 
this study only virus-specific IgG levels were measured, due in main to logistics, as 
there was limited availability of appropriate assays, resources or personnel to 
conduct them. Furthermore, it has proved difficult to detect T cell responses to these 
vaccines (Taylor et al. 1995; Fogg et al. 2001).   
The low numbers of significant alleles observed in this chapter could be because the 
alleles and polymorphisms in pockets of DRB3 have a greater effect on the Th1 
pathway. In Chapter 3 and in this chapter, as summarized in tables 4.3, 4.4, 4.5 and 
4.6 it is demonstrated that the DRB3 alleles and pockets were more significantly 
associated with a Th1 (IgG2 and IFN-γ) response than with IgG1. It is important to 
consider these implications for vaccine design as for many intracellular pathogens, 
such as viruses, the protective mechanism is more closely related to a Th1 than a Th2 
response (Brown, Rice-Ficht, & Estes 1998). In addition there are differences in the 
alleles which are associated with IgG1 and IgG2 response (Table 4.4 and Chapter 
3).  
There are not many associations which have been noted between single stimuli and 
the DRB3 alleles and some are not highly significant. However, when all the 
associations are taken together it becomes more convincing that there are significant 
associations.  
This chapter and Chapter 3 have highlighted DRB3 alleles which have a significant 
association with more than one vaccine IgG response; DRB3*0901, *0701, *1601 
and *1701 (Table 4.3). Allele *0901 was significant for the response to BHV1, 
BRSV and in Chapter 3 to the FMDV peptide. This allele is also suggested to have 
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an association with reduced SCC (Table 4.1). The *0701 and *1601 alleles were both 
significant for IgG to BHV1 and FMDV. Finding alleles that confer a higher 
response to vaccination against many pathogens might provide new targets for 
breeding programs (Wilkie & Mallard 1999; Gay et al. 2007). Juliarena et al.  (2009) 
suggest that selecting for BLV resistant cattle would not affect the response to 
several other vaccines, including BHV1 and FMDV. Important considerations would 
be to ascertain that any breeding programs did not adversely affect other immune 
responses.  For example, it would be important not to diminish the ability of cattle to 
make protective responses to vaccination nor increase the propensity for 
pathogenesis in response to vaccination.  Furthermore it would also be important to 
ensure that any breeding programme did not increase susceptibility to infection.  
In this study alleles *1701 and *0601 were significantly associated with the PBMC 
response to Staph. aureus.  However, neither of these alleles have been associated 
with mastitis in other studies, nor were any other traits described in this thesis 
associated with *0601.  However, *1701 was associated with higher levels of PBMC 
proliferation to both Staph. aureus and PHA (Table 4.4). 
It is interesting to note that allele *1701 was significant for the response to 
vaccination against BRSV, BHV1 and the PBMC response to both Staph. aureus and 
PHA. A single copy of *1701 resulted in higher BHV1-specific IgG levels after 
vaccination, and higher proliferative PBMC response to both Staph. aureus and to 
PHA. However, for the BRSV-specific IgG response a single copy of *1701 resulted 
in a significantly lower response at day 49. DRB3*1701 was identified as a possible 
marker for breeding BLV resistant cattle due to a strong association with low 
proviral load (Juliarena et al. 2009). Unfortunately the female population used in 
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Chapter 3 had only two animals positive for the allele *1701 and it was at a low 
frequency within the whole RoBoGen population; therefore the results should be 
treated with caution and would need further validation.   
Alleles *2703 and *2707 have been previously identified as significantly associated 
with mastitis, although there is contradictory evidence as to whether these alleles are 
of benefit or are detrimental to mastitis outcome (Table 4.1).  In this chapter, 
suggestive evidence indicates that these alleles were associated with an increase in 
the PBMC proliferation to Staph. aureus. The *2703 and *2707 alleles differ by only 
2 base pairs (Chapter 2), and all the alleles starting *270 have near identical 
nucleotide sequences. The variety in the mastitis pathogen population may result in 
different alleles providing different levels of protection and hence might explain the 
contradiction in some populations.   
PHA was chosen as a positive control for the stimulation of PBMC in the Staph. 
aureus assay (Young 2002). PHA stimulates non-specific proliferation of T 
lymphocytes and therefore would be a measure of innate immunity. A study by Dietz 
et al. (1997) investigating several immune parameters found no significant 
association of DRB3 alleles after stimulation with PHA or ConA. Therefore it is 
interesting to note that in this study a few associations were observed with the DRB3 
alleles and the PBC pockets.  In Chapter 3 ConA was used as a positive control in 
the stimulation of cell division for T cells and production of IFN-γ. The results from 
Chapter 3 (Table 4.4) showed that there were many alleles significantly associated 
with IFN-γ production after stimulation with ConA. 
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There is no single allele which is a marker for general disease resistance, although 
there are several alleles which appear to be significant in both the humoral and 
cellular response (Tables 4.3 and 4.4). Allele *1701 is significant for the antibody 
responses to BRSV and BHV-1 as well as being significant for higher PBMC 
proliferation to both Staph. aureus and PHA. Allele *2707 is significant for a lower 
response to the FMDV15 peptide for IgG1 and IgG2, and a low IFN-γ response. 
DRB3*2707 is also nearing significance for the PBMC response to Staph. aureus, 
with an increase in PBMC proliferation. Allele *1601 is significant for a lower 
response to the FMDV15 peptide for IgG1 and IgG2. However, having the alleles 
results in a higher level of IgG to BHV-1 and is also associated with a lower 
response to PHA. 
As observed in Chapter 3, amino acids within the pockets of the PBC were 
significantly associated with the humoral and cell mediated response to 
immunisation with a FMDV peptide. Here it is demonstrated that the amino acids 
within the PBC also have significant associations with the antibody response to 
whole virus vaccines and the cell mediated response to Staph. aureus. There are 
several positions within the PBC which are significant at different time points for the 
response to vaccination. However, no single position is significant across multiple 
vaccines or stimuli (Table 4.5 and 4.6). Interestingly several pocket positions were 
associated with the level of antibody prior to vaccination, with pocket 9 β37 being 
significant for BRSV IgG levels at day -28, but no significance was seen after 
vaccination. The specific antibody responses were not measured prior to vaccination 
for BHV1. However, at day 0 pockets 7 β67 and pocket 9 β57 were significant. 
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The centrally located pocket 4 has several amino acids which were significant. An 
asparagine at β74 (in pocket 4) has a highly significant association with BRSV-
specific IgG at all time points post-vaccination, with animals possessing an 
asparagine having lower antibody levels. This position was also significant for the 
levels of specific IgG1 and IgG2 to FMDV15 (Table 4.5). Position β70 was 
significantly associated with the response to PIV3 and BRSV, and furthermore this 
position was also significantly associated with the IgG1, IgG2 and IFN-γ response to 
FMDV15 (Baxter et al. 2009). However, the presence of glutamic acid (E) or 
arginine (R) in this position had opposite effects in that E was associated with higher 
PIV3 antibody levels and R was associated with lower BRSV IgG, whereas R was 
associated with higher FMDV-specific IgG1, IgG2 and IFN-γ levels. In Chapter 3 
Figures 3.13 and 3.14 indicate that a change in amino acid at this position results in a 
conformational and electrostatic change in the PBC, which may therefore have an 
effect on the binding affinity of processed peptides.   
There are 19 associations of vaccine response with pocket positions, with 7 being 
within pocket 7 (Table 4.5). Although this is less than for the response to FMDV it is 
important for any future vaccine design to consider the role of other pockets.  
The pockets within the PBC have been associated with mastitis: Sharif et al (2003) 
found that a glutamine at position β74 was associated with the occurrence of mastitis. 
In this study no association was found between β74 and the PBMC proliferation to 
Staph. aureus, only pocket 4 position β71 was significantly associated. In addition 
certain motifs have been associated with either resistance or susceptibility to a range 
of mastitis-causing pathogens, with a Q-S-S-Y motif at positions β9-11-13-30 being 
associated with susceptibility and a Q-H-G-H motif at the same position being 
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associated with resistance. Whilst this chapter has not investigated the effect of 
motifs on the PBMC proliferation, only position β11 (pocket 6) was significant, but 
neither an H nor an S at this position was significant. It is interesting however to note 
that there are no significant pocket positions for PHA.  
It would be unlikely to find single alleles which have a beneficial effect on the 
response to all pathogens, as due to the function of the MHC molecules, each allele 
would have positive or negative associations. Instead it would be more likely to find 
groups of alleles with similar motifs which may be associated with a wider range of 
epitopes. The pocket information provides a means of investigating whether there are 
any motifs or specific positions associated with different responses to a wide range of 
pathogens. The combined data in Tables 4.5 and 4.6 indicate that there are more 
associations with pocket positions than with alleles. From this analysis a few 
positions stand out as having more associations, particularly those within pocket 4 
and 7/9, especially positions β70, 71 and 61. Position β70 within this population has 
a limited number of amino acids, E, R or Q. From the analysis, having a positive R at 
this position resulted in higher levels of IgG1 and IgG2 to FMDV15 and IgG to 
BRSV; however, there was a lower level of IgG to PIV3.  This suggests that in terms 
of vaccine design, pocket 4 and 7/9 may have a larger effect and it would be 
interesting to further explore the associations with these pockets and other diseases 
and vaccines. 
Investigating the associations of the DRB3 alleles and pockets to the different 
antigens (either peptide, vaccine or bacteria) and comparing the different immune 
responses (humoral and cellular) has given a much clearer picture of the roles that 
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the polymorphisms within the Class II DRB3 gene can have. It highlights the 
complexity of the immune response and provides avenues for further research.  
Measuring the antibody response to vaccination may not reveal all the mechanisms 
involved in producing long lasting protection through vaccination. Instead it would 
be beneficial to understand the role of the cellular response. This information, in 
conjunction with knowledge of protective epitopes and the alleles of the BoLA 
genes, could be used to design more effective vaccination programs.  Understanding 
the genetics underlying the response to vaccines could lead to increased efficacy 
through improvements in design. This would greatly improve animal welfare and 
reduce the cost of infectious disease in livestock. The identification of candidates for 
selective breeding for disease resistance would reduce the levels of intervention, such 
as culling and use of antibiotics.  
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5 Microarray typing of BoLA-DQA and Class I and 
qPCR for copy number of BoLA-DQA  
 
5.1 Introduction 
The BoLA region is highly complex with a high degree of polymorphism observed 
within the classical genes. In the BoLA Class II region there is a duplication of the 
polymorphic DQ genes in many haplotypes which further adds to the complexity of 
the region. This makes it difficult to accurately assess the polymorphisms in these 
genes and the possible role they play in response to pathogens and vaccines, thus a 
robust and accurate method of typing is required.  
The bovine classical Class I genes are polymorphic and have been associated with 
mastitis (Aarestrup, Jensen, & Ostergard 1995) but due to poorly defined haplotypes, 
studying the exact polymorphisms which have an impact on immune response has 
proved difficult (Ellis et al. 2005). 
The BoLA Class II region has duplicated DQ genes in about half of all the known 
haplotypes (Andersson & Rask 1988; Ballingall, Luyai, & Mckeever 1997) which 
has led to problems in typing these loci accurately. Moreover, the duplication of the 
DQ genes has been linked to immune responsiveness (Glass, Oliver, & Russell 2000; 
Park et al. 2004; Norimine & Brown 2005; Takeshima et al. 2008). It has been 
demonstrated that when the DQ genes are duplicated then both sets are expressed, 
thereby increasing the repertoire of T cell restriction (Xu, Park, & Lewin 1994).  
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Therefore the DQA genes are good candidates for the study of general disease 
resistance.  
5.2 Microarray typing of BoLA genes 
Studies investigating genes which are involved in response to pathogens or 
vaccination benefit from using large numbers of animals. To type large populations 
at specific loci a robust, cheap and high through-put genotyping technology is 
essential. Microarray technologies are relatively accessible and offer an inexpensive 
method of accurately typing large numbers of DNA samples quickly.  
As the DQ and Class I genes are complex and have many polymorphisms, accurate 
typing has been problematic in the past (Chapter 2). A typing microarray for 
interrogating the alleles of some of the highly polymorphic genes would enable 
associations studies, e.g. on mastitis (Park et al. 2004), to be carried out in whole 
herds.   
Microarrays have been primarily used in the detection of gene expression from 
RNA/cDNA. A typing array works in a similar fashion, with probes being ‘spotted’ 
onto glass slides followed by the hybridisation of ‘test’ DNA (Call, Chandler, & 
Brockman 2001). DNA microarrays have been used to study microbial genomics 
(reviewed by Cummings & Relman (2000)) and host genomics (reviewed by Jares 
(2006)). The fluorescent pattern of the hybridised probes allows for the identification 
of alleles. This then enables many DNA samples to be simultaneously typed at a 
specific locus.  
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5.3 DQA duplication  
For many years Southern blots and in situ hybridisation have been used to test for 
copy number variations in genes.  However, these techniques are limited as they can 
be time-consuming, laborious and require large quantities of DNA (Hoebeeck, 
Speleman, & Vandesompele 2007). An alternative method is to utilise real-time 
quantitative PCR techniques, which are reliable, fast and can be used on limited 
quantities of DNA. Real-time qPCR offers the possibility of quickly and reliably 
detecting DQ gene duplication.  
5.4 Aim 
This chapter aims to investigate microarray typing for the BoLA DQA genes and the 
MHC Class I region. In addition this chapter aims to investigate the feasibility of 
using real-time qPCR for assessing the copy number of DQA genes. 
The microarray technique which was designed by Dr. Chris Davies (Park et al. 2004) 
presented a great opportunity to type the RoBoGen animals at the MHC Class I loci. 
To do this I raised suitable funds for a 6 week visit to Dr Chris Davies’ laboratory at 
Washington State University, U.S.A. This provided an opportunity to learn a novel 
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5.5 Materials and methods 
5.5.1 Microarrays 
5.5.1.1 Samples 
Genomic DNA from the RoBoGen herd was used for all the microarray experiments 
(Chapter 2, sections 2.3.1 and 2.3.2).  
5.5.1.2 PCR protocols for microarray 
All PCR amplification protocols and oligonucleotide primers were designed by Dr. 
Chris Davies (presently at Utah State University), to amplify all known MHC Class I 
alleles at exon 2 and exon 3 and DQA1 and DQA2 alleles (primer sequences 
Appendix D.1, D4 and D.6). 
5.5.1.3 MHC Class I exon 2 PCR 
PCR was carried out on ~200 ng genomic DNA. The PCR reaction mix was: 1 unit 
Taq polymerase (Fisher Scientific, USA), PCR 10X buffer B (Fisher Scientific), 25 
mM MgCl2 (Fisher Scientific), 25 mM dNTPs (Invitrogen, USA) and 
diethylpyrocarbonate (DEPC)-treated water (Invitrogen). Primers were 0.8 µM 
biotinylated forward primer BoC1FP-E2A (5’d[biotin-ACG TGG ACG ACA CGC 
ACT TC] 3’) and 0.8 µM biotinylated reverse primer BoC1RP-E2A (5’d[biotin-CTC 
GCT CTG GT GTA GTA GCC]3’) in final volume of 50 µl. Briefly the thermal set-
up was denature at 94oC for 4 min, followed by 35 cycles of 94oC for 1 min, 54oC for 
30 sec and 72oC for 1 min and 30 sec followed by a final extension for 5 min at 
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72oC. Samples were run on a 1.5% agarose gel. PCR products were stored at -20oC 
until use.  
5.5.1.4 MHC Class I exon 3 PCR 
The PCR conditions for the amplification of exon 3 are the same as section 5.5.1.3 
but using primers; BoC1FP-E3D (5’d[biotin-TGG TCG GGG CGG GTC AGG GTC 
TCA C]3’) and BoC1RP-E3C (5’d[biotin-CCT TCC CGT TCT CCA GGT ATC 
TGC GGA GC]3’). The annealing temperature was 64oC.   
5.5.1.5 DQA exon 2  
The PCR conditions for DQA are the same as the previous protocol (section 5.5.1.3) 
but with the following primers; 0.8 µM BoDQA1FP-E2A 5’d[biotin-
CTCCGACTCAGCTGACCACATTGG]3’), 0.8 µM Biotinylated Forward Primer 
BoDQA2FP-E2B (5’d[biotin-CCTCAATTATCAGCTGACCACGTTGG]3’), 0.8µM 
Biotinylated Reverse Primer BoDQA1RP-E2A (5’d[biotin-
TACTGTTGGTAGCAGCAGTAGAGTTGG]3’) and 0.8 µM Biotinylated Reverse 
Primer BoDQA2RP-E2B (5’d[biotin-
GGTGGACACTTACCATTGATAACAGGG]3’). The annealing temperature was 
58oC. 
5.5.1.6 Class I exon 2 and exon 3 microarrays 
Class I exon 2 and exon 3 microarrays were printed at Washington State University, 
USA by Dr Chris Davies (Call, Chandler, & Brockman 2001; Park et al. 2004; 
Davies et al. 2006). Briefly the probes (Appendix D.5 and D.7) were printed on 
Teflon masked microscope slides (Tekdon's Masked slides, Florida) using a 
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microgrid II arrayer (Genomic Solutions, Ann Arbor, MI, USA). In total 104 
oligonucleotides (20-22 bp) probes were printed in duplicate on the slides for both 
exon 2 and exon 3. The probes were designed using an alignment of all known Class 
I sequences. 
5.5.1.7 DQA microarray  
The DQA microarrays were printed at Utah State University (Logan, USA) by Dr. 
Chris Davies. The arrays were printed on Teflon masked glass slides (Tekdon's 
Masked slides, Florida) using a microgrid II arrayer. In total 58 oligonucleotides (20-
22 bp) probes were printed in duplicate on to the slides (Appendix D.2). The probes 
were designed using an alignment of all the DQA alleles defined to date 
(http://www.ebi.ac.uk/ipd/mhc/bola/). 
5.5.1.8 Hybridising PCR products to array 
The slides were washed twice with double distilled (dd) H2O at 50
oC for 5 minutes 
on a plate shaker (~45 rpm) followed by a wash  in ddH2O at room temperature (RT) 
for 5 min on a plate shaker (~45 rpm). The slides were dried using a minifuge 
(ArrayIT, USA) for 10-15 sec and were then placed into a hybridising chamber  with 
5X SSPE (3 M NaCl, 0.2 M NaH2PO4-H2O, 0.02 M EDTA dissolved in H2O). 40 µl 
1X pre-hybridisation (50X Denhardt’s (Invitogen), 20X SSPE) was placed on each 
well in the slide. The hybridisation chamber was sealed and left at RT for 30 min.   
For each PCR sample 12 µl of product was mixed with 79 µl 1.14X hybridisation 
(50X Denhardt’s, 20X SSPE) solution. The PCR product/hybridisation solution was 
then denatured at 95oC for 5 min in a heat block and cooled rapidly on ice.  Using a 
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pipette, the pre-hybridisation solution was removed from each of the wells and was 
replaced with 40 µl of PCR product/hybridisation solution. Each sample was 
hybridised in duplicate (2 separate wells). The hybridisation chamber was closed and 
placed in a sealed plastic bag to incubate overnight at 50oC.  
The slides were then removed from the chamber and washed twice in 2X SSPE with 
10% SDS at RT for 5 min followed by two washes in 0.5X SSPE at RT for 5 min 
each.  For 5 slides a conjugation solution was prepared with 36 ml H2O, 10 ml 20X 
SSPE, 4 ml 50X Denhardt’s (Invitrogen) and 20 µl Streptavidin-Alexa Fluor 555 
conjugate (Invitrogen). 50 ml of conjugate solution were added to each slide staining 
jar and left in the dark at RT for 30 min on a plate shaker. After 30 min each slide 
was washed twice in 0.5X SSPE at RT for 5 min and spun dry in a minifuge for 10-
15 sec. Slides were then stored in the dark until they were scanned.  
5.5.2 Scanning of Slides 
5.5.2.1 Class I exon 2 and exon 3 slides 
The Class I exon 2 and exon 3 slides were scanned at Washington State University 
using an ArrayWorx (USA) scanner and all images were saved as .jpeg files. 
5.5.2.2 DQA exon 2 slides 
The slides were scanned using the Ark Genomics facility (http://www.ark-
genomics.org) on an Axon GenePix scanner at a wavelength of 532 nm (Molecular 
Devices, USA) and images were saved as .jpeg files.  
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5.5.2.3 Editing of scanned images 
 
The jpeg files were edited using Adobe Photoshop (Adobe, USA). The images were 
auto-corrected using auto-levels and auto-contrast. The duplicated wells were placed 
side-by-side into a new document to allow easier analysis of the hybridisation 
patterns.  
5.5.2.4 Analysis of Class I array microarray  
The edited Photoshop images were scored subjectively by eye according to the 
hybridisation scale (Figure 5.1). Each sample was hybridised in duplicate (2 wells) 
and each spot was printed in duplicate in each array. The scoring of the spots used all 
four replicates and a subjective average score was determined. Each score was 
entered into a simple program, CYTOFILE matrix analysis software (Davies et al. 
1994), which re-arranges data into a new file. The program first organises the data 
into groups dependent on probe groupings (Appendix D.8), then arranges into 
similarity. When all of the allele specific probes scored at least 6, the sample was 
scored as a positive for that allele.  
8 6 4 2 1
negativepositive
 
Figure 5.1 Rough scale of hybridisation for the Class I and DQA typing microarrays, for 
subjectively scoring of probe hybridisation on the microarrays. 
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5.5.2.5 Analysis of DQA microarray 
As the DQA microarrays were hybridised at The Roslin Institute, a new method of 
data analysis was investigated. The slides were scanned on an Axon scanner 
(Molecular Devices, USA) using a 10 micron scan and GenePix Pro software 
(Molecular Devices) was utilised for the analysis. Each probe was identified using a 
.gal file template to allow quantification. The measurement of intensity of each spot 
was then transferred into a Microsoft Excel (Microsoft, USA) spreadsheet format. 
The spreadsheet contained information on the position of the spot, probe name 
(Appendix D.1, D.2 and D.3), size of spot and intensity of fluorescence.  
5.5.2.6 Assignment of haplotypes and alleles 
The results from the CYTOFILE program (described in section 5.5.4.2) allow the 
allocation of Class I haplotypes and DQA alleles. The probes were designed based on 
the polymorphic regions in the known Class I and DQA sequences by Dr Chris 
Davies. The grouping together of the probes is based on the full Class I and DQA 
sequences, for example an animal positive for the A14 haplotype would have 
positive probes from the N*02301 and N*02401 sequences.  
5.5.3 qPCR DQA genes 
As duplication in the DQA and DQB genes is likely to have an effect on the immune 
response, it would be useful to have a rapid and easy way of identifying animals with 
the duplication. A qPCR method offers a way of assessing copy number in the 
genome and was considered to be a possible avenue for use with the DQA genes. 
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5.5.3.1 DNA samples 
The genomic DNA used in the qPCR assay was extracted from bovine cell lines 
(Table 5.1) using a Qiagen DNeasy blood and tissue kit (Qiagen, UK), following the 
manufacturers instructions. The cell lines were chosen as they had previously been 
typed at the DQA locus (Davies et al. 1994; Glass, Oliver, & Russell 2000) or had an 
inferred number of DQA genes based on the DRB3 alleles and therefore have a 
known copy number of DQA genes to allow validation of this technique.  











DRB3 alleles Number of DQA genes# 
10814 (a) 
and (b) 
WK-50 15B/24A *1001/*0101 2 
10795 (a) 
and (b) 
WK-029 08A/24A *1201/*0101 3 
10775 (c) ND 03A/24A *1001/*0101 3 
10757(c) ND 24A/28A *0101/*0701 3 
2390 (c) ND 18A/18A *1801/*1801 4 
2858 (b) WK-31 03A/22C *1001/*1101 4 
2859 (b) WK032 03A/18A *1001/*1801 4 
10812 (b) WK-53 18A/28A *1801/*0701 4 
(a) Glass, Oliver, & Russell 2000 (b) 5th BoLA Workshop (Davies et al. 1994) and (c) Glass 
unpublished data.  
# Except in the case of cell line 10814 and 10795, the number of DQ genes was inferred 
from the typing of the DRB3 alleles and available DR-DQ haplotypes Appendix D.9. 
ND Not done at workshop. 
 
Table 5.1 Cell line DNA used in DQA copy number qPCR assay and inferred DQA copy 
number (alleles).   
 
5.5.3.2 Designing and optimisation of primers 
Exon 2 of DQA is highly polymorphic and it was not possible to design suitable 
primers, so, using an alignment of DQA sequences, primers were designed for the 
exon 3 region. Primers DQAex3F (5’[CCC AAC ACY CTC ATC TGT CA]3’) and 
DQAex3R (5’[CAG TGC TCC ACT TTG CAC TG]3’)  were designed using 
DQA*0101 as a template in Primer3 (Rozen & Skaletsky 2000). A degenerate base 
was used at position 9 to enable amplification of all known alleles. The amplification 
protocol was as follows: 10X buffer (Bioline), MgCl2 at two concentrations (1.5 mM 
or 2.0 mM), DQAex3F 15 pmol, DQAex3R 15 pmol, 25 mM dNTPs (Bioline), H2O 
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and 1 unit Taq polymerase (Bioline). Cycles were run at 3 different annealing 
temperatures 55oC, 56oC and 57oC.  The PCR cycle consisted of 95oC for 10 min 
followed by 30 cycles of 95oC for 1 min (annealing temperature; 55oC, 56oC or 
57oC) for 1 min and 72oC for 1 min, followed by a final extension of 72oC for 5 min.  
5.5.3.3 Sequencing 
The PCR products from the DQA touchdown protocol with 10% DMSO were 
sequenced using the same method as described in Chapter 2, section 2.3.4. From the 
sequencing it was possible to see that there was an error in the design of the forward 
primer of DQAex3F, as the consensus obtained from 
http://www.ebi.ac.uk/ipd/mhc/bola/  had a G at 242 bp. However, it appeared that at 
this position the base is either polymorphic or is a C, but from 8 sequenced animals 
this base was consistently a ‘C’. The primer was re-designed using this information 
to DQAex3Fv.2 (5’[CAC TGC AAA GTG GAG CAC TG]3’) (Figure 5.2). A new 
annealing temperature of 55oC was used with 10% DMSO and 5 pmol primer and the 
resulting product was run on a 1.5% agarose gel.  
5.5.4 qPCR assay 
5.5.4.1 Design of Taqman probe for DQA 
A non-extending oligonucleotide probe was designed using Primer3 software to 
anneal to the DQA exon 3 sequence between the two amplification primers 
(DQAex3Fv.2 and DQAex3R), using the consensus sequence information from 
http://www.ebi.ac.uk/ipd/mhc/bola/. The DQA Taqman oligonucleotide probe 
sequence is (5’[AYG GGC AYK YRG TCA YAG AG]3’) (Figure 5.2). The 
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Taqman® MGB (Applied Biosystems, USA) probe is in the middle of exon 3 and 











Figure 5.2 DQA exon 3 consensus sequence. qPCR primer positions are underlined in green and 
probe position is underlined in pink.  The red ‘C’ in the reverse primer is the base changed from 
the original design after sequencing.   
5.5.4.2 DRA control gene 
The DRA gene was chosen as a control for the qPCR assay as it encodes the alpha 
chain of the DR molecule and so was considered to be similar to the DQA gene. 
DRA is monomorphic and only a single copy is present in the bovine genome. DRA 
primers DRAex3F (5’[TG ACTT TGA TGG TGA TGA GA] 3’) and DRAex3R (5’ 
[GAG CGC TTT ATC ATG ATC TC] 3’) and non-extending oligonucleotide probe 
(5’ [AAT TTG GAC ATT TTG CCA GA]3’), which was labelled with VIC, were 
designed with Primer3 software. The PCR for the DRA gene used the same 
conditions as the PCR for the DQA gene.  
5.5.4.3 Quantitative real-time PCR conditions  
The final qPCR protocol was used for both DQA and DRA primers and probes. 
Briefly the reaction contained: 2X Taqman buffer (Applied Biosystems, USA), 5 
pmol DQAex3Fv2, 5 pmol DQAex3R, 10% DMSO, 250 nM Taqman® MGB probe 
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DQA (Applied Biosystems), and H20 in a final volume of 20 µl. The PCR was run 
using the same conditions as stated previously (section 5.5.3.2). The qPCR was run 
on a Stratagene (USA) qPCR machine and analyzed with Mx3000 and MxPro 
(Stratagene, USA). All samples were carried out in triplicate.  
5.6 Results 
5.6.1 MHC Class I 
A total of 108 samples from the RoBoGen herd, which had been typed at the DRB3 
locus using the SBT technique (Chapter 2) and represented all of the DRB3 alleles 
in this herd, were hybridised to the MHC Class I exon 2 and exon 3 microarray 
slides. The hybridisation of the PCR products allowed clear identification of positive 
spots (Figure 5.3). The spots were scored using the subjective scoring method 
described previously (Figure 5.1). From Figure 5.3 it is possible to easily identify the 
strongly positive spots e.g. the G1, H1 pair and also those which are still positive but 
not as strong, e.g. the A2, B2 pair. Using the hybridisation pattern of both exon 2 and 
exon 3 arrays, 82 animals were successfully allocated MHC Class I haplotypes using 
the CYTOFILE program example of output shown in Figure 5.4. The Class I probes 
were designed by Dr. Chris Davies, they included all known sequence data and 
serological defined haplotypes. The allocation of the haplotypes using the microarray 
identifies allele specific probes and the haplotypes to which the probes belong e.g. 
probes for N*01301 and N*01302 would all hybridise for haplotype A18. As Class I 
alleles have not been allocated to loci the Class I region the microarray uses the 
originally defined serology haplotypes (Davies et al. 1994) (Appendix D.8). 
However, due to the complexity of the Class I region, it was not possible to reliably 
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Figure 5.3 Microarray scanned and edited image of RoBoGen animal 15082 on Class I slide for 
exon 2. Each spot is printed in duplicate side by side, e.g. A1 and B1. The circled spots are 
positive controls (A1, B1, O1, P1, A13 B13 O13, P13). The image has grid lines to allow easier 
identification of probes. The image represents a typical example of a hybridised microarray.  
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DRB3G1.SBC "11-02-2006","11-10-2006“
































Figure 5.4 An example of data output from CYTOFILE.  Red boxes indicate positive probes grouped together to allow easier identification of 
alleles/haplotypes. Alleles across the top with probes underneath (read from top to bottom), animal identification numbers listed on left hand side.
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The most common haplotype seen was A12 which was found in 54% of the animals 
tested on the microarray (Table 5.2). The least common haplotypes were A70, A71 and 
A72 (definition of haplotypes by Dr C Davies, personal communication). A single 
animal, animal 164, had four MHC Class I haplotypes defined by the microarray, A33, 
A06, A18 and A61.  
It was possible to hypothesise Class I-DRB3 haplotypes from the results of the Class I 
microarrays and the DRB3 typing (Table 5.3). The most convincing haplotype was for 
DRB3*2707 and Class I, A12 due to the large number of animals with this haplotype 
(n=34).
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A67*  11 
A68*  1 
A70*  1 
A71*  1 
A72*  1 
Table 5.2 MHC Class I haplotypes defined by microarray and alleles (# http://www.ebi.ac.uk/cgi-
bin/ipd/mhc/view_nomenclature) and number of animals. (* haplotypes defined by Dr Chris 
Davies, personal communication). 
 
DRB3 allele Class I haplotypes No. of animals 
*2707 A12 34 
*1101 A14/A67 6 
*1601 A33 7 
*0201 A14 6 
Table 5.3 Hypothesised DRB3/Class I haplotypes from the microarray and SBT results in the 
RoBoGen herd.  
5.6.2 DQA 
The PCR for DQA produced a clear product which was then hybridised to the 
microarray slide. The slides were scanned using an Axon scanner and produced an 
image of the whole slide (Figure 5.5). Initially an attempt was made to use the GenePix 
software to identify spots and to measure their intensity. The results from the Genepix 
software indicated difficulties in locating the positive spots, as they varied in position 
and size between the different arrays. The Excel spreadsheet of the probe intensities 
showed a huge range of scores for positive hybridisations, for example a control probe 
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had an average intensity of 6933, while a positive test probe had an intensity of 11887 
which is nearly double the value.  In addition it was found that the values for the 
positive spots varied between the arrays, with a control probe having an intensity score 
of 19358 on 1 array and the same probe having a score of 8863 on another array on the 
same slide. This variation in intensities meant that it was impossible to automate the 
scoring of probes.  
 
Figure 5.5 Image from GenePix software of entire microscope slide with 8 microarrays, with .gal 
file template overlaid on image. The magnified picture shows 1 microarray (1 sample). Each of the 
green positive spots has been identified by the GenePix .gal file.    
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The scoring of the DQA slides was done manually using the Photoshop .jpeg images. 
However, the majority of the scanned images were poor in quality and this is 
highlighted in Figure 5.6. Using Photoshop it was possible to manipulate the images to 
allow the scoring of spots, although the accuracy of the scoring is reduced (Figure 5.7). 
The images of the slides were sent to Dr. Chris Davies (Utah State University) and he 
allocated alleles, based on his previous microarray knowledge.  
 







Figure 5.6 Image of scanned slide of DQA microarray showing entire scan area. Animal 
identification numbers in black and duplicates side by side. This image illustrates the poor quality 
of the scanned images.  
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Figure 5.7 Microarray scanned and edited image of RoBoGen animal 101 on DQA array showing 
both replicates. Each spot is printed in duplicate side by side. The image has grid lines to allow 
easier identification of probes. The image represents a typical example of a DQA hybridised 
microarray.  
 
Due to the difficulty with haplotype allocation discussed in section 5.6.2, only 31 
complete DQA alleles/haplotypes were allocated for the 78 animals used in the 
microarray experiment.  There were 7 animals which had partial identification of 
haplotypes with a single DQA allele. Eighteen DQA alleles were identified in 38 
animals (Table 5.4). Fifteen of the alleles were in duplicated haplotypes. The most 
common duplicated haplotype in the herd was DQA2*12021, DQA2*22021 which was 
found for 6 animals, all of which had DRB3*1601. The DRB3*2707 allele, which is the 
most common DRB3 allele, was found with 2 different DQA haplotypes, either 
DQA1*0203 or DQA1*1203 and DQA2*2201.  
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DQA allele 
No. of animals for 
each for allele duplicated 
DQA1*0101 3 yes 
DQA1*0102 1 no 
DQA1*0203 7 no 
DQA1*0302 6 no 
DQA1*10011 2 yes 
DQA1*10012 5 yes 
DQA1*12011 3 yes 
DQA1*12021 3 yes 
DQA1*1203 5 yes 
DQA2*2101 6 yes 
DQA2*2201 12 yes 
DQA2*2202 1 yes 
DQA2*22021 8 yes 
DQA2*22031 1 yes 
DQA2*2206 1 yes 
DQA3*25012 4 yes 
DQA3*25013 1 yes 
DQA3*2901 1 yes 
Table 5.4 DQA alleles identified with the typing microarray in 38 RoBoGen animals and their 
duplication status. 
5.6.3 qPCR  
DQA and DRA primers were successfully designed to amplify exon 3 from the 
monomorphic DRA and the polymorphic and duplicated DQA genes. TaqMan® non-
extending MGBTM nucleotide probes were designed and used to measure the PCR 
amplification.   
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5.6.3.1 Touchdown qPCR 
The samples from the touchdown qPCR (detailed in section 5.5.3.2) were run on a 1.5% 
agarose gel (Figure. 5.8).  
1 2 3 4 5 6 7 8 9
1 2 3 4 5 6 7 8 9
1 2 3 4 5 6 7 8 9 2 3 4 5 6 7 8 9
2 3 4 5 6 7 8 9















Figure 5.8 Agarose gel electrophoresis of DQA PCR amplification with primers DQAex3F and 
DQAex3R. Lane 1: hyperladder I (Appendix B.2), lane 2: Holstein cell line DNA animal 18014, lane 
3: Holstein cell line DNA animal 18014, lane 4: Holstein cell line DNA animal 10757, lane 5: 
Holstein cell line DNA animal 10757, lane 6: Holstein cell line DNA animal 10795, lane 7: Holstein 
cell line DNA animal 10757, lane 8: RoBoGen DNA animal 101 and lane 9 –ve control. In –ve 
control lanes the primer dimer band is visible.    
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Multiple bands were seen for each animal, suggesting non-specific amplification of the 
DQA exon 3. A touchdown protocol was implemented to resolve this problem, with a 
starting annealing temperature of 57oC decreasing to 54oC by 1oC every 2nd cycle. All 
other conditions were kept the same as in previous reactions with the addition of 5% 
DMSO (dimethyl sulfoxide) (Figure. 5.9) 









Figure 5.9 Agarose gel electrophoresis of DQA PCR amplification with primers DQAex3F and 
DQAex3R using 5% DMSO. Lane 1: hyperladder I (Appendix B.2), lane 2: Holstein cell line DNA 
animal 18014, lane 3: Holstein cell line DNA animal 18014, lane 4: Holstein cell line DNA animal 
10757, lane 5: Holstein cell line DNA animal 10757, lane 6: Holstein cell line DNA animal 10795, 
lane 7: Holstein cell line DNA animal 10757 and lane 8: RoBoGen DNA animal 101.  
 
From the touchdown PCR there were still too many non-specific bands of PCR product. 
Touchdown PCR was repeated using 10% DMSO and 5 pmol of each primer and run on 
a 1.5% agarose gel (Figure 5.10). The touchdown PCR showed a single PCR product 
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band (and primer dimer), which was purified for sequencing. 
1 2 3 4 5 6 7 8 9
 
Figure 5.10 Agarose gel electrophoresis of DQA PCR amplification with primers DQAex3F and 
DQAex3R using 10% DMSO and touchdown PCR protocol. Lane 1: hyperladder I (Appendix B.2), 
lane 2: Holstein cell line DNA animal 18014, lane 3: Holstein cell line DNA animal 18014, lane 4: 
Holstein cell line DNA animal 10757, lane 5: Holstein cell line DNA animal 10757, lane 6: Holstein 
cell line DNA animal 10795, lane 7: Holstein cell line DNA animal 10757, lane 8: RoBoGen DNA 
animal 101 and lane 9 –ve control. Primer dimers are visible in all lanes.   
 
5.6.3.2 Sequencing 
The PCR products from the DQA touchdown protocol with 10% DMSO Figure 5.10 
were sequenced using the same method described in Chapter 2, section 2.3.4. (an 
example of DQA exon 3 sequence shown in Figure 5.11). The sequence trace also 
confirmed that it was DQA exon 3 which was being amplified by PCR.  
 
Figure 5.11 Fragment of sequence trace file of RoBoGen animal 101.  The blue highlighted ‘C’ base 
lies in the forward primer DQAex3F.  
The DRA and DQA genes were successfully amplified using the qPCR protocol (Figure 
5.12). The amplification plots were obtained using the MxPro software (Applied 
Biosystems) (Figure 5.13). The Ct value at which the amplification crossed the 
   
 194 
threshold was obtained from the amplification plots and used in subsequent 
calculations. The threshold value was kept the same for all samples.  
1 2 3 4 5 6 7 8 9















Figure 5.12 1.5% agarose gel electrophoresis of DQA and DRA PCR amplification with primers 
DQAex3F and DQAex3R (top row) and DRAex3F and DRAex3R (bottom row) Lane 1: 
hyperladder I (Appendix B.2);  lane 2: Holstein cell line DNA animal 18014; lane 3: Holstein cell 
line DNA animal 18014; lane 4: Holstein cell line DNA animal 10757; lane 5: Holstein cell line DNA 
animal 10757; lane 6: Holstein cell line DNA animal 10795; lane 7: Holstein cell line DNA animal 
10757; lane 8: Holstein cell line DNA animal 2858; lane 9: Holstein cell line DNA animal 2859. 
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Figure 5.13 Screen shot taken from MxPro output. Each coloured line represents the amplification 
profile of a single DNA sample. This output shows the fluorescence (dR) of each sample and the 
number of cycles of amplification. The green horizontal line is the threshold measurement for JOE 
and the blue horizontal line the threshold measurement for FAM. 
5.6.3.3 Analysis of qPCR 
For the determination of copy number of the DQA gene the 2-∆∆Ct method was chosen 
(Livak & Schmittgen 2001). To allow valid calculations using the 2-∆∆Ct method the 
amplification efficiencies of both the DQA and DRA genes must be similar. The Ct 
values were measured over a tenfold dilution range of a control DNA that contains two 
copies of DQA and DRA (cell line animal 10814 (Glass et al. 1991)). Standard curves 
were created and an R2 value obtained, (R2 was 98% for both the DQA and DRA). The 
determination of the real-time qPCR efficiencies of the reference gene, DRA, and the 
target gene, DQA, were calculated according to the equation E=10(-1/slope) (Pfaffl 2001).  
The efficiencies were similar for the DQA and DRA gene PCR amplification (E=2.25 
and E=2.31 respectively) (Figure 5.14) allowing the valid use of the 2-∆∆Ct method. 


















Figure 5.14 Determination and comparison of the PCR efficiency for DQA (Efficiency 2.31) and 
DRA (Efficiency 2.31) genes.   
 
The gene copy number was calculated by the formula 2-∆∆Ct, where; 
 
∆∆Ct = (CtDRAcalibrator –CtDRAtest) - (CtDQAcalibrator -CtDQAtest).  
 
Ct is defined as the point that the florescence rises above the baseline (Bodin, Beaune & 
Loriot 2005).  
DRA 
DQA 
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The efficiencies of the PCR amplification were calculated using a standard curve 
(Figure 5.14) giving values of 2.25 and 2.31, indicating similar efficiencies. Using the 
2*2 ∆∆Ct method the copy number of each gene was calculated using animal 10814 as the 
control with only 2 copies of the DQA gene. The results of the qPCR copy number 
calculation are shown in Figure 5.15. The qPCR copy number agrees with the expected 
copy number for each of the animal samples (Table 5.1). From the qPCR animal 10814 
was confirmed as having 2 copies of DQA, animals 10795 and 10775 were confirmed as 

























Figure 5.15 DQA copy number calculated using qPCR. The expected number of DQA copies 
generated from previous work (Table 5.1) and the calculated copy number using the 2*2 ∆∆Ct 
method. 
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5.7 Discussion 
In this study two different approaches have been used to investigate the Class I region 
and the DQA genes. The DNA typing microarray used known information on the alleles 
of the DQA genes and the Class I genes to allow the deciphering of hybridisation 
patterns and allocation of alleles/haplotypes in the RoBoGen population. This technique 
however was only partially successful. The second approach was to utilise real-time 
qPCR as a quick and simple way to check for duplication of the DQA genes, which 
proved to be successful, although more thorough testing would be required.  
The microarray technique was used to allocate alleles for the DQA genes and for Class I 
haplotypes. The success of a microarray is dependent upon the alleles which are present 
in the test population being represented on the array. These arrays were originally 
designed for the Holstein breed of cattle and for bison, which may account for some of 
the difficulties in the typing of the RoBoGen cross population. Nonetheless, it was still 
possible to identify the DQA and Class I alleles present in the majority of animals 
tested.  
The Class I microarray used the known Class I haplotypes which were originally gained 
from older typing techniques (Chapter 2). However there is still much which is 
unknown about the organisation and structure of the Class I region in cattle, thus 
creating difficulty in assigning alleles/haplotypes within this region (Ellis et al. 1999). 
The array used both exon 2 and exon 3 sequences to identify ‘haplotypes’. The majority 
of animals were assigned with at least 1 haplotype (Appendix D.8), but it is possible 
that there were more Class I genes present in the Charolais breed which are not 
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represented on the array. Also there could be difficulties when using the microarray on 
other breeds of cattle, as the defined Class I ‘haplotypes’ might not be the same. 
It was intended that the information on spot intensity and probe identity would allow for 
the allocation of alleles. However, the attempted automation of microarray analysis was 
unsuccessful for several reasons. The microarray scanner used at the Ark Genomics 
facility is primarily for use on expression microarrays using dyes of Cy3 (green) and 
Cy5 (red). The wavelength was set to read at the Cy3 setting (532 nm). However, the 
optimum wavelength for the Alex Fluor 555 is 555 nm which unfortunately resulted in 
the quality of the scanned image being poor (Figure. 5.6). This in turn meant that the 
GenePix .gal file had difficulty identifying the positive spots so that manual selection of 
each spot was required in the majority of cases. Another problem with the automation 
was the variation in the original printing of the array, as each spot was not of uniform 
size, or in orientation to one another. This again resulted in a failure of the software to 
identified positive spots. The substantial differences in the area of the spots and 
irregularities in the spot quality meant that the average intensity over the entire spot 
would not be an accurate measure of intensity.  
Once the spots were assigned an intensity value, it was intended that a program would 
be designed to automatically sort and allocate alleles. The Excel file was manipulated so 
that only spots/probes with high intensity ‘positive’ values were displayed. The probes 
which were listed positive were organised into the corresponding alleles. However, due 
to the problems in measuring the intensity values and the fact that the cut-off ‘high’ 
value was different between each slide, the computer algorithm failed to be applicable 
across all slides.  
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As the attempt to automate the analysis failed, all slide .jpeg images were emailed to Dr. 
Chris Davies to allow for subjective analysis and identification of alleles. The 
identification was done in conjugation with the known DRB3 alleles and previous 
experience in reading the hybridisation patterns which assisted in DQA allele allocation. 
The problems encountered in the typing of the animals using the DQA arrays were, for 
the most part, due to the technology. The hybridisation of the PCR products to the 
probes appears to have been successful; however, the analysis of the slides posed many 
problems. The scanning of the slides resulted in poor quality images which 
consequently led to an inability to visualise the positive probes. Manual assignment of 
positive probes was also difficult due to the poor quality of the scanned images. The 
final allele assignment method was determined in conjunction with the known DRB3 
alleles (Chapter 2), and experience in ‘reading’ the hybridisation patterns although it 
still is rather subjective. Whilst this did provide some information on the DQA alleles it 
was very time consuming and would be difficult to utilise in large population studies.   
Despite the problems in the arrays it was possible to hypothesise the Class I-DRB3 
haplotypes in the RoBoGen herd from the results. The typing of the MHC Class I region 
revealed that Class I haplotypes were linked with the DRB3 alleles, for example 
DRB3*2707 has Class I haplotype A12 in 34 animals (Table 5.3). The A12:DRB3*2707 
haplotype also is found with DQA*0302 in 6 animals. The allele DRB3*2707 is one of 
most frequent within the entire herd as 3 of the 4 founding sires had this allele, and 
therefore it is likely that the Charolais founding sires had the A12 Class I haplotype. 
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Real-time quantitative PCR has primarily been used in the study of gene expression but 
it has been adapted to investigate copy number variation (CNV) in a number of specific 
genes (Bodin, Beaune & Loriot 2005) and is a viable alternative to Southern blot and in 
situ hybridisation techniques (Hoebeeck, Speleman & Vandesompele 2007). In the 
present study, real-time qPCR was utilised to investigate the duplication in the BoLA-
DQA genes. The duplication in these genes is a unique attribute of cattle (ruminants) 
(Ellis 2004), and is likely to improve the immune response by increasing the number of 
possible DQ molecules (Glass, Oliver & Russell 2000). The duplication of the DQ 
genes also allows for inter- and intra-haplotype paring of the alpha and beta chains,  
increasing  the number of possible peptides which can be presented to T cells (Norimine 
& Brown 2005). Together with the high number of polymorphisms observed in these 
genes, it would indicate that the duplication of DQA and DQB would be advantageous. 
The duplication of the genes improves the level of resistance to mastitis (Park et al. 
2004) and therefore might prove to be of benefit for a general level of disease 
resistance.  
In this study I have developed a TaqMan real-time qPCR assay for the quantification of 
the BoLA-DQA genes. The DQA genes are highly polymorphic with 44 different alleles 
identified to date (http://www.ebi.ac.uk/ipd/mhc/bola/). For this reason it was 
problematic to design qPCR primers that lie in exon 2. Instead, the less polymorphic 
exon 3 was chosen. The main difficulty in using exon 3 for the designing of primer and 
probes for assay was the lack of sequence information available. Indeed, it was found 
that the sequence information was incorrect, with a C instead of a G in the reverse 
primer region. Nonetheless successful amplification of exon 3 was achieved after re-
designing the primers to produce specific PCR products. DRA was chosen as a control 
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gene, as it is monomorphic and therefore easier to design suitable primers and probes as 
well as only being represented once on each chromosome. The qPCR assay allowed 
discrimination between the 2, 3 and 4 copies of DQA in each of the samples tested. 
Further validation on additional animals is necessary so that the qPCR method can be 
tested for accuracy and robustness.  
The two techniques described in this chapter have been developed to increase the 
information on the Class I and DQA genes. The microarray typing has been utilised in 
typing and functional studies of the MHC genes (Park et al. 2004; Traul et al. 2005). 
The microarray technique could be further improved through greater levels of 
automation which might reduce the need for human analysis. The qPCR technique 
requires further testing for robustness, but could provide a simple and quick way of 
testing for duplication in the DQ genes. The qPCR assay could be used in functional 
studies with an aim to see if duplication increases disease resistance (further discussed 
in Chapter 6).    
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6 General discussion 
Infectious disease has a substantial impact both on the economy of the livestock 
industry and the welfare of the animals. As it is now possible to further our 
understanding of the genetics underlying immune response to infections, we can start to 
utilise this information to design safer and more efficacious vaccines.  It also opens up 
the possibility of breeding animals for increased disease resistance.  
The alleles of BoLA DRB3 have been previously reported to have significant 
associations with immune responses (Chapter 1, Table 1.1). DRB3 is highly 
polymorphic and to date 106 alleles have been reported 
(http://www.ebi.ac.uk/ipd/mhc/bola/). This project was focussed on DRB3 as it was 
highly probable that due to the function of the DR molecule, associations would be 
discovered in relation to the immune traits which were measured. In addition, it was 
feasible to accurately assign alleles to heterozygous animals.  
The major resource for this PhD project was a large cattle cross population (RoBoGen 
herd) which was initially created for the study of production traits and locating possible 
QTLs. The production measurements and immune phenotypes were taken previous to 
the start of this project but included the response to immunisation with a peptide derived 
from FMDV, the IgG response to two respiratory disease vaccines, and the PBMC 
proliferation to Staph. aureus. Previous PhD projects had already found a strong sire-
based genetic effect in the response to the respiratory vaccines (O'Neill et al. 2006; 
O'Neill 2006) and the PBMC proliferation response to Staph. aureus (Young 2002). 
This PhD study was unique however as its aim was to assess the associations between 
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polymorphisms present in BoLA genes and the previously measured immune 
phenotypes.  
6.1 Overview 
6.1.1 Key findings 
The main findings from each of the 5 chapters are summarized below.  
Chapter 2 
• Improving a sequence-based typing method for BoLA- DRB3 
Chapter 3 
• Six DRB3 alleles and seven PBC positions had significant associations with  
IgG1-specific response to FMDV15 
• Three DRB3 alleles and twelve PBC positions had significant associations with 
IgG2-specific response to FMDV15 
• Three DRB3 alleles and six PBC positions had significant associations with  T 
cell proliferative response to FMDV15  
• Two DRB3 alleles and five PBC positions had significant associations with T 
cell proliferative response  to ConA 
• Three DRB3 alleles and fifteen PBC positions had significant associations with 
IFN-γ production in response to FMDV15 
• Three DRB3 alleles and ten PBC positions had significant associations with 
IFN-γ production in response to ConA 
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Chapter 4 
• Four DRB3 alleles and six PBC positions had significant associations with  IgG 
response to vaccination against BRSV 
• Five DRB3 alleles and five PBC positions had significant associations with  IgG 
response to vaccination against BHV-1 
• No DRB3 alleles and four PBC positions had significant associations with  IgG 
response to vaccination against PIV-3 
• DRB3 alleles and PBC positions had significant association with PMBC 
proliferation in response to Staph. aureus and PHA 
Chapter 5 
• Typing of MHC Class I haplotypes using a DNA microarray 
• Typing of DQA alleles using a DNA microarray both at Washington State 
University and at the Roslin Institute 
• Design of a novel qPCR technique for identifying duplication in DQA genes 
 
In this PhD study a substantial number of significant associations between 
polymorphisms of the DRB3 gene and the specific pocket positions within the PBC and 
the measured immune phenotypes were detected. The results when taken together are 
suggestive that the DRB3 gene is important for the responses to vaccination. Moreover 
the specific amino acids within the PBC have significant associations with the humoral 
as well as cellular response with all the measured immune parameters.  
In addition, as part of the overall project, typing of the DQA and Class I genes was 
undertaken (Chapter 5). There has been great difficulty with the typing of these genes 
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due to the high level of complexity. The DQA genes are duplicated in half the known 
haplotypes and are polymorphic (Andersson & Rask 1988; Ballingall, Luyai & 
Mckeever 1997). Using a sequence-based typing (SBT) method is difficult due to 
problems with allele identification. However, Takeshima et al. (2007) used SBT to type 
only at the DQA1 locus. The number of Class I genes varies with haplotype, which has 
limited the research. Nonetheless, some alleles have been allocated to loci (Birch et al. 
2006). These hurdles have restricted the study of these genes even though the 
polymorphisms in both sets of genes are likely to have a role in the mounting of an 
effective immune response. The animals of the RoBoGen herd had not been typed at 
either the DQA or Class I loci and so as part of the study investigating the BoLA region 
an attempt was made to distinguish their alleles using a typing microarray. In Chapter 5 
a novel qPCR technique was designed for the quantification of the number of DQA 
alleles, as the duplication of DQ gene may be of benefit to the immune response.  
This project was part of a larger QTL investigation into production traits. The two 
breeds were chosen with the assumption that genes involved in either dairy or beef 
production would be fixed in the founder populations. However, it would be unlikely 
that those genes involved in the immune response would be fixed and instead has 
provided an opportunity to investigate the role of the BoLA genes in a heterogeneous 
population.  
This project was constrained by a number of factors, including the original design of the 
test population. Unfortunately the RoBoGen herd had a poor design as there were only 4 
founding Charolais sires crossed with 111 Holstein dams, with some dams having 
multiple offspring through embryo transfer. This resulted in DRB3*2707 being there 
most frequent allele as it was derived from 3 of the 4 founding Charolais sires. Little is 
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known about the frequencies of DRB3 alleles in breeds other than Holsteins, as the 
majority of the typing has been carried out on this breed (Sigurdardottir et al. 1992; 
Davies et al. 1997). Nonetheless even though the RoBoGen population had only 22 
alleles some significant associations were found.  It would have been interesting to have 
a higher number of founding sires or to have female Charolais crossed with male 
Holstein-Friesians which may have led to a more diverse range of DRB3 alleles, 
although this might have reduced the overall significance of the data.  
The FMDV15 peptide was used on the herd for a variety of reasons. It was a peptide to 
which the animals would have no prior exposure and therefore there would be no 
maternal antibodies. Thus it was considered that immunisation with the peptide would 
facilitate assessment of the role of BoLA genes on both the primary and secondary 
immune responses. The use of peptide/synthetic vaccines is a real commercial 
possibility and so a measure of the impact that the DRB3 alleles have on the response to 
such a potential vaccine would be useful, however it has to be noted that to-date there 
are no commercial peptide vaccines in use for humans. Even though the peptide is only 
a 40-mer there are still high levels of complexity seen in both the response and in the 
DRB3 associations observed. Those alleles which were significantly associated with the 
humoral and cellular responses are different, for example the *1601 allele which is 
significant for both IgG1 and IgG2 did not have any significance for T cell proliferation, 
indicating that the mechanisms directing the immune response are complex, and that a 
deeper understanding would be required to design efficacious vaccines. Although the 
FMDV15 peptide is a useful tool for exploring the BoLA associations with immune 
response it is not a viable commercial vaccine, and indeed it is unlikely that FMDV 
peptide vaccines would ever induce the protection needed to be used prophylactically.   
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The efficacy of the Imuresp vaccine (as addressed in Chapter 4) to induce an antibody 
response is not very convincing, with a low response for both anti-PIV3 IgG and anti-
BHV1 IgG. Thus the relevance of the significant DRB3 alleles to response to these 
pathogens is unclear, and may instead represent associations with clearance of maternal 
antibody or natural exposure. The contributing factor of circulating maternal antibodies 
also may have had an impact on the results from the Rispoval vaccine IgG 
measurements (O'Neill et al. 2006). It may have been possible to find more associations 
with the respiratory vaccines without the presence of the maternal antibodies.  
There is currently no literature on the impact of the polymorphisms of the BoLA genes 
on commercially available vaccines such as those described in Chapter 4. As the 
interaction between the adaptive immune system and a vaccine is crucial for vaccine 
efficacy, an understanding of the role of the MHC molecules is vital. Firstly, this study 
highlights that the alleles of the DRB3 gene are associated with the production of 
antibodies to a vaccine and secondly, it indicates that the PBC pockets would appear to 
have a substantial role.  
It is very unlikely that the microarrays described in Chapter 5 could ever realistically 
be implemented on a large population for typing at any of the BoLA loci. The 
identification of the DQA alleles was close to impossible if the DRB3 alleles weren’t 
known, in addition this is based on the assumption that the DQA-DRB3 haplotypes were 
the same in all breed of cattle, which has not been proven. In the Class I microarrays it 
proved difficult to define haplotypes without extensive knowledge of the hybridisation 
patterns.  
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6.2 Further Research  
Since the start of this project, there have been a number of advances in the available 
technologies. The SBT technique as described in Chapter 2 could be further improved 
by using newer high through-put sequencing techniques, such as pyrosequencing which 
has been used for the genotyping of complex genes and regions (Babik et al. 2009). 
Indeed pyrosequencing methodology has already been implemented for the complex 
Class I region of macaques (Wiseman et al. 2009). The sequencing and allele allocation 
of the Class I and Class II genes could both be improved by the use of pyrosequencing. 
However the complexity of gene duplication in the DQ genes and the complexity of the 
Class I region may still pose difficulties in accurately assigning haplotypes.   
An original aim of this project was to define haplotypes over the entire BoLA region 
using single nucleotide polymorphism (SNP) markers (described in Chapter 1). The 
use of SNP haplotypes has been implemented extensively in humans (Gibbs et al. 
2003). It would be valuable to define haplotypes in the BoLA region as they could be 
used to investigate for associations between haplotypes and/or individual SNPs with 
immune phenotypes.  However to establish a SNP haplotyping method, it was necessary 
to first establish the position of the genes within the BoLA region. A map was produced 
in silico using BLAST information with human and bovine MHC genes (Chapter 1) 
and the Btau 3 assembly, with the intention of identifying the BAC (bacterial artificial 
chromosomes) clones used in the assembly of the genome which contained BoLA 
genes. However, this region has high levels of duplication and gaps in the bovine 
assembly, which resulted in low confidence in the order of the clones. The BAC clones 
need to be in the correct order so that the positions of SNPs, and therefore the 
haplotypes could be correctly allocated. 
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The results presented in Chapter 3 described the associations of the BoLA DRB3 alleles 
and polymorphisms with the immune response to FMDV15 peptide. Many significant 
associations were noted between the DRB3 alleles and IgG1, IgG2, IFN-γ and to a lesser 
extent T cell proliferation post-immunisation. In addition the pockets within the PBC 
also showed many highly significant associations.  
A possible addition to the FMDV work would have been to test sera from high and low 
responders to the whole FMDV virus by ELISA and also by neutralisation tests. These 
would have to be carried out at a Category 4 facility such as Institute for Animal Health 
(Pirbright). This would allow any correlations between neutralising antibodies and the 
DRB3 alleles to be tested. To further this research a challenge study with FMDV after 
the immunisation would have provided information on correlations between the high 
responders in Chapter 3 and those which demonstrated protection. However challenge 
facilities within the UK are very limited in terms of the number of animals that can be 
accommodated and instead typing animals from an FMDV endemic country could 
potentially provide valuable data.   
The cellular and humoral phenotypes were measured in response to the peptide and 
different alleles were associated with each. A future project would be to select those 
animals positive for alleles which were associated with a high/or low response to 
FMDV15 and challenge them with the live virus.  
The binding of the peptide fragments to a variety of high and low responders’ DRB3 
alleles could be carried out through purification of MHC molecules and a binding assay 
(Haghparast et al. 2000). This could be then carried through to the crystal modelling of 
both the peptide fragment and DR molecules, although this would be costly and require 
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a vast amount of work. Nonetheless understanding the binding of peptide to DR 
molecules may assist in the design of future vaccines.  
A future project for the extension of the research in Chapter 4 could be to investigate T 
cell proliferation in response to the vaccines and associations with DRB3 alleles, as 
there were low responses measured for both anti-PIV3 and BHV1 IgG1. Again the use 
of binding assays as described above could be implemented and peptide vaccines could 
be used to produce a stronger response. A further way to develop the Staph. aureus 
assay would be to test whether those animals with alleles which were associated with a 
high/low PBMC proliferation response were more or less susceptible to mastitis.   
The advancement of epitope prediction using bioinformatics is expanding the scope for 
vaccine research. Sequence information for cattle pathogens is readily available but the 
binding motifs are not yet available, therefore predicting T cell epitopes is not currently 
possible. In humans the use of computer algorithms to predict T cell epitopes has been 
used. This has been more successful in Class I molecules due to the relative ease as 
predicting the motifs in the bound peptides (Nielsen et al. 2008). 
An important consideration in the use of peptide vaccines is that not all peptides will 
bind to MHC molecules for presentation, and even if peptide do bind it may not be 
functionally important e.g. the recognition of the spacer region of the FMDV peptide 
(Glass & Millar 1995). In addition, the binding of a peptide to an MHC molecule is only 
part of the required interactions to initiate an effective adaptive immune response. The 
bound peptide has to interact with the TCR on the T cells. This interaction would need 
to be sufficient to mount and effective adaptive immune response.  Knowledge on T cell 
epitopes in cattle is limited, however it has been possible in the case of FMDV to 
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identify MHC restriction and anchor residues through lymphocyte proliferation assays 
and alanine substitutions in peptides (Gerner et al. 2009).  
Several associations have been found between the DRB3 alleles and PBC positions, and 
to the response to ConA. ConA is a mitogen and therefore should elicit a non-specific 
proliferation of T cells, and so these associations were not expected and are difficult to 
explain. A different T cell mitogen, such as PHA (Chapter 5) could have been used as 
there were no significant alleles or pockets identified in response to PHA.  
The qPCR technique described in Chapter 5 could potentially provide a quick and easy 
way to determine the copy number of the DQ genes. It would be useful to further 
investigate this technique on more animals to prove its robustness, and explore whether 
the duplications have an impact on the level of immune response as has been previously 
suggested (Glass, Oliver & Russell 2000; Park et al. 2004).  
The advances in the qPCR technique may even pave the way to distinguish between DQ 
alleles using allele-specific TaqMan probes (Wang & Smith 2007). This would enable 
the testing of the theory of heterozygote advantage at these loci (Takeshima et al. 2008). 
The relative importance of the DR and the DQ molecules is unknown, with many of the 
associations being linked to the easier-to-type DRB3 gene. Increased research into the 
DQ genes may begin to ascertain the importance of these genes for response to infection 
and vaccination.   
It is not possible to fully quantify the role that the DRB3 polymorphisms have in the 
response to vaccination without fully comprehending the haplotype structure of this 
region. The DQ genes are likely to be linked to DRB3 and at least in the case of FMDV 
peptides (Glass, Oliver & Russell 2000) code for functional restriction elements. 
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Therefore haplotypes of DRB3-DQA-DQB may show stronger associations and 
appropriate SNPs in these genes distinguishing such haplotypes may provide markers 
for breeding for improved vaccine responders and/or disease resistance. Much is still 
unknown about BoLA haplotype structure across the whole region. This lack of 
information on the structure and organisation of the bovine MHC is hampering research 
and would ideally be resolved in the near future, possibly by sequencing the whole 
region using many animals.  
Although the present study has clearly underlined the importance of the MHC region in 
determining immune responsiveness, the variation in response to vaccines and 
infectious pathogens is clearly polygenic (Hill 1998). Ongoing research into the 
response to BSRV vaccination and FMDV immunisation has shown many QTLs which 
lie over non-MHC regions as well as the MHC region on BTA23 (Leach et al. 2010).  
Non-MHC genes will be having an impact on the responses discussed in this thesis. 
However, the data in Chapters 3 and 4, as well as that of Sharif et al (2000) and 
Yoshida et al (2009), indicate that the DRB3 PBC is associated with immune response 
and taking it into consideration when designing vaccines would certainly be advisable. 
The amino acids within pocket 4 are especially significant, as in humans pocket 4 has 
been demonstrated to have a major influence on the binding of peptides in the DR 
molecule (Fu et al. 1995). In addition in cattle there have been a number of associations 
between immune response and pocket 4 (Sharif, Mallard, & Sargeant 2000; Baxter et al. 
2009). Pocket 4 is centrally located and is entirely encoded by exon 2 of DRB3. It has 
also been demonstrated to be under positive selection (Takeshima et al. 2009). 
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For an effective vaccine an appropriate adaptive immune response and the generation of 
memory cells need to be provoked. Whilst the binding of vaccine peptides to MHC 
molecules is an important consideration, the TCR recognition of peptides as foreign is 
essential. The mechanisms by which the MHC:peptide complex interact with the TCR 
are still unknown, which would therefore limit the commercial possibilites of designing 
peptide vaccines.  
6.3 Conclusion  
In conclusion this thesis has confirmed that the BoLA genes have an important role in 
the bovine immune response, and that the DRB3 polymorphisms have significant 
associations with both the humoral and cellular responses to a variety of stimuli. In 
addition this project has investigated the associations of DRB3 alleles with response to 
commercially available viral vaccines, which have not previously been published. As a 
whole, the data presented here give an insight into the role of polymorphism in DRB3 in 
the immune response, which could be utilised to improve vaccine design or breeding for 
disease resistance. Knowledge of these genes could be further expanded and utilised not 
only in livestock but in other species.  
However, the BoLA region is very complex, with high levels of polymorphism and 
gene duplications. It would be beneficial to further research these genes and endeavour 
to fully unravel the complexities and polymorphisms to enable the design of better 
vaccines and allow for the breeding of cattle with higher resistance to infectious disease.  
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Bovine mRNA MHC gene list and RefSeq IDs   
Bovine MHC genes Bovine mRNA RefSeq ID 
BoLA-A NM_001040532 
BoLA DRB3 NM_001012680.2 
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R A or G 
Y C or T 
S G or C 
W A or T 
K G or T 
M A or C 
 IUPAC nomenclature for nucleotide bases.  
 
DRB3 allele allocations for RoBoGen animals 
 
Animal ID  Sire ID Allele 1 Allele2 
1 R11 0501 1601 
2 R21 1101 0701 
3 R21 1101 1601 
4 H26 2707 2002 
5 R02 2707 2707 
6 R11 1601 2707 
7 R05 0201 1101 
8 R21 1101 0701 
9 R11 1101 2707 
10 R05 0201 1501 
11 R19 0701 0901 
12 R01 0601 2707 
13 R11 0501 1101 
14 R21 1101 1101 
15 R21 0101 1101 
16 R11 2707 1101 
   
 243 
17 R21 0201 1101 
18 R01 0201 1101 
19 R19 0901 1601 
20 R19 0901 1601 
21 R15 2707 1002 
22 H26 2707 1101 
23 R11 0501 2703 
24 R21 0201 1101 
25 R21 0201 1001 
26 R01 0101 1101 
27 H25 1601 2707 
28 R01 0601 0201 
29 R21 0501 1101 
30 R05 0201 1601 
31 R02 0601 2707 
32 R01 0601 2707 
33 R15 1201 2707 
34 H27 2707 2707 
35 R11 1601 2707 
36 H26 0201 0101 
37 R15 2707 0701 
38 R19 1601 2703 
39 H27 0901 2707 
40 H25 1601 2707 
41 R19 0901 1101 
42 H26 0201 2707 
43 H26 1701 2707 
44 R02 0601 2707 
45 H25 1601 2707 
46 H27 0501 1101 
47 H27 0701 1101 
48 R11 0501 1101 
49 H27 1101 0701 
50 H25 0501 1101 
51 H25 1601 2707 
52 R19 0101 0901 
   
 244 
53 R19 0901 0101 
54 R11 0701 2707 
55 R02 0601 0901 
56 R01 0901 1101 
57 R01 1101 2707 
58 R02 0901 2707 
59 R02 0902 2707 
60 R02 2707 2707 
61 R02 0201 2707 
62 R01 1101 2002 
63 R02 0601 2703 
64 R19 0901 1101 
65 R19 1601 1701 
66 R19 1601 0201 
67 R11 0902 2707 
68 R02 0601 0901 
69 R15 1201 1601 
70 R01 0601 2002 
71 R21 1101 2707 
72 R15 2707 0101 
73 R01 0601 2002 
74 R02 2707 0601 
75 R02 0601 0902 
76 R19 1601 2707 
77 R02 0601 2703 
78 R15 2707 1201 
79 R11 0501 1201 
80 R02 0601 0901 
81 R05 1601 2703 
82 R02 0901 2707 
83 R11 0501 0501 
84 R02 2707 0901 
85 R02 0601 2707 
86 R02 1601 2707 
87 R05 0201 0201 
88 R05 0201 0201 
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89 R05 0201 0101 
90 R21 1101 0101 
91 R15 1201 0201 
92 R19 0901 0901 
93 R01 1101 1101 
94 R01 1101 14011 
95 R02 0601 0902 
96 R02 0902 2707 
97 R01 1101 1101 
98 R11 0501 1101 
99 R19 0901 0201 
100 H26 1601 2707 
101 R02 0601 2707 
102 H26 0201 1201 
103 R21 1001 1001 
104 R01 0601 1201 
105 H26 2707 2707 
106 H26 2707 2707 
107 R11 2707 0902 
108 R02 0601 0902 
109 R05 0201 1201 
110 H27 2707 0701 
111 R05 1601 1101 
112 R05 1601 2707 
113 R21 1001 0201 
114 R21 1001 1201 
115 H27 1101 0101 
116 R19 0901 0701 
117 R02 0601 0902 
118 R21 1001 0902 
119 R05 1601 0101 
120 R19 1601 3201 
121 R15 1201 1601 
122 H27 2707 2707 
123 R19 1601 2707 
124 R11 0501 1201 
   
 246 
125 R05 1601 1601 
126 R19 1601 1601 
127 R21 1001 1201 
128 R15 0101 0101 
129 R19 0901 1601 
130 R21 2707 1001 
131 R19 0901 0101 
132 R19 1601 1601 
133 R19 0901 0101 
134 R19 1601 0701 
135 R02 2707 2703 
136 R19 1601 1101 
137 R19 1601 2707 
138 R19 0901 0101 
139 R02 2707 1201 
140 R12 1101 1201 
141 R15 2707 2707 
142 R19 1601 0201 
143 R19 0901 1101 
144 R19 0901 0701 
145 R11 0501 2707 
146 R19 1601 2707 
147 H26 0201 1001 
148 R11 2707 0101 
149 H25 1601 2002 
150 H25 1101 2707 
151 R01 1101 2707 
152 H25 1601 2707 
153 R11 2707 2707 
154 R21 1101 0901 
155 R01 0601 2707 
156 R12 1101 1601 
157 R05 1601 1001 
158 R11 2707 0901 
159 R02 2707 0601 
160 R02 2707 0601 
   
 247 
161 R11 0501 1101 
162 R15 1201 1601 
163 R21 1101 1101 
164 R15 1201 1101 
165 R11 2707 0101 
166 R01 1101 0201 
167 H27 2707 0101 
168 R19 1601 1101 
169 H26 0201 2707 
170 R05 1601 1102 
171 R15 1201 1101 
172 R21 1101 2707 
173 R15 2707 0201 
174 R01 1101 2707 
175 R19 0901 1101 
176 R01 0601 1101 
177 R05 0201 0101 
178 R02 0101 2707 
179 R21 0701 1001 
180 R11 2707 1101 
181 R12 2707 1101 
182 R02 0601 2707 
183 H26 1101 2707 
184 R12 2707 1601 
185 R02 2707 1201 
186 R19 1601 0901 
187 R05 0201 1101 
188 R05 0201 0201 
189 R02 0601 1101 
190 R19 1601 1101 
191 R21 1001 2703 
192 H27 2707 0701 
193 R21 1001 1801 
194 R01 0601 0501 
195 R02 0601 1701 
196 H27 1101 2707 
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197 R02 2707 0101 
198 R19 1601 2002 
199 H27 2707 1601 
200 H27 2707 0701 
201 R02 0601 1501 
202 H27 1101 1801 
203 H147 2707 1101 
204 H147 2707 1101 
205 H25 1101 0902 
206 R01 1101 0101 
207 R21 1001 0501 
208 R21 1101 0101 
209 R21 1001 1801 
210 R12 1101 0101 
211 R02 2707 1201 
212 H25 1601 1601 
213 R12 1101 2703 
214 H27 2707 0101 
215 R05 0201 1501 
216 R15 2707 1601 
217 R01 0601 0701 
218 H26 0201 0101 
219 R15 1201 1601 
220 R02 1101 2707 
221 H26 1001 2707 
222 R21 0601 1101 
223 R15 2707 2707 
224 H25 1101 0201 
225 R02 2707 1101 
226 R21 2707 1101 
227 R15 1201 2707 
228 R11 1601 2707 
229 R21 1001 1101 
230 R12 2707 1102 
231 R15 1201 1101 
232 R19 0901 0101 
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233 R19 0901 1101 
234 H25 1601 2707 
235 H26 2707 1201 
236 R19 1601 0902 
237 R21 1101 0101 
238 H26 2707 2707 
239 H25 1601 0501 
240 H25 1601 2707 
241 H27 2707 2707 
242 H27 1101 1202 
243 H26 0201 0701 
244 R19 1601 2801 
245 R12 2707 0501 
246 R19 1601 1801 
247 R05 1601 1001 
248 R15 2707 0902 
249 R01 1101 0101 
250 R11 2707 0101 
251 R05 1601 0501 
252 R21 1001 1501 
253 R19 0901 3201 
254 R12 1101 1701 
255 R05 1601 0601 
256 R19 1601 1101 
257 R15 2707 1001 
258 R19 1601 2707 
259 H27 1101 0901 
260 R21 1101 0701 
261 H147 1701 1201 
262 R11 0501 0101 
263 R21 1101 0101 
264 R21 1101 0101 
265 R12 2707 1801 
266 R12 2707 0902 
267 R11 0501 1101 
268 R15 2707 0101 
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269 R01 1101 1001 
270 R19 0901 1101 
271 H26 2707 0701 
272 R19 0901 0201 
273 R11 2707 2707 
274 R15 2707 0701 
275 R19 0901 0101 
276 R15 2707 1501 
277 H26 2707 2707 
278 H147 2707 0201 
279 R02 2707 0101 
280 R12 2707 0601 
281 R05 1601 0101 
282 R19 1601 2707 
283 R19 0901 1001 
284 R19 0901 2707 
285 R19 0901 1701 
286 R19 1601 1101 
287 R19 0901 0101 
288 R01 1101 0201 
289 R19 0901 0901 
290 R19 1601 2707 
291 R01 0601 0101 
292 R19 0901 0101 
293 R19 0901 0101 
294 R21 1001 1601 
295 R21 1101 1601 
296 H27 2707 0501 
297 R21 1101 1101 
298 R21 1101 0701 
299 R21 1001 1101 
300 R11 2707 1101 
301 R11 1601 0501 
302 R05 0201 1001 
303 R05 0201 1001 
304 R12 2707 2703 
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305 R02 2707 2002 
306 R05 0201 1101 
307 R05 0201 1501 
308 R05 1601 1201 
309 RO5 1601 1201 
310 RO5 1001 1601 
311 R21 1001 0201 
312 H25 1601 2707 
313 R12 1101 0101 
314 R02 2707 2707 
315 R02 0601 0601 
316  R15 2707 0101 
317 R02 2707 1101 
318 R21 1101 1801 
319 R01 1101 0201 
320 R02 2707 2707 
321 H26 0201 2707 
322 CH 108 2707 2707 
323 R21 1101 1101 
324 R05 1601 1601 
325 R21 1001 1101 
326 R21 1101 0801 
327 R15 2707 2707 
328 R01 0601 14011 
329 R02 2707 0902 
330 R21 1001 2707 
331 R19 1601 3201 
332 H147 1707 0101 
333 R01 1101 0201 
334 H25 1601 1001 
335 R19 1601 0101 
336 H147 2707 1101 
337 R05 1601 1601 
338 H25 1101 1201 
339 R21 1001 1001 
340 H25 1601 2707 
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341 R15 1201 1001 
342 R01 0601 0601 
343 H147 2707 0601 
344 R01 1101 1001 
345 R01 1101 1201 
346 R11 2707 1101 
347 R15 1201 1101 
348 R15 1201 1101 
349 R19 1601 1701 
350 R05 0201 0501 
351 H27 2707 0101 
352 R12 1101 0902 
353 R19 1601 2707 
354 R19 0901 0101 
355 R19 0901 0101 
356 R21 1001 1201 
357 R19 0901 1101 
358 R12 2707 1201 
359 R02 0601 1601 
360 R01 0601 0601 
361 R15 1201 1101 
362 R15 1201 1101 
363 H147 1701 2707 
364 R19 1601 0101 
365 R15 2707 1101 
366 R11 0501 1201 
367 R19 0101 1601 
368 R12 1101 1201 
369 H26 2707 2707 
370 R19 1601 0101 
371 R12 0201 1101 
372 R19 0901 1101 
373 R19 1601 2002 
374 R15 1201 1101 
375 R19 1601 1601 
376 R02 0601 0601 
   
 253 
377 R19 1601 0201 
378 R11 0501 1101 
379 R19 0901 0101 
380 R19 1601 0101 
381 R19 0901 0101 
382 R01 1101 1501 
383 R15 1201 1101 
384 R19 0901 0601 
385 R15 2707 1101 
386 R11 2707 1101 
387 R11 0501 0101 
388 R15 2707 1601 
389 R02 2707 2002 
390 R15 1201 0201 
391 R15 2707 0601 
392 R05 0201 1101 
393 R21 0501 1101 
394 R11 0501 1101 
395 R15 1201 0902 
396 R15 2707 1601 
397 R19 1601 0201 
398 R15 2707 1101 
399 R11 0501 0601 
400 R15 1201 1201 
401 R19 1601 2707 
402 R15 2707 0902 
403 R19 0901 2707 
404 R19 0901 1101 
405 R19 1601 1101 
406 R19 0901 1201 
407 R19 1601 1701 
408 R19 0901 0101 
409 R19 1601 1201 
 
   
 254 
Appendix B.2  
Hyperladder I. 
 
Hyperladder I (Bioline, UK) used as molecular weight ladder in all agarose gel 
electrophoresis images. 




Appendix C.1  
Trapezoid rule  
 
Allows estimate of area under a line. The formula is used in geometry to calculate the 
area of a trapezoid, height (h), base length (b1) and base length (b2). By subdividing the 
area under a line the total area can be calculated. 
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Appendix C.2 
Cell proliferation assay for response to FMDV15 and ConA 
(Chapter 3) 
 
Whole blood in heparin (150 µl) was diluted with 750 µl RPMI 1640 (Sigma, UK) 
supplemented with 25 mM HEPES, 2 mM glutamine (Invitrogen, UK), 10% foetal calf 
serum (Perbio, EU origin), 5 x 10-5 M 2-mercaptoethanol (Invitrogen).  For each animal, 
seven cultures were prepared: a medium only negative control, three final 
concentrations of concanavalin A (ConA) (0.25, 2.5 and 10 µg/ml (Sigma, UK) as 
positive controls and three final concentrations of FMDV15 peptide (0.1, 1 and 2.0 
µg/ml).  Quadruplicate cultures in 96-well tissue culture grade flat plates (Nunc, UK) 
were incubated at 37oC with 5% CO2 for 6 days.  For the last 6 hours the cells were 
labelled with 0.037 MBq 3H-Thymidine per well (GE Healthcare, UK) and uptake 
assessed by liquid scintillation counting using a 1450 Microbeta (Wallac, now 
PerkinElmer). Results were expressed as counts per minute (cpm) of 3H-Thymidine 
incorporation (mean of quadruplicates).  
 
IFN-γ assay for response to FMDV15 and ConA (Chapter 3) 
 
1ml of whole heparinised blood was diluted with 1ml RPMI supplemented as described 
above for the cell proliferation assay, and was added to each well of a 24-well plate 
(Nunc, UK).  Each animal had three samples: medium alone as the negative control, 2.5 
ug/ml ConA as the positive control, and 1ug/ml FMDV15 (both final concentrations).  
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Samples were incubated for 24 hours at 37oC and 5% CO2. After incubation, samples 
were mixed with a pipette and transferred to a centrifuge tube. Tubes were spun at 750 g 
for 10 minutes and supernatants harvested and frozen at -20oC until use in the EASIA.   
All assay tests were done in duplicate. The EASIA kit is a 2 step enzyme immunometric 
assay designed to measure bovine IFN-γ, and consists of a capture monoclonal antibody 
to bovine IFN-γ fixed to the well, and an anti-bovine IFN-γ horse radish peroxidise 
(HRP) conjugate.  Firstly, 100 µl of the ovine rIFN-γ standards (4000, 3000, 2000, 
1000, 500, 100 pg/ml diluted in RPMI supplemented as described above), control and 
test samples were added to 96-well strips together with 50µl of “Incubation Buffer” 
(Biosource kit) and incubated at room temperature for 60 minutes on a shaker, before 
being washed 3 times with 400 µl of “Working Washing Solution”. 100 µl of 
appropriately diluted conjugate was added to each well, and again incubated at room 
temperature for 60 minutes, on a shaker. The plates were washed 3 further times and 
then 100 µl of TMB was added to each well and all samples were incubated at room 
temperature for 15 minutes on a shaker. Finally 200 µl of “Stop Solution” was added 
and the optical density of each well was read at 450 nm on a Victor2 1420 Multilabel 
counter (Wallac).  Optical density (OD) values were converted into concentrations using 
a standard curve derived from dilutions of ovine IFN-γ using a simple linear regression 
(Genstat, 9.0v, VSN International) and the results were expressed in pg/ml. The intra- 
and inter-plate replicates were high with r2 values of at least 0.80.
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FMDV IgG1 DRB3 alleles and pockets  
All results from REML model analysis for IgG1 response to FMDV15.  
IgG1 DRB3 alleles 
WEEK 0101 0201 0501 0601 0701 0901 0902 1001 1101 1201 1501 1601 1701 1801 2002 2703 2707 3201 
2 n.s. n.s. n.s. n.s. n.s. 0.031 n.s. 0.063 n.s. n.s. n.s. 0.035 n.s. n.s. n.s. n.s. <0.001 n.s. 
4 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.004 n.s. n.s. n.s. n.s. n.s. n.s. 
8 n.s. n.s. n.s. n.s. n.s. 0.015 0.012 0.031 n.s. n.s. n.s. 0.023 n.s. n.s. n.s. n.s. 0.041 n.s. 
10 n.s. n.s. n.s. n.s. 0.036 n.s. n.s. 0.038 n.s. n.s. n.s. 0.007 n.s. n.s. n.s. n.s. n.s. n.s. 
AUC n.s. n.s. n.s. n.s. 0.034 <0.001 n.s. 0.02 n.s. n.s. n.s. 0.023 n.s. n.s. n.s. n.s. 0.032 n.s. 
p values from REML analysis of  DRB3 alleles and IgG1 response to FMDV15 









2 n.s. 0.020 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.048 0.042 n.s. n.s. n.s. 
4 n.s. n.s. n.s n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
8 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.022 n.s. n.s. n.s. n.s. 
10 0.011 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.017 n.s. n.s. n.s. n.s 
p values from REML analysis of binding pockets and IgG1 response to FMDV15 
 
 




Weeks IgG1 13 70 71 74 
2 n.s. <0.001 n.s. n.s. 
4 n.s. n.s. n.s. n.s. 
8 n.s. n.s. n.s. 0.024 
10 n.s. n.s. n.s. n.s. 
AUC n.s. n.s. n.s. n.s. 
position 13 position 70 position 71 position 74 
Weeks IgG1 G S K R E R Q K R A E A E N 
2 n.s. n.s. n.s. 0.029 <0.001 <0.001 n.s. n.s. 0.022 n.s. n.s. n.s. 0.050 0.003 
4 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.030 
8 n.s. n.s. n.s. n.s. 0.027 n.s. n.s. n.s. 0.092 n.s. n.s. n.s. n.s. 0.012 
10 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.094 
AUC n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.001 
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Appendix C.3  
FMDV IgG2 DRB3 alleles and pockets 
All results from REML model analysis for IgG2 response to FMDV15. 
IgG2 DRB3 alleles 
WEEK 0101 0201 0501 0601 0701 0901 0902 1001 1101 1201 1501 1601 1701 1801 2002 2703 2707 3201 
2 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.013 n.s. n.s. n.s. <0.001 n.s. n.s. n.s. n.s. 0.001 n.s. 
4 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. <0.001 n.s. n.s. n.s. n.s. n.s. n.s. 
8 0.002 n.s. n.s. n.s. 0.026 n.s. n.s. 0.005 n.s. n.s. n.s. <0.001 n.s. n.s. n.s. n.s. n.s. n.s. 
10 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.012 n.s. n.s. n.s. 0.003 n.s. n.s. n.s. n.s. n.s. n.s. 
AUC n.s. n.s. n.s. n.s. 0.058 0.01 n.s. 0.047 n.s. n.s. n.s. 0.005 n.s. n.s. n.s. n.s. 0.031 n.s. 
: p values from the REML analysis of DRB3 alleles with IgG2 response to FMDV15 





6 28 30 47 61 67 71 9 37 57 60 61 
Pocket 10 
pos 56 
2 n.s. <0.001 n.s. 0.029 n.s. 0.022 n.s. n.s. 0.056 <0.001 <0.001 0.020 0.022 0.001 
4 0.046 n.s. 0.036 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.036 n.s. n.s. 0.018 
8 0.031 n.s. n.s. n.s. n.s. 0.009 n.s. 0.043 n.s. n.s. <0.001 0.083 0.011 <0.001 
10 n.s. n.s. n.s. n.s. n.s. 0.041 n.s. n.s. n.s. n.s. 0.006 n.s. 0.040 0.003 
 p values for the REML analysis of binding pockets with  IgG2 response to FMDV15 
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Pocket 4 
Weeks IgG1 13 70 71 74 
2 n.s. <0.001 n.s. 0.021 
4 0.016 0.020 n.s. n.s. 
8 0.037 0.004 0.043 n.s. 
10 n.s. n.s. n.s. n.s. 
AUC n.s. 0.004 n.s. n.s. 
position 13 position 70 position 71 position 74   
Weeks IgG1 G S K R E R Q K R A E A E N 
2 n.s. n.s. 0.031 n.s. <0.001 <0.001 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.011 
4 n.s. n.s. 0.021 n.s. 0.003 0.006 n.s. 0.024 n.s. n.s. n.s. n.s. n.s. n.s. 
8 n.s. n.s. 0.016 n.s. <0.001 <0.001 n.s. 0.004 n.s. 0.044 n.s. n.s. n.s. n.s. 
10 n.s. n.s. 0.016 n.s. 0.024 0.036 n.s. 0.046 n.s. n.s. n.s. n.s. n.s. n.s. 
AUC n.s. n.s. n.s. n.s. <0.001 0.001 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.03 
p values from the REML analysis of binding pocket 4 and response IgG2 to FMDV15





FMDV T Cell Proliferation DRB3 alleles and pockets  
All results from REML model analysis for T cell proliferation response to FMDV15. 
T Cell 
FMDV15 DRB3 alleles 
WEEK 0101 0201 0501 0601 0701 0901 0902 1001 1101 1201 1501 1601 1701 1801 2002 2703 2707 3201 
0 n.s. n.s. <0.001 n.s. n.s. n.s. n.s. n.s. 0.051 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
4 0.014 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
8 n.s. n.s. n.s. n.s. n.s. n.s. 0.027 <0.001 n.s. n.s. n.s. n.s. n.s. n.s. <0.001 n.s. n.s. n.s. 
10 n.s. n.s. n.s. n.s. n.s. n.s. 0.007 0.004 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
p values from REML analysis of  DRB3 alleles and T cell proliferation in response to FMDV15 
pocket 7 pocket 9 
Week 
FMDV15 pocket 1 pocket 6 28 30 47 61 67 71 9 37 57 60 61 
Pocket 10 
pos 56 
0 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.006 n.s. n.s. n.s. n.s. n.s. 
4 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.051 n.s. n.s. n.s. n.s. n.s. 
8 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
10 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
: p values from REML analysis of DRB3 pockets and T cell proliferation in response to FMDV15 




ConA T Cell Proliferation DRB3 alleles and pockets  
All results from REML model analysis for T cell proliferation response to ConA. 
T Cell 
ConA DRB3 alleles 
WEEK 0101 0201 0501 0601 0701 0901 0902 1001 1101 1201 1501 1601 1701 1801 2002 2703 2707 3201 
0 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.088 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
4 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.029 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
8 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.004 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
10 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.006 n.s. n.s. 0.027 n.s. n.s. n.s. n.s. n.s. 
p values from REML analysis of DRB3 alleles and T cell proliferation in response to ConA 
pocket 7 pocket 9 
ConA 
Week  pocket 1 pocket 6 28 30 47 61 67 71 9 37 57 60 61 pocket 10 
2 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
4 n.s. n.s. 0.020 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
8 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
10 n.s. n.s. 0.040 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
 p values from REML analysis of  DRB3 pockets and T cell proliferation in response to ConA 
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Appendix C.6 
FMDV15 IFN-γ DRB3 alleles 
All results from GLIMM model analysis for IFN-γ production response to FMDV15 and ConA 
IFN-γ 
 FMDV15 DRB3 alleles 
WEEK 0101 0201 0501 0601 0701 0901 0902 1001 1101 1201 1501 1601 1701 1801 2002 2703 2707 3201 
0 n.s. n.s. n.s. n.s. 0.049 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.038 n.s. n.s. 
4 0.013 n.s. n.s. n.s. n.s. n.s. n.s. n.s. <0.001 0.013 n.s. 0.005 n.s. n.s. n.s. n.s. n.s. n.s. 
8 n.s. n.s. n.s. n.s. n.s. n.s. 0.003 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
10 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.034 0.003 n.s. n.s. n.s. n.s. n.s. n.s. 0.014 n.s. 
 p values from GLIMM analysis of DRB3 alleles IFN-γ levels in response to FMDV15 
IFN-γ  
ConA DRB3 alleles 
WEEK 0101 0201 0501 0601 0701 0901 0902 1001 1101 1201 1501 1601 1701 1801 2002 2703 2707 3201 
0 n.s. n.s. n.s. n.s. n.s. 0.053 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.006 n.s. n.s. 
4 <0.001 0.026 <0.001 n.s. n.s. n.s. n.s. n.s. n.s. n.s. 0.015 n.s. n.s. n.s. n.s. n.s. <0.001 n.s. 
8 n.s. n.s. n.s. n.s. n.s. n.s. 0.027 n.s. n.s. 0.016 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
10 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
p values from GLIMM analysis of DRB3 alleles IFN-γ levels in response to ConA 
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Appendix C.7  



















Probes for DQA Microarray  
 
Oligonucleotide 
probe  Sequence base pairs 
DQA-A01R2 ATTCTGCGCCGTAGGTG 17 
DQA-A04R2 GATGCTTATGCCATAGGTG 19 
DQA-A05R3 GAAGTCTGTGCCATAAGT 18 
DQA-A06R3 GAAGTCTGCGCCATAAG 17 
DQA-A13R2 AGATGTTTATGCCATAGGCA 20 
DQA-A14R3 CGTTTATGCCATAGGCA 17 
DQA-A16R ATCACTGTGCCATAGGAG 18 
DQA-B09R TTCCTGGGTGTACTGGTCA 19 
DQA-C01R2 AGGTCCACATAAAACATCTC 20 
DQA-C02R3 AGATCCACATAAAACATCTC 20 
DQA-C03R3 AGGTCCACATAAAACAGCT 19 
DQA-C05R3 TCCACATAAAACAACTCGT 19 
DQA-C07R3 TTCTAGGTCCACGTAGAA 18 
DQA-C08R3 TTCCAGGTCCACGTAGAA 18 
DQA-C10R2 TCCACATAAAACAACTCATC 20 
DQA-C11R2 TCCACATAAAGCAACTCGT 19 
DQA-C12R GTCCACATAAAACAGCTTGT 20 
DQA-D11R GCCGCCAGACAGTCTCTTT 19 
DQA-E01L GCATGTGTTTAGTAAATTTGCAAGTT 26 
DQA-E02L CCCCTATTTAGCAGAATGTTAAGTT 25 
DQA-E06L TATGTTTAGCCAGTTTGCAGGTTTT 25 
DQA-E08L GCCTATGTTTGATAAATTAAGACGTTTT 28 
DQA-E09L CCTATGTTTGATAAATTACGTTTCCA 26 
DQA-E10L2 GCCTATGTTTGATAAATTACGTTTTCA 27 
DQA-E11L CTATGTTTGGTGAATTAACAAGTTTTG 27 
DQA-E12L2 CTATGTTTGGTGAATTAACAGGTTTTGA 28 
DQA-E13L TATGTTTGGTGATTTAACAAGTTTTGA 27 
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DQA-E14L CTATTTTTAGCCAGTTTGCAGGTT 24 
DQA-E15L2 GCCTCTGTTTAGTAAATTTAGACGTT 26 
DQA-E16L2 GCCTGTGTTTAGTAAATTTACAAGTTTTG 29 
DQA-E17L2 CCTGTGTTTAGTAAATTTGCAACTTTTG 28 
DQA-E18L2 CTGTGTTTAGTAAATTTGCAAGTTTT 26 
DQA-E20 CCTATGTTTAGCCAGTTTGCAAG 23 
DQA-F01L AGCACAAGATGCGCTGAATGAAA 23 
DQA-F02L AGCACAAGATGCGCTGATGAAA 22 
DQA-F08L2 CCGCAAGGTGCACTGAGAAAC 21 
DQA-F14 CACAGGCTATACTGAGGAACA 21 
DQA-G03S2 AGCAAAACACAACTTGGAT 19 
DQA-G04S2 CGAAGCACAATTTGGAGA 18 
DQA-G06S2 GTGAAGCACAATTTGGAGA 19 
DQA-G07S2 TGAAGCACAATTTGGAGG 18 
DQA-G08S2 CATCAAAACACAACTTGGAT 20 
DQA-G09S2 CATCAAAACACAATTTGGATAT 22 
DQA-G11S2 ACGATGAAGCACAATTTGG 19 
DQA-G15S2 TATAGTGAAGCACAATTTGG 20 
DQA-G20 TTCATCAAAACACAACTTGGAT 22 
DQA-G21 CAGCAAAATTCAACTTGGATC 21 
DQA-G22 CTATATCAAAACACAACTTGAATA 24 
DQA-H04S2 GATCATGATTCGAAGGTC 18 
DQA-H05S2 ATCGTGATTCAAAGGTCC 18 
DQA-H07S2 GATCTTGATTCAAAGGTCC 19 
DQA-H09S GGTCATGATTCGAAGGTC 18 
DQA-H10S2 GGTCTTGATTCAAAGGTC 18 
DQA-H13S2 TCCTGACTAAACGCTACA 18 
DQA-H14S CCTGACTAAACGCTCCAA 18 
DQA-H17S CCTGACTAAACGCTCTAA 18 
DQA-H18 GATATCGTGATTCAAAGGTC 20 
DQA-H19 GAATATCATGATTAAATACTCCAA 24 
DQA Standards  
DQA-S01R CCAATGTGGTCAGCTGAGTC 20 
DQA-S04 CCCTGTTATCAATGGTAAGTGTC 23 
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Appendix D.2 
DQA Microarray probe layout 
 
S3R(1) B10L2 B14L B19 B25L2 B30 B36 S2R(1) 
B5 B10 B14 B18N B24L2 B29L B35 B41 
B4L2 B9 B13 B18L B24L B28 B34 B42 
B4 B8L B12L B18 B23 B27 B33L B40 
B3 B8L2 B12 B17L B22L B26L2 B32L B39 
B2L B7 B11N B16L B20L B26L B31L B38 
B1L2 B5L B11 B15L B19L B25L3 B30L B37 
A3S2 A6N2 A9L A15 A20 A25 A30 B1 
A2S A6N A9 A14S2 A19L3 A23L2 A29 A34 
A2 A5 A8S2 A13 A19L2 A23 A28 A33 
A1S2 A4L2 A8 A12L A18L2 A22 A27L A32 
A1 A4L A7L A11 A17S A21S2 A27 A31 
S2R(2) A3S A7 A10 A17 A21 A26S2 S3R(2) 
 
   
 269 
 
Appendix D.3  
DQA allele definition for microarray probes 
 
DQA Allele DQA-A DQA-B DQA-C DQA-D DQA-E DQA-F DQA-G DQA-H 
DQA1*0101  A09R  B07R C08R3 D03R E16L2 F11 G05S H10S2 
DQA1*0102  A09R  B07R C08R3 D03R E16L2 F11 G06S2 H07S2 
DQA1*0103  A14R3 B07R C08R3 D03R E16L2 F11 G10S H04S2 
DQA1*0201  A08R2 B07R C08R3 D02R2 E15L2 F11 G06S2 H05S2 
DQA1*0202  A09R  B08R2 C08R3 D02R2 E15L2 F11 G06S2 H05S2 
DQA1*0203  A09R  B07R C08R3 D02R2 E15L2 F11 G06S2 H05S2 
DQA1*0204  A13R2 B07R C08R3 D02R2 E15L2 F11 G04S2 H05S2 
DQA1*0301  A09R  B07R C08R3 D02R2 E15L2 F11 G10S H02 
DQA1*0302  A09R  B07R C08R3 D02R2 E15L2 F12 G10S H03 
DQA1*0401  A09R  B07R C08R3 D02R2 E15L2 F11 G05S H10S2 
DQA1*0801  A09R  B07R C06R2 D03R E18L2 F11 G04S2 H08 
DQA1*0802  A09R  B07R C06R2 D03R E01L F11 G04S2 H08 
DQA1*10011  A04R2 B07R C07R3 D03R E16L2 F11 G15S2 H05S2 
DQA1*10012  A04R2 B07R C08R3 D03R E16L2 F11 G15S2 H05S2 
DQA1*1002  A14R3 B07R C08R3 D03R E16L2 F11 G15S2 H18 
DQA1*1101  A09R  B07R C08R3 D03R E17L2 F11 G11S2 H05S2 
DQA1*12011  A04R2 B07R C08R3 D03R E17L2 F11 G09S2 H05S2 
DQA1*12012  A04R2 B07R C08R3 D03R E17L2 F11 G10S H05S2 
DQA1*12021 A04R2 B07R C08R3 D03R E17L2 F11 G11S2 H05S2 
DQA1*12022  A04R2 B07R C08R3 D03R E17L2 F11 G11S2 H05S2 
DQA1*1203  A04R2 B07R C08R3 D03R E17L2 F11 G12 H10S2 
DQA1*1204  A04R2 B07R C08R3 D03R E17L2 F11 G10S H05S2 
DQA1*1301  A09R  B07R C06R2 D01R2 E17L2 F11 G18 H09 
DQA1*1302  A09R  B07R C06R2 D01R3 E17L2 F11 G18 H09 
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DQA1*1401 A09R  B07R C08R3 D03R E18L2 F11 G19 H09 
DQA2*2001 A11R B02R C01R2 D08R2 E04 F03 G08S2 H14S 
DQA2*2002  A11R B02R C01R2 D08R2 E03S F04 G08S2 H14S 
DQA2*2101  A11R B02R C01R2 D08R2 E14L F07L G08S2 H14S 
DQA2*2201  A11R B02R C01R2 D08R2 E06L F04 G08S2 H14S 
DQA2*22021  A11R B02R C01R2 D08R2 E06L F04 G03S2 H14S 
DQA2*22022  A11R B02R C01R2 D06R2 E05L F04 G03S2 H14S 
DQA2*22023  A11R B02R C01R2 D07R E05L F04 G03S2 H14S 
DQA2*22031  A11R B02R C03R3 D07R E05L F04 G03S2 H14S 
DQA2*22032  A11R B02R C03R3 D08R2 E06L F04 G03S2 H14S 
DQA2*2204  A11R B02R C01R2 D08R2 E19 F04 G03S2 H14S 
DQA2*2205  A10R2 B02R C01R2 D08R2 E07S F04 G08S2 H14S 
DQA2*2206  A11R B02R C01R2 D08R2 E06L F07L G21 H14S 
DQA2*2401  A11R B01R2 C03R3 D08R2 E13L F05 G09S2 H11S 
DQA2* (wsu-2-3) A16R B09R C12R D11R E20 F14 G22 H19 
DQA3*2301  A12R B06R C02R3 D08R2 E12L2 F10 G02S H12S 
DQA3*25011  A05R3 B04R2 C04R D05R2 E09L F08L2 G14S H16S 
DQA3*25012  A05R3 B04R2 C04R D05R2 E10L2 F08L2 G14S H15 
DQA3*2502  A06R3 B04R2 C04R D05R2 E10L2 F08L2 G13S H13S2 
DQA3*2601  A05R3 B04R2 C04R D05R2 E08L F09 G17S H13S2 
DQA3*2602  A05R3 B04R2 C04R D05R2 E08L F08L2 G17S H13S2 
DQA3*2603  A05R3 B04R2 C04R D05R2 E08L F08L2 G14S H13S2 
DQA3*27011 A03R B06R C10R2 D09R2 E11L F01L G01S H14S 
DQA3*27012  A02R2 B05R2 C05R3 D09R2 E11L F01L G01S H14S 
DQA3*2702  A01R2 B05R2 C10R2 D09R2 E11L F02L G01S H14S 
DQA3*2901  A15R B06R C11R2 D10R E12L2 F13 G20 H17S 
DQA4*2801 A07R2 B03R2 C09R D04R2 E02L F06 G16S H01S 
New(Y10564)-0102 A09R  B07R C08R3 D03R E16L2 F11 G07S2 H10S2 
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Appendix D.4 
Probes for BoLA-Class 1Exon 2 Microarray 
 
Oligonucleotides 
probe Sequence base pairs Tm oC 
Exon 2, Series A, Codons 62-67  
BoLA-C1Ex2A01   CGGGAGACGCAAAGGGCC 18 57 
BoLA-C1Ex2A01S2   CGGGAGACGCAAAGGGC 17 54 
BoLA-C1Ex2A02   CAGGAGACGCGAAAGGCC 18 55 
BoLA-C1Ex2A02S     GGAGACGCGAAAGGCC 16 51 
BoLA-C1Ex2A03S2   CGGAACACGCGAAACGC 17 52 
BoLA-C1Ex2A03S   CGGAACACGCGAAACG 16 49 
BoLA-C1Ex2A04L ATCGAAACACGAGAATCTACAA 22 49 
BoLA-C1Ex2A04L2 TCGAAACACGAGAATCTACA     
BoLA-C1Ex2A05   GAGCAGACGCGAATAGTC 18 50 
BoLA-C1Ex2A06   CGCGAGACGCGAAACTCC 18 55 
BoLA-C1Ex2A06N GACGCGAAACTCCAAGGAA     
BoLA-C1Ex2A07   CGCGAGACTCAAATCTCC 18 50 
BoLA-C1Ex2A07L   CGCGAGACTCAAATCTCCA 19 51 
BoLA-C1Ex2A8   CGCGAGACGCGAATCTCC 18 55 
BoLA-C1Ex2A08S2   CGCGAGACGCGAATCTC 17 52 
BoLA-C1Ex2A09   CAGAACACGCGAAACTCC 18 50 
BoLA-C1Ex2A10   GAGGAGACGTGGAGAGCC 18 55 
BoLA-C1Ex2A11   CAGGAGACGCAGAGAACT 18 50 
BoLA-C1Ex2A12L  TCAAGAGACGCGGATACAAA 20 50 
BoLA-C1Ex2A13   CAGGCGACGCAGAGAACT 18 53 
BoLA-C1Ex2A13S AGGCGACGCAGAGAACT     
BoLA-C1Ex2A14   CAGGAGACGCGAAACGCC 18 55 
BoLA-C1Ex2A14S     GGAGACGCGAAACGCC 16 51 
BoLA-C1Ex2A15   GAGATGACACGAGATGCC 18 50 
BoLA-C1Ex2A17   GACGAGACGCGAATCTCC 18 53 
BoLA-C1Ex2A17S   GACGAGACGCGAATCTC 17 49 
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BoLA-C1Ex2A18L2 CGCGAAACTTCAAGGACACCG 21 56 
BoLA-C1Ex2A19L2  GCGAAACTTAAAGGGCGCCG 20 56 
BoLA-C1Ex2A19L3 CGCGAAACTTAAAGGGCGCCG 21 58 
BoLA-C1Ex2A20   GCGATGACAAGAGATGCC 18 50 
BoLA-C1Ex2A21   CAGAACACGCGAAACGCC 18 53 
BoLA-C1Ex2A21S   CAGAACACGCGAAACGC 17 49 
BoLA-C1Ex2A22   CAGGAGACGCAGAGGACT 18 53 
BoLA-C1Ex2A23   CAGGAGACGCAGATAACT 18 48 
BoLA-C1Ex2A23L2  ATCAGGAGACGCAGATAACT 20 50 
BoLA-C1Ex2A25   GAGGAAACGCAAAGGGCC 18 53 
BoLA-C1Ex2A26S GAGGAGACGCAAAGGG 16 49 
BoLA-C1Ex226S2   GAGGAGACGCAAAGGGC 17 52 
BoLA-C1Ex2A27 TCGAAACACGAGGATCTACA 20 50 
Exon2, Series B, Codons 72-77 
BoLA-C1Ex2B01 CAGATTTTCCGAGTGAGC 18 48 
BoLA-C1Ex2B01L CAGATTTTCCGAGTGAGCC 19 51 
BoLA-C1Ex2B02L2 CAATTTTTCCGAGTGAGCC 19 49 
BoLA-C1Ex2B02L CAATTTTTCCGAGTGAGCCT 20 50 
BoLA-C1Ex2B03 CAGACTTTCCGGGCGAAC 18 53 
BoLA-C1Ex2B04 CAGAGTTTCCGAGTGAAC 18 48 
BoLA-C1Ex2B04L2 CAGAGTTTCCGAGTGAACC 19 51 
BoLA-C1Ex2B05 CAGACTTTCCGAGTGGAC 18 50 
BoLA-C1Ex2B07 CAGACTTTCCGAGCGAAC 18 50 
BoLA-C1Ex2B08 CAGACTTTCCGAGTGTAC 18 48 
BoLA-C1Ex2B08L2 ACAGACTTTCCGAGTGTAC 19 49 
BoLA-C1Ex2B09 CAGATTTTCCGGGCGAAC 18 50 
BoLA-C1Ex2B10 CAGATTTTCCGAGTGGAC 18 48 
BoLA-C1Ex2B10L2 ACAGATTTTCCGAGTGGAC 19 49 
BoLA-C1Ex2B11 CAGTCTTTCCGAGTGGGC 18 53 
BoLA-C1Ex2B11N ACAGTCTTTCCGAGTGGG     
BoLA-C1Ex2B12 CTGTGGTACCGAGAGGCC 18 55 
BoLA-C1Ex2B13 CTGGTGTATCGAGGGAGC 18 53 
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BoLA-C1Ex2B14 CTGGTGTATCGAGAGAGC 18 50 
BoLA-C1Ex2B14L ACTGGTGTATCGAGAGAGC 19 51 
BoLA-C1Ex2B15L CTGGTATATCGAGAGAGCC 19 51 
BoLA-C1Ex2B16 CAATTTTTCCGACGGGGC 18 50 
BoLA-C1Ex2B16L CAATTTTTCCGACGGGGCC 19 53 
BoLA-C1Ex2B17L ACAATTTTTCCGAGTGTACCT 21 49 
BoLA-C1Ex2B18 CAGAATTTCCGAGTGGGC 18 50 
BoLA-C1Ex2B18N GAATTTCCGAGTGGGCC     
BoLA-C1Ex2B19 CAGACTTTCCGAGCAAAC 18 48 
BoLA-C1Ex2B19L ACAGACTTTCCGAGCAAAC 19 49 
BoLA-C1Ex2B20 AGAGTTTCCGAGTGGGC 17 49 
BoLA-C1Ex2B22L CTGCTGTATCGAGAGAACC 19 51 
BoLA-C1Ex2B23 CTGAAGTACCGAGAGGCC 18 53 
BoLA-C1Ex2B24L CAGAAATCCCGATTATGCTTG 21 50 
BoLA-C1Ex2B24L2 AGAAATCCCGATTATGCTTGT     
BoLA-C1Ex2B25L2 CAGGAATCCCGATTATGCT 19 49 
BoLA-C1Ex2B25L3 AGGAATCCCGATTATGCTTG     
BoLA-C1Ex2B26L CTGCTGTATCGAAAGAACC 19 49 
BoLA-C1Ex2B26L2 CTGCTGTATCGAAAGAACCT 20 50 
BoLA-C1Ex2B27 CAGAGATTGCGAACGGGC 18 53 
BoLA-C1Ex2B28 CAGACTTTCCGAGTGAAC 18 48 
BoLA-C1Ex2B29L CAGAGATCCCAATTATGCTTG 21 50 
BoLA-C1Ex2B30 CAGTCTTTCCGAGTGAAC 18 48 
BoLA-C1Ex2B30L CAGTCTTTCCGAGTGAACC 19 51 
BoLA-C1Ex2B31L CAGTTTCCGAGTGAACCTGA 20 52 
BoLA-C1Ex2B31L2 CAGTTTCCGAGTGAACCTG     
BoLA-C1Ex2B32L CAGGTTTTCCAAGTGAACCT 20 50 
BoLA-C1Ex2B33L CAGGTTTTCCGAGTGAACC 19 51 
 Class I Exon 2 Standards 
BoLA-C1Ex2S01R CGTCGCTGTCGAACCG 16 51 
BoLA-C1Ex2S02R GGCGTCGCTGTCGAACCG 18 57 
 
   
 274 
Appendix D.5 
Class I exon 2 Microarray probe layout 
 
S4(1) B16 B20 B25 B30 B35 B42 S3R(1) 
B11L B15 B19L2 B24 B29S2 B34L B41 C01 
B10 B14 B19L B23S B29S B33L2 B40S B47 
B9 B13S B18L B23 B28 B33L B39S 
 
B46 
B8 B13 B18 B22S B27 B32L B39 B45 
B7 
 
B12S B17L B21 B26L B31L B38L3 B44 
B6L B12 B16S B20L B25L B30L B38L2 B43 
A5R A9R A13R A18R A22R A26R A31R B6 
A4R2 A8R A12R2 A17R2 A21R A25R A30R B1 
A3R A7R2 A12R A17R A20R A24R A29R A34R 
A2R A7R A11R A16R A19R2 A23R2 A28R A33R 
A1R2 A6R2 A10R A15R A19R A23R A27R2 A32R 
S3R(2) A6R A9R2 A14R2 A18R2 A22R2 A27R S4(2) 
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Appendix D.6 
Probes for BoLA-Class 1Exon 3 Microarray 
 
Oligonucleotide 
Probe Sequence base pairs Tm 
Exon 3 Series A Oligos Codons 110-116 (18 bp) 
BoLA-C1Ex3A01R GGCGTCCTGCCTGTATCC 18 55 
BoLA-C1Ex3A02R GCCGAACTGCTCATAGCC 18 53 
BoLA-C1Ex3A03R GGCGTTCTGCCAGATCCC 18 55 
BoLA-C1Ex3A04R GGCGTCCTGCCTGTACC 17 54 
BoLA-C1Ex3A05R AGCGTCCTGCCTGTACCC 18 55 
BoLA-C1Ex3A05R2 AGCGTCCTGCCTGTACC 17 52 
BoLA-C1Ex3A06R GGCGTACTGCCTGTACCC 18 55 
BoLA-C1Ex3A07R GGCGTCCTGACTGTACCC 18 55 
BoLA-C1Ex3A07R2 GGCGTCCTGACTGTACC 17 52 
BoLA-C1Ex3A08R GGCGAACTGATCGTACCC 18 53 
BoLA-C1Ex3A08R GGCGAACTGATCGTACCC 17 53 
BoLA-C1Ex3A09R GGCGAGCTGATTATACCCG 19 53 
BoLA-C1Ex3A10R GGCGTCCTGATTATACCCG 19 53 
BoLA-C1Ex3A11R GCCGAACTGCGTATACCC 18 53 
BoLA-C1Ex3A12R GGCGTCCTGCTCATACCC 18 55 
BoLA-C1Ex3A13R GCCGTACTGCTCATACCC 18 53 
BoLA-C1Ex3A13R2 GCCGTACTGCTCATACC 17 49 
BoLA-C1Ex3A14R GCCGTACTGATCATACCCG 19 53 
BoLA-C1Ex3A14R2 GCCGTACTGATCATACCC 18 50 
BoLA-C1Ex3A15R GGCTAACTGATCATACCCG 19 51 
BoLA-C1Ex3A15R2 GGCTAACTGATCATACCC 18 48 
BoLA-C1Ex3A16R GGCGAACTGATCATACCCG 19 53 
BoLA-C1Ex3A16R2 GGCGAACTGATCATACCC 18 50 
BoLA-C1Ex3A17R GCCGTACTGCTAATACCCG 19 53 
BoLA-C1Ex3A18R GGCGAACTGCTTGAACCC 18 53 
BoLA-C1Ex3A18R2 GGCGAACTGCTTGAACC 17 49 
BoLA-C1Ex3A19R GCCGAACTGCGTGAACCC 18 55 
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BoLA-C1Ex3A19R2 GCCGAACTGCGTGAACC 17 52 
BoLA-C1Ex3A20R GGCGTCCTGCATGAACCC 18 55 
BoLA-C1Ex3A20R2 GGCGTCCTGCATGAACC 17 52 
BoLA-C1Ex3A21R GCCGTACTGCATGAACCC 18 53 
BoLA-C1Ex3A21R2 GCCGTACTGCATGAACC 17 49 
BoLA-C1Ex3A22R GGCGAACTGCATGAACCC 18 53 
BoLA-C1Ex3A22R2 GGCGAACTGCATGAACC 17 49 
BoLA-C1Ex3A23R GCCGAACTGCATGAACCC 18 53 
BoLA-C1Ex3A23R2 GCCGAACTGCATGAACC 17 49 
BoLA-C1Ex3A24R GCCGAACTGCCAGAACCC 18 55 
BoLA-C1Ex3A25R GCCGAACTGCCAAAACCC 18 53 
BoLA-C1Ex3A26R GGCGAACTGATCATACCGC 19 53 
BoLA-C1Ex3A27R GGCCTTCTGCCAGAATCCA 19 53 
Exon 3 Series B Oligos Codons 151-157 
BoLA-C1Ex3B01 CGCTGAGGAGAGACACAC 18 53 
BoLA-C1Ex3B06 GCAGGCAAAGATCCAACG 18 50 
BoLA-C1Ex3B06L GGCAGGCAAAGATCCAACG 19 53 
BoLA-C1Ex3B07 GGAGGCAGAGTTCCAACG 18 53 
BoLA-C1Ex3B08 TAATGCGGAGAGCGAGAG 18 50 
BoLA-C1Ex3B09 TAATGCGGAGAGCGGGAG 18 53 
BoLA-C1Ex3B09S TAATGCGGAGAGCGGGA 17 49 
BoLA-C1Ex3B10 TCGTGCGGAGAGATTCAG 18 50 
BoLA-C1Ex3B11L GTGAAGCTGAGGTACAGAG 19 51 
BoLA-C1Ex3B12 TGAGGCGGAGAGACAGAG 18 53 
BoLA-C1Ex3B12N TGAGGCGGAGAGACACAG 18 53 
BoLA-C1Ex3B13 TGAGGCGGAGAGACGCAG 18 55 
BoLA-C1Ex3B13S TGAGGCGGAGAGACGCA 17 52 
BoLA-C1Ex3B15 TGAGGCGGAGAGATTCAG 18 50 
BoLA-C1Ex3B16 TGATGCCGCGCGTGTGAG 18 55 
BoLA-C1Ex3B16S TGATGCCGCGCGTGTGA 17 52 
BoLA-C1Ex3B17 TGATGCGGAGACTTGGAG 18 50 
BoLA-C1Ex3B17L GTGATGCGGAGACTTGGAG 19 53 
BoLA-C1Ex3B18 TGATGCGGAGAGACAGAG 18 50 
BoLA-C1Ex3B18L GTGATGCGGAGAGACAGAG 19 53 
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BoLA-C1Ex3B19 TGATGCGGAGAGATTAAG 18 46 
BoLA-C1Ex3B19L GGTGATGCGGAGAGATTAAG 20 52 
BoLA-C1Ex3B19L2 GTGATGCGGAGAGATTAAG 19 49 
BoLA-C1Ex3B20 TGATGCGGAGAGATTCAG 18 48 
BoLA-C1Ex3B20L GTGATGCGGAGAGATTCAG 19 51 
BoLA-C1Ex3B21 TGATGCGGAGGGACACAG 18 53 
BoLA-C1Ex3B22 TGATGCGGCGCGTGTGAG 18 55 
BoLA-C1Ex3B22S TGATGCGGCGCGTGTGA 17 52 
BoLA-C1Ex3B23 TGCTGCGAAGGGCGAGAG 18 55 
BoLA-C1Ex3B23S TGCTGCGAAGGGCGAGA 17 52 
BoLA-C1Ex3B24 TGCTGCGGAGACTTGGAG 18 53 
BoLA-C1Ex3B25 TGCTGCGGAGAGACAGAG 18 53 
BoLA-C1Ex3B25L TGCTGCGGAGAGACAGA 17 49 
BoLA-C1Ex3B26 TGCTGCGGAGAGATTAAG 18 48 
BoLA-C1Ex3B26L GTGCTGCGGAGAGATTAAG 19 51 
BoLA-C1Ex3B27 TGCTGCGGAGAGATTCAG 18 50 
BoLA-C1Ex3B28 TGCTGCGGAGCGTGTGAG 18 55 
BoLA-C1Ex3B29S TGCTGCGGAGGGCGAGA 17 54 
BoLA-C1Ex3B30 TGTTGCGGAGAGATTCAG 18 48 
BoLA-C1Ex3B30L GTGTTGCGGAGAGATTCAG 19 51 
BoLA-C1Ex3B31L GTTACGCTGAGGTACAGAG 19 51 
BoLA-C1Ex3B32 TTATGCTGAGGTACAGAG 18 46 
BoLA-C1Ex3B32L GTTATGCTGAGGTACAGAG 19 49 
BoLA-C1Ex3B33L CAGATTATGCTGAGTCTTTGA 21 49 
BoLA-C1Ex3B33L2 CAGATTATGCTGAGTCTTTG 20 48 
BoLA-C1Ex3B34L GGTTCTACGGACTTTTACAG 20 50 
BoLA-C1Ex3B35 TTCTGCGGAGAGCGGGAG 18 55 
BoLA-C1Ex3B35S TTCTGCGGAGAGCGGGA 17 52 
BoLA-C1Ex3B38L AAGGTTATGCTGAGTCTTTGA 21 49 
BoLA-C1Ex3B38L2 AAGGTTATGCTGAGTCTTTG 20 48 
Class 1 Exon 3 Standards   
BoLA-C1Ex3S01R GTCCTCGTTCAGGGCGA 17 52 
BoLA-C1Ex3S2 TCGCCCTGAACGAGGACCTG 20 58 
BoLA-C1Ex3S2R CAGGTCCTCGTTCAGGCGA 20 58 




Class I exon 3 Microarray probe layout 
 
S041 G13S F11 E15L2 D10R C06R2 A15R S01R1 
H08 G14S F12S E16L2 D11R C07R3 A16R A01R2 
H09 G15S2 F13 E17L2 E01L C08R3 B01R2 A02R2 
H09S G16S F14 E18L2 E02L C09R B02R A03R 
H10S2 G17S G01S E19 E03S C10R2 B03R2 A04R2 
H11S G18 G02S E20 E04 C11R2 B04R2 A05R3 
H12S G19 G03S2 F01L E05L C12R B05R2 A06R3 
H13S2 G20 G04S2 F02L E06L D01R2 B06R A07R2 
H14 G21 G05S* F03 E07S D02R2 B07R A08R2 
H14S G22 G06S2 F04 E08L D03R B08R2 A09R 
H15 H01S G07S2 F05 E09L D04R2 B09R A10R2 
H16S H02 G08S2 F06 E10L2 D05R2 C01R2 A11R 
H17S H03 G09S2 F07L E11L D06R2 C02R3 A12R 
H18 H04S2 G10S F08L2 E12L2 D07R C03R3 A13R2 
H19 H05S2 G11S2 F09 E13L D08R2 C04R A14R3 
S01R2 H07S2 G12 F10 E14L D09R2 C05R3 S042 
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Appendix D. 8  
MHC Class I probe definitions for each haplotype 
 
AH-02 AH-03 AH-07 AH-10 AH-11 AH-12 AH-13 AH-14 AH-15 AH-06 AH-18 
Exon 2 
A probes 
ExA03S Ex2A19L2 Ex2A02 ExA02 Ex2A01 Ex2A06N Ex2A02 Ex2A04L Ex2A02 Ex2A02 Ex2A02 
ExA03S2 Ex2A19L3 Ex2A02S Ex2A02S Ex2A01S Ex2A06N2 Ex2A02S Ex2A04L2 Ex2A02S Ex2A02S Ex2A02S 
ExA04L Ex2A21 Ex2A21 Ex2A03S Ex2A03S Ex2A08 Ex2A04L Ex2A05 Ex2A04L Ex2A07 Ex2A07 
ExA04L2 Ex2A21S2 Ex2A21S2 Ex2A03S2 Ex2A03S2 Ex208S2 Ex2A04L2 Ex2A08 Ex2A04L2 Ex2A07L Ex2A07L 
ExA08  Ex2A22 Ex2A09 Ex2A04L  Ex2A05 Ex2A08S2 Ex2A05  Ex2A11 
ExA08S2   Ex2A09L Ex2A04L2  Ex2A08 Ex2A13 Ex2A08   
   Ex2A18   Ex2A08S2 Ex2A25 Ex2A08S2   
   Ex2A21   Ex2A13  Ex2A13   
   Ex2A21S   Ex2A25  Ex2A27   
   Ex2A22     Ex2A27L   
Exon 2 
B probes 
Ex2B04 Ex2B05 Ex2B04 Ex2B02L Ex2B01L2 Ex2B13 Ex2B05 Ex2B08L Ex2B08L Ex2B12 Ex2B04 
Ex2B04L2 Ex2B05L Ex2B04L Ex2B05 Ex2B09  Ex2B05L Ex2B08L2 Ex2B08L2 Ex2B12L Ex2B04L2 
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Ex2B05 Ex2B07 Ex2B05 Ex2B05L Ex2B31L  Ex2B18 Ex2B14 Ex2B13 Ex2B23 Ex2B17L 
Ex2B05L  Ex2B05L Ex2B31   Ex2B18N Ex2B14L   Ex2B23 
Ex2B08L  Ex2B31L    Ex2B18L Ex2B24L   Ex2B24L 
Ex2B08L2      Ex2B25L2 Ex2B24L2   Ex2B24L2 
      Ex2B25L3 Ex2B33L    
      Ex2B26L     
      Ex2B26L2     
 
AH-02 AH-03 AH-07 AH-10 AH-11 AH-12 AH-13 AH-14 AH-15 AH-06 AH-18 
Exon 3  
A probes 
Ex3A13R Ex3A04R2 Ex3A09R Ex3A01R2 Ex3A13R Ex3A14R2 Ex3A04R2 Ex3A07R Ex3A04R2 Ex3A11R Ex3A13R 
Ex3A18R Ex3A21R Ex3A09R2 Ex3A04R2 Ex3A21R Ex3A20R Ex3A13R Ex3A07R2 Ex3A07R  Ex3A16R 
Ex3A18R2  Ex3A21R Ex3A05R Ex3A22R Ex3A Ex3A22R Ex3A09R Ex3A07R2   
Ex3A21R   Ex3A09R Ex3A22R2  Ex3A27R Ex3A09R2 Ex3A09R   
Ex3A23R   Ex3A09R2   Ex3A27R2 Ex3A25R Ex3A09R2   
Ex3A23R2   Ex3A17R     Ex3A25R   
   Ex3A21R        
   Ex3A23R        
   Ex3A23R2        
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Exon 3  
B probes 
Ex3B08 Ex3B01 Ex3B19L Ex3B11L Ex3B12 Ex3B06 Ex3B06 Ex3B09 Ex3B16 Ex3B18 Ex3B12 
Ex3B24 Ex3B33L Ex3B19L2 Ex3B19L Ex3B12S Ex3B06L Ex3B06L Ex3B1623S Ex3B16S Ex3B18L Ex3B12S 
Ex3B32L Ex3B33L2 Ex3B29S Ex3B19L2 Ex3B23 Ex3B17L Ex3B33L Ex3B23S Ex3B23  Ex3B16 
  Ex3B29S2 Ex3B29S Ex3B23S Ex3B30 Ex3B33L2 Ex3B29S Ex3B 23S  Ex3B 16S 
  Ex3B32L Ex3B29S2 Ex3B25 Ex3B30L  Ex3B29S2 Ex3B 29S  Ex3B 19L 
   Ex3B32 Ex3B25L   Ex3B38L2 Ex3B38L2  Ex3B19L2 
   Ex3B39 Ex3B31L   Ex3B38L3 Ex3B 38L3  Ex3B 27 
   Ex3B39S        
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AH-19 AH-20 AH-31 AH-33 AH-44 AH-60 AH-61 AH-62 AH-63 AH-64 AH-65 
Exon 2 
A probes 
Ex2A02 Ex2A02 Ex2A05 Ex2A03S Ex2A04 Ex2A06N Ex2A02 Ex2A03S Ex2A02 Ex2A10 Ex2A08 
Ex2A02S Ex2A02S Ex2A08 Ex2A03S2 Ex2A04L2 Ex2A06N2 Ex2A02S Ex2A03S2 Ex2A02S Ex2A28 Ex2A08S2 
Ex2A04L Ex2A03S Ex2A08S2 Ex2A04L Ex2A21 Ex2A08 Ex2A07 Ex2A04L04L2 Ex2A05  Ex2A11 
Ex2A04L2 Ex2A03S2 Ex2A13 Ex2A04L2 Ex2A21S Ex2A08S Ex2A07L Ex2A07 Ex2A07  Ex2A28 
Ex2A07 Ex2A08  Ex2A13   Ex2A11 Ex2A07L Ex2A07L   
Ex2A07L Ex2A08S2     Ex2A12L Ex2A11 Ex2A08   
 Ex2A22       Ex2A08S2   
        Ex2A19L2   
        Ex2A19L3   
        Ex2A22   
        Ex2A28   
Exon 2 
B probes 
Ex2B08L Ex2B05 Ex2B11 Ex2B04 Ex2B18 Ex2B13 Ex2B12 Ex2B04 Ex2B03  Ex2B17L 
Ex2B08L2 Ex2B05L Ex2B11N Ex2B04L2 Ex2B18N  Ex2B12L Ex2B04L2 Ex2B05  Ex2B35 
Ex2B23 Ex2B20L Ex2B13 Ex2B10 Ex2B18L   Ex2B23 Ex2B05L  Ex2B36 
Ex2B25L2 Ex2B31L Ex2B22L Ex2B10L2 Ex2B24L   Ex2B34 Ex2B13   
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Ex2B25L3  Ex2B24L Ex2B24L Ex2B24L2    Ex2B17L   
  Ex2B24L2 Ex2B24L2     Ex2B23   
        Ex2B28   
        Ex2B30   
        Ex2B30L   
        Ex2B36   
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AH-19 AH-20 AH-31 AH-33 AH-44 AH-60 AH-61 AH-62 AH-63 AH-64 AH-65 
Exon 3 
A probes 
Ex3A13R Ex3A09R Ex3A06R Ex3A21R Ex3A17R Ex3A09R Ex3A13R Ex3A09R Ex3A04R2 Ex3A02R Ex3A06R 
Ex3A17R Ex3A09R2 Ex3A06R2 Ex3A24R Ex3A17R2 Ex3A09R2  Ex3A09R2 Ex3A07R Ex3A05S Ex3A06R2 
Ex3A17R2 Ex3A13R Ex3A12R  Ex3A20R Ex3A19R2  Ex3A21R Ex3A07R2  Ex3A09R 
Ex3A19R Ex3A21R Ex3A12R2  Ex3A22R Ex3A20R  Ex3A29R Ex3A13R  Ex3A09R2 
Ex3A19R2    Ex3A22R2   Ex3A31R Ex3A14R2   
Ex3A 23R        Ex3A29R   
Ex3A23R2        Ex3A30R   
Ex3A27R        Ex3A32R   
Ex3A27R2           
Exon 3 
B probes 
Ex3B19L Ex3B19L Ex3B20  Ex3B24 Ex3B19L Ex3B14 Ex3B19L Ex3B27 Ex3B19L Ex3B34L Ex3B16 
Ex3B19L2 Ex3B19L2 Ex3B20L Ex3B32L Ex3B19L2 Ex3B17L Ex3B19L2 Ex3B32L Ex3B19L2  Ex3B16S 
Ex3B33L Ex3B33L Ex3B23  Ex3B21  Ex3B27 Ex3B38L2 Ex3B27  Ex3B30 
Ex3B33L2 Ex3B33L2 Ex3B23S  Ex3B33L   Ex3B38L3 Ex3B29S  Ex3B30L 
  Ex3B26L  Ex3B33L2    Ex3B29S2   
        Ex3B30   
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        Ex3B30L   
        Ex3B40S   
 
   
 286 
 
AH-66 AH67 AH68 MISC. 
Exon 2 
A probes 
Ex2A02 Ex2A02 Ex2A02 Ex2A14S2 
Ex2A02S Ex2A02S Ex2A02S Ex2A23 
Ex2A03S Ex2A04L Ex2A03S Ex2A23L2 
Ex2A03S2 Ex2A04L2 Ex2A03S2 Ex2A26S2 
 Ex2A11 Ex2A05 Ex2A28 
 Ex2A25 Ex2A07  
  Ex2A07L  
Exon 2 
B probes 
Ex2B03 Ex2B05 Ex2B04 Ex2B13L 
Ex2B04 Ex2B08L Ex2B04L2 Ex2B16L 
Ex2B04L2 Ex2B08L2 Ex2B05 Ex2B28 
Ex2B05 Ex2B17L Ex2B05L Ex2B29 
Ex2B05L Ex2B33L Ex2B23 Ex2B32 
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AH-66 AH67 AH68 MISC. 
Exon 3 
A probes 
Ex3A19R Ex3A13R Ex3A07R Ex3A03R 
Ex3A19R2 Ex3A25R Ex3A07R2 Ex3A08R 
Ex3A21R  Ex3A13R Ex3A10R 
Ex3A29R  Ex3A19R  
Ex3A30R  Ex3A19R2  
Ex3A32R  Ex3A21R  
  Ex3A29R  
Exon 3 
B probes 
Ex3B19L Ex3B09 Ex3B27 Ex3B07 
Ex3B19L2 Ex3B27 Ex3B32L Ex3B10 
Ex3B32L  Ex3B33L Ex3B13 
Ex3B40S  Ex3B33L2 Ex3B13S 
  Ex3B38L2 Ex3B28 
  Ex3B38L3  
  Ex3B40S  
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Appendix D.9 






*0101 N (Glass, Oliver, & Russell 2000) 
*0201 N (Park et al. 2004) 
*0501 N (Sigurdardottir et al. 1992) 
*0601 Y (Park et al. 2004) 
*0701 Y (Sigurdardottir et al. 1992) 
*0901 Y (Sigurdardottir et al. 1992) 
*0902 N (Park et al. 2004) 
*1001 Y (Park et al. 2004) 
*1101 Y (Park et al. 2004) 
*1201 Y 
(Glass, Oliver, & Russell 2000; Park J.Y. et al. 
2004) 
*1202 Y (Sigurdardottir et al. 1992) 
*1501 Y (Park et al. 2004) 
*1601 Y (Sigurdardottir et al. 1992) 
*1701 Y (Park et al. 2004) 
*2002 N (Glass, Oliver, & Russell 2000) 
*2703 Y (Park et al. 2004) 
*3201 Y (Sigurdardottir et al. 1992) 
 
 
 
 
 
 
 
 
 
 
 
 
